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ABSTRACT
By first separating mutant from nonmutant DNA sequences on the basis of their
melting temperatures and then increasing the number of copies by high-fidelity PCR,
observation of point mutations in biological samples at fractions at or above 10-6 has been
achieved. Using this method, hotspot point mutations that lie in 100 bp of the
mitochondrial genome (bp 10,030-10,130) in samples of cultured cells and human tissues
have been detected. Seventeen hotspot mutants were isolated, their fractions ranging from 2
x10 -3 down to the limit of detection of 10-6. These hotspots are primarily transitions.
Several human tissues such as colon, lung and muscle, and cultured human
lymphoblastoid cells, contained the same set of mutational hotspots. Mutational spectra
were also determined in bronchial epithelial cells of smokers and nonsmokers in order to
specifically address whether smoking induces hotspot mitochondrial mutations. Among
the individuals sampled were three pairs of monozygotic twins in which one twin never
smoked and the other had a significant smoking history. The mutational spectra in
smokers' samples did not differ significantly from the mutational spectra in nonsmokers.
No smoking-specific hotspots were detected and the overall mitochondrial mutant fractions
in this sequence in smokers' samples were not elevated compared to nonsmokers. In fact,
as much variability was observed among sections of the same individual's lung as among
samples from smokers and nonsmokers. The similarity of the hotspot sets in different
organs and in vitro, and the lack of smoking-induced mutations in bronchial epithelial cells,
support the conclusion that human mitochondrial point mutations in the sequence studied
are primarily spontaneous in origin and arise either from DNA replication errors or
reactions of DNA with endogenous metabolites.
While the same mitochondrial mutants were observed in multiple samples, the
frequencies varied considerably. In approximately 2% of observations, a particular
mutation was observed at greater than five-fold times the mean for the particular mutant.
These cases are interpreted to represent the accumulation of multiple mutant mitochondrial
DNA copies in a bronchial epithelial stem cell and its descendants.
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1. INTRODUCTION
While the hypothesis that chemicals in the environment induce mutations that
transform normal human cells into a tumorous phenotype is plausible, except for a few
clear cases, a causal link has not been demonstrated. Interest in testing this central premise
has guided the experimental goal of measuring the point mutational spectra in human
tissues. Studies in phage, bacteria, and human cell culture have demonstrated that treating
cells with different chemicals results in characteristic mutational spectra (Benzer et al.,
1958; Cariello et al., 1990; Coulondre et al., 1977; Keohavong et al., 1992). We
hypothesized that the most important mutagenic agents in human tissues could be identified
based on the mutational spectra observed.
Toward this end, a method was developed that permits measurement of hotspot
point mutants that lie in a defined 100 bp target sequence in the mitochondrial DNA of
human cell and tissue samples (Khrapko et al., 1997). Single base pair point mutants
present at fractions as low as 10-6 are detectable with this technique. The methodology
employs an initial separation of DNA copies containing mutations in the target sequence
from wild-type DNA with constant denaturant gel electrophoresis (CDGE) (Hovig et al.,
1991) followed by high-fidelity PCR with Pfu DNA polymerase. For further enrichment
of mutants and visualization of mutational spectra, constant denaturant capillary
electrophoresis (CDCE), a variant of capillary electrophoresis that includes a high
temperature zone for separation of mutants (Khrapko et al., 1994b), is employed due to its
speed, reproducibility, and excellent resolution.
The presence of several hundred to a thousand copies of mitochondrial DNA per
cell (Khrapko et al., 1997; Robin et al., 1988) permits greater statistical power for a given
sample size. Use of a mitochondrial DNA target has permitted reproducible detection of
rare mutants from the small number of cells obtainable from bronchoscopy samples. While
the accumulation of somatic point mutations in mitochondrial DNA has been suggested as
an important contributor to human diseases, including cancer (Shay et al., 1987; Warburg,
1956; Yamamoto et al., 1992) and aging (Aspnes et al., 1997; Bandy et al., 1990;
Cortopassi et al., 1990; de Grey, 1997), the most important contributors to mutagenesis in
mitochondrial DNA are not necessarily also the most significant mutagenic agents in
nuclear DNA.
Experiments were performed to determine the frequencies of mutations present in
human tissue samples from multiple organs, two tumor samples and cells in culture. In
addition, whether smoking induces a significant change in the kind and number of
mutations in the mitochondrial DNA of smokers' bronchial epithelial cells was specifically
addressed. Smoking was selected as a model for testing whether a particular environmental
agent is inducing a characteristic mutational spectra. Smoking is an appealing candidate as
a model because it represents a clear case of high and continuous exposure to a mixture of
chemicals containing known, powerful chemical mutagens. Also, a clear dose response
relationship between the number of cigarettes smoked per day and lung cancer risk has
been demonstrated by several large epidemiological studies (IARC, 1986). Further, dose
information is easily obtainable for smoking as opposed to many other environmental
agents for which exposure is often difficult to assess.
Smokers are good candidates for such experiments because the target cell for
smoking-induced lung cancer, the bronchial epithelial cell, can be harvested for analysis.
In these experiments, bronchial epithelial cells were obtained by brush biopsy from several
individuals including three pairs of monozygotic twins discordant for smoking. Bronchial
epithelial cells were also harvested from whole, dissected lungs. The mitochondrial
mutational spectra of these samples was determined in order to test for smoking-induced
mutations.
2. LITERATURE REVIEW
2.1 MUTATIONAL SPECTRA
2.1.1 Introduction
Mutational spectra were discovered by Seymour Benzer and Ernest Freese (Benzer,
1961; Benzer et al., 1958) who showed that the position and frequency of mutations in the
genome of the T4 bacterial virus were different for untreated and chemically treated virus
populations (see Figure 1). Each mutagen was observed to induce a set of characteristic
mutagenic "hotspots:" specific mutations, base substitutions or small deletions or
insertions, that occur within a treated population more frequently than would be expected
by chance. Since then, the specificity of mutational spectra for many mutagens has been
extended to bacteria, yeast, and rodent and human cells [(Thilly, 1990) and references
therein (Armstrong et al., 1990; Roy et al., 1994)]. In particular it has been recognized that
spontaneous mutations are also characterized by a reproducible set of predominant point
mutations (Benzer et al., 1958; Oller et al., 1992).
The experimental goal addressed in the studies presented herein has been to
determine the pattern of mutations that have accumulated in somatic cells in human tissues
over the course of an individual's life. Ultimately, such observations may provide
information about which of the many mutagenic agents to which humans are continuously
exposed are most important in terms of producing mutations.
2.1.2 Phenotypic selection
Most investigators of mutational spectra use an approach in which cells containing
mutations in a target gene are selected based on a change in phenotype. DNA isolated from
individual colonies, each containing a single mutant, is sequenced. Mutational spectra data
are therefore generated one mutant at a time.
The most frequently employed target for these studies is the hypoxanthine-guanine
phosphoribosyl transferase (hprt) gene. The HPRT enzyme permits cells to salvage
purines from the cell's microenvironment and incorporate them into synthesized DNA.
Cells with mutations in the hprt gene that render their HPRT enzymes defective, are
resistant to the effects of toxic purine analogs including 6-thioguanine (6TG) (Szybalski et
al., 1962). By plating cells in the presence and absence of 6TG, it is possible to determine
the hprt mutant fraction for a given cell population (Furth et al., 1981).
Albertini and colleagues pioneered a method for plating T-lymphocytes derived
from human peripheral blood in the presence and absence of 6TG to determine the hprt
mutant fraction of human samples (Albertini, 1985; Albertini et al., 1982; Albertini et al.,
1985). This approach is now being used by investigators at several laboratories. The
methodology has permitted determination of the average mutant fraction and the variation in
this mutant fraction within and among individuals. 6-thioguanine resistant (6TG r) mutant
fractions in lymphocytes of adults generally range from 1 x 10-6 to 4 x 10-5 (Tates et al.,
1991). Multiple studies have reported linear increases in mutant frequencies with age
(Robinson et al., 1994; Tates et al., 1991; Vijayalaxmi et al., 1984). In these experiments,
it is important to be careful not to confuse a decrease in cloning efficiency with age with a
rise in mutant fraction with age. Decreased cloning efficiency can lead to artifactual
increases in mutant fraction because the presence of wild-type cells in the selection plates
can suppress the recovery of HPRT mutants in the assay, and the suppression is stronger
in samples with high cloning efficiencies (Khaidakov et al., 1996). A meta-analysis of the
effects of age on mutant fraction from four different laboratories revealed that a doubling of
age was associated with a 52% increase in mutant frequency in one laboratory, a 66%
increase in mutant frequency in another, an 87% increase in mutant frequency in a third and
Fig. 1: Demonstration that mutational spectra are characteristic of the mutagen.
Distribution of mutations induced by a variety of compounds on the rlI gene in
bacteriophage.
Source: Benzer, 1961.
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no increase in the fourth (Robinson et al., 1994) (see Figure 2). As is clear from Figure 2,
infants have significantly lower hprt mutant fractions than adults (note that the scale is log).
A mean hprt mutant frequency of 0.64 x 10-6 was found in 45 placental blood samples,
which is approximately 10-fold lower than mean values in normal adults (McGinniss et al.,
1990). Increased hprt mutant fractions have been observed among populations exposed to
mutagens in an occupational setting [for instance, in cyclophosphamide production
(Htittner et al., 1990)] or as a treatment for cancer (Nicklas et al., 1991; Branda, 1991;
Caggana, 1991).
When hprt mutant fractions are determined by cloning individual T-cells, it is
possible to assess the contribution that expansion of a single clone makes to the hprt mutant
fraction observed (Curry et al., 1995; Nicklas et al., 1986). Each T-cell clone expresses a
T-cell receptor with a characteristic restriction pattern due to gene rearrangement. The T-
cell receptor restriction pattern of each 6TG r clone can be characterized in order to
differentiate whether two clones received the same mutation independently or whether the
two clones were derived from clonal expansion of a single mutant T-cell. Descendants of a
clonal expansion of a single T cell carrying an hprt mutation have been observed to
represent a substantial fraction of the mutants isolated from a single individual (Curry et al.,
1995; Nicklas et al., 1988).
There are two major limitations of determining mutational spectra by plating for 6-
thioguanine resistance. First, generating the necessary number of mutants to draw
statistically significant results is labor intensive and expensive when mutants are isolated
one at a time. Second, it is generally necessary to use a cell type with a high plating
efficiency in vitro and that can be grown in culture for sufficient time to allow phenotypic
selection. This requirement has generally [although not completely, see (Martin et al.,
1996)] limited use of the hprt mutation assay to T-lymphocytes.
Other approaches have also been used to measure mutant fractions in human tissues
for different genes. An assay for mutations in the HLA locus has been developed that
permits measurement and molecular analysis of both gene and chromosomal mutations
(Janatipour et al., 1988; McCarron et al., 1989). Individuals heterozygous for HLA-A2 or
HLA-A3 can be studied. In such individuals, there is a single copy of the target gene
(either HLA-A2 or HLA-A3) and thus mutants within it are selectable. Mutant
lymphocytes are immunoselected by exposing them to monoclonal antibodies against the
appropriate HLA followed by complement. Wild-type cells are killed by the treatment;
HLA mutants survive. Mutant frequency can be calculated as the ratio of the cloning
efficiency for selected cells to the cloning efficiency for non-selected cells. DNA isolated
from expanded mutant clones can be examined for the presence or absence of polymorphic
loci on chromosome 6 where the targeted HLA genes reside. Point mutations, gene
deletions, mitotic recombination, gene conversion or whole chromosome hemizygosity can
consequently be detected. The results of 167 assays in 73 individuals showed that mutant
frequencies increased significantly with age from a mean of 0.71 x 10-5 in neonates to 6.53
x 10-5 in elderly (Grist et al., 1992). Molecular analysis of 434 mutants from 31
individuals revealed that gene deletion events (defined as loss of the selected allele and no
loss of heterozygosity elsewhere) had occurred in 2.8% of cases, mitotic recombination
(defined as loss of the selected allele and loss of heterozygosity at the nearby factor XIIIA
gene) in 32.5% of cases and no change on Southern blotting (suggesting that a point
mutation is responsible for the phenotypic alterations) in 64.7%.
2.1.3 Mutational spectra to define mutational pathways
Mutational spectra data have been pivotal in the assignment of the most likely
mutagenic pathway for several model systems. For instance, determination of the
mutational spectra of the lacI gene in E. coli revealed that the two most highly mutable
hotspots, which incurred mutations at 10-fold higher than the average frequency, were
Fig. 2: Hprt mutant fraction as a function of age.
Mutant frequency adjusted for cloning efficiency plotted against subject age. The line
indicates the best fit for all the combined data assuming non-smoking status, and 50%
cloning efficiency. (A) Sussex. newborns, children and adults: non-smokers 0; smokers,
*. (B) Vermont. newborns, children, and normal laboratory subjects: non-smokers, 0;
smokers 0. Nurses: non-smokers, +; smokers, X. Breast cancer controls: nonsmokers,
0; smokers, 0. Twins: nonsmokers, A; smokers, filled A. (C) Leiden. Normal subjects:
non-smokers, 0: smokers, 0. (D) Paris. Laboratory controls and breast cancer patients
before treatment: nonsmokers, 0; smokers, 0.
Source: Robinson et al., 1994
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cytosines that were discovered to be methylated (Coulondre et al., 1978). When a novel
methylated cytosine was engineered into the sequence, this site was also a hotspot for GC-
>AT transitions (Coulondre et al., 1978). Deamination of 5-methylated cytosine or
misreplication past a 5-methylcytosine, are consequently candidates for the most important
mutational pathway in this system.
Mutational spectra data also proved valuable in identifying the mutagenic pathways
contributing to mutations observed in tumors of individuals with a disease that causes a
predisposition to colon cancer termed hereditary nonpolyposis colorectal cancer (HNPCC).
These patients inherited a defect in one of the proteins involved in mismatch repair
(Papadopoulos et al., 1994; Hemminki, 1994; Leach, 1993; Nicolaides, 1994). Colon
tumors in individuals with inherited defects in mismatch repair proteins show an increase in
frameshift mutations (Aaltonen et al., 1993; Fishel, 1993; Ionov, 1993; Boyer, 1995). An
increased frequency of frameshifts has also been observed in sporadic patients in addition
to those with a family history (Chen et al., 1997), and this particular pathway may be
important in as much as 20% of colon cancers (Heinen et al., 1995). These frameshifts
may reflect polymerase slippage due to a transient misalignment of the primer and template
(Streisinger et al., 1966; Kunkel, 1990). Increased frequency of frameshifts had been
previously shown to be a phenotype of mismatch repair deficient cells (Levinson et al.,
1987)., and this correlation between the in vivo spectra and in vitro spectra
2.1.4 En masse mutational spectra
The goal of the W. Thilly laboratory has been to develop an unselected approach to
mutational spectra that would permit analysis of statistically significant hotspot mutations in
a variety of human tissues. One important milestone along this path was development of a
method that allows processing of many mutants at once, thus permitting identification of
statistically significant hotspots without sequencing many individual colonies (Cariello et
al., 1990; Keohavong et al., 1992; Thilly, 1985) (see Figure 3). Human lymphoblastoid
cells from the cell line TK6 (Skopek et al., 1978) were treated with mutagenic agents, and
selected en masse for mutants in the hprt gene with 6TG. This selection increased the
mutant fraction for an individual mutant from approximately 10-7 to 10-3 . DNA was
extracted from 6TGr cells and hprt exon 3 was amplified with a high-fidelity DNA
polymerase. Hotspot mutants were detected with denaturing gradient gel electrophoresis
(DGGE).
DGGE was developed by Fischer and Lerman (Fischer et al., 1983) as a practical
application of statistical mechanics concerning cooperative equilibria in macromolecules that
predict DNA would melt in cooperative domains (Gotoh et al., 1981; Poland, 1974; Poland
et al., 1966). Mutations in the low melting domain of a DNA fragment with a biphasic
melting profile were discovered to alter the melting temperature (Fischer et al., 1983). As
DNA is electrophoresed through a gel containing an increasing gradient of denaturing
chemicals, specifically urea and formamide, the low melting domain of fragments with a
biphasic melting temperature "opens" at a given denaturant concentration. In this "open"
conformation, the high melting domain portion of the sequence remains double stranded
while the low melting domain is denatured for a significant portion of the time. DNA in the
open conformation moves more slowly through the gel and therefore appears to "focus" at
a denaturant concentration that reflects the melting temperature of the low melting domain.
Mutations in the low melting domain consequently affect the position in the gel at which
DNA focuses. Mutants can be converted into heteroduplexes, i.e., double stranded
molecules that have a single base mismatch, for instance A<>C or G<>T, by denaturing
and reannealing the products to force mutants to anneal with the wild-type in excess.
Heteroduplexes have an even greater difference in melting temperatures from wild-type,
thus creating heteroduplexes makes the hotspots more easily resolved from wild-type. This
Fig. 3: En masse approach to mutational spectra.
The protocol for an en masse approach to detecting mutational spectra is shown. Cells are
exposed to a mutagen, and 6-thioguanine resistant cells are selected. DNA is isolated and
subjected to high-fidelity PCR to amplify the DNA region of interest. DNA is melted and
reannealed so that mutants are present as heteroduplexes containing a mismatched base.
DNA is separated by DGGE to determine hotspots, and individual mutants can be excised
and sequenced.
Source: E. C. Friedberg et al., (eds.) DNA Repair and Mutagenesis, 1995.
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approach permitted detection of hotspot point mutations in DNA isomelting domains of
approximately 100 bp in cultured human cells treated with mutagenic compounds (Cariello
et al., 1990; Chen et al., 1994; Kat, 1992; Keohavong et al., 1992; Oller et al., 1992).
2.1.5 Examples of mutational spectra
The en masse selection approach was applied to several different compounds and to
untreated cells. Mutational spectra were discovered to be characteristic of the mutagen
used. Such experiments were performed with cells treated, for example, with MNNG
(Cariello et al., 1990), benzo[a]pyrene-diol-epoxide (BPDE) (Keohavong et al., 1992),
and hydrogen peroxide (Oller et al., 1992). A summary of these results is provided in
Figure 4 and the spectra for spontaneous cultures and three compounds are described in
more detail below.
2.1.5.1 N-methyl-N'-nitro-N-nitrosoguanidine (MNNG)
The mutational spectra induced by N-methyl-N'-nitro-N-nitrosoguanidine (MNNG)
at the third exon of hprt was determined in two cultures of TK6 cells. The cells were
treated with MNNG, one culture at 10 ng/ml and one culture at 15 ng/ml (Cariello et al.,
1990). The population treated with 10 ng/ml showed hotspot GC->AT transitions at the
second and third guanine in a run of six guanines with the third guanine mutated more
frequently than the second. The population treated with 15 ng/ml MNNG showed a single
GC->AT transition hotspot at the second guanine in the six guanine sequence.
2.1.5.2 Benzo[a]pyrene-diol-epoxide
The mutational spectra induced by the polycyclic aromatic hydrocarbon (BPDE) in
human TK6 cells was determined by en masse treatment and selection in quadruplicate
cultures (Keohavong et al., 1992). An average of 1.6 x 104 6TG r mutants were created
per culture. High-fidelity PCR and DGGE separation revealed 16 mutations in exon 3 that
were extremely reproducible among the cultures. The mutations were predominantly GC-
>TA transversions, although GC->AT, GC->CG, and AT->TA substitutions, single base
pair deletions and other more complex substitutions were also observed. The mutant
frequencies of the specific mutants observed ranged from 0.7 to 2.0% of the 6-thioguanine
resistant cells. Of the mutations observed, 6 occurred within a run of 6 guanines and 5
occurred in the sequence 5'-GAAGAG-3'.
2.1.5.3 Hydrogen peroxide
Triplicate cultures of TK6 cells were treated with hydrogen peroxide to induce hprt
mutant fractions ranging from 2.1 x 10-6 to 3.8 x 10-6 above the mutant fraction in cells
before treatment (Oller et al., 1992). Hydrogen peroxide- (H202)-induced mutations (1
hr, 20 mM) differed from the spontaneous spectrum. Four H202-induced hotspots were
observed in exon 3 of hprt. An AT->TA transversion was present at an average frequency
of 3% of all 6TG r mutants; two GC->CG transversions were detected at an average
frequency of 0.6% and 0.4%, respectively; and a five bp deletion (bp 274-278) was
present at an average frequency of 0.3%. The AT->TA transversion was detected in all
three replicate cultures; the other three mutations were detected in two out of three replicate
cultures.
Fig. 4: Mutational spectra in hprt exon 3 induced by different chemicals and detected by
DGGE.
Comparison of the mutational spectra induced by a variety of mutagens on the same
portion of the hprt gene using en masse treatment and selection followed by PCR and
DGGE. Mutational spectra induced by MNNG, benzo[a]pyrene diol epoxide, and
hydrogen peroxide, and the spontaneous spectra are shown.
Sources: Cariello et al., 1990; Keohavong and Thilly, 1992; and Oller and Thilly, 1992.
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2.1.5.4 Spontaneous
Large cultures of 7 x 108 TK6 cells were grown for 19 days without treatment to
generate spontaneous mutations, and then selected for hprt mutants with 6TG (Oller et al.,
1992). The 6TG r mutant fractions in the triplicate cultures after growth were 3.2 x 10-6 to
5.5 x 10-6. DNA isolated from the cultures was analyzed for point mutational hotspots in
the third exon of the hprt gene using DNA amplification and denaturing gradient gel
electrophoresis. Two point mutational hotspots were observed. A deletion of the two
adenines in the sequence GAAT and deletion of both guanines in the sequence CTGGAT
were detected in triplicate cultures. Each of the hotspots comprised about 1% of the total
6TG r mutants.
2.1.6 Unselected mutational spectra
Determining the most important mutagenic pathways in human tissues requires a
methodology for determining mutational spectra that is independent of phenotypic selection
for mutants. Recently, approaches to detecting rare (<10-4 ) mutations in DNA based on
genotype rather than phenotype have been developed. For example, allele specific PCR
(Cha et al., 1992; Wu et al., 1989a), ligase chain reaction (Landegren et al., 1988; Wu et
al., 1989b; Barany, 1991; Abravaya, 1995), or high efficiency restriction digestion
(Felley-Bosco et al., 1991; Kan et al., 1978; Khrapko et al., 1994a; Kumar et al., 1990)
permit detection of point mutations in target sequences from one to six base pairs.
In order to detect mutational spectra for 100 base pair target sequences, separation
of mutant and wild-type DNA was achieved by physical-chemical means. Enriching for
mutants prior to PCR is critical so that PCR noise does not obscure visualization of
mutants. The errors introduced even by an extremely faithful DNA polymerase that
generates 1 erroneous base pair in 106 base pair duplications (Keohavong et al., 1989),
after 106 -fold amplification (20 doublings) of a 200 base pair sequence, would result in
product DNA in which a 4 x 10-3 fraction of the single stranded copies contained a
mutation, an average of 2 x 10- 5 per base pair. This level of background errors could
obscure mutations present in human tissues at the level of 10-6 .
K. Khrapko, through a collaboration between the W. Thilly laboratory at MIT and
B. Karger's laboratory at the Barnett Institute of Northeastern University, adapted the
principles of constant denaturant gel electrophoresis (Hovig et al., 1991) to a capillary gel
electrophoresis (Cohen et al., 1988) format to create a separation method called "constant
denaturant capillary electrophoresis" (CDCE) (Khrapko et al., 1994b). Constant
denaturant electrophoresis can be used to separate DNA sequences with a biphasic melting
profile that contain mutations in the low melting domain. Separation of mutants is based on
the principle that the DNA fragment travels with a slower velocity when the low melting
domain is partially melted than when it is closed, presumably due to differences in the cross
sectional area of the fragment. At a carefully selected temperature, the molecules of a
fragment with a biphasic melting temperature will be in an equilibrium between the partially
melted and double stranded conformations. Even single base pair mutations in the low
melting domain will affect the equilibrium. Point mutations will cause the DNA fragment
to spend more or less time in the double stranded conformation, depending upon whether
the mutation makes the low melting domain more or less thermodynamically stable,
respectively. Differences in mobility therefore result. High Tm mutants, for instance, AT-
>GC mutations, exhibit increased mobility while low Tm mutants, GC->AT mutations,
have decreased mobility. Constant denaturant gel electrophoresis takes advantage of these
principles (Hovig et al., 1991). DNA is electrophoresed through an acrylamide slab gel
bathed in a temperature bath heated to a specific temperature designed to optimize mutant
separation.
K. Khrapko and colleagues converted a capillary electrophoresis instrument into a
constant denaturant capillary electrophoresis instrument by adding a water jacket to bathe a
portion of the capillary at a specific temperature, thus subjecting DNA to denaturing
conditions during a portion of the capillary electrophoresis run. Individual point mutants
can thereby be separated as homoduplexes and heteroduplexes using this technique.
Separation by CDCE enabled K. Khrapko and colleagues to measure mutant
fractions as low as 10-6 in model reconstruction experiments with mixtures of PCR
fragments (Khrapko et al., 1994b). Experiments by K. Khrapko, X.-C. Li and P. Andre
demonstrated the feasibility of applying the approach to detecting mutations in a
mitochondrial target sequence from genomic DNA isolated from cells and tissues. After
DNA isolation and restriction digestion to liberate the target fragment, the sample was
boiled and reannealed with a fluorescein-labeled probe, followed by successive rounds of
CDCE for mutant enrichment and high-fidelity PCR for target sequence amplification. The
technique was applied to several tissue samples and TK6 cells. The capillary outputs
suggested that a similar pattern of mutations was present in the tissue samples and, at a
lower frequency, in TK6 cells. Many of these mutants were then purified and sequenced
by K. Khrapko, X.-C. Li and P. Andre. CDCE enrichment, PCR conditions, and the
target sequence used for these experiments, in addition to the sequences of isolated
mutants, are described in more detail in the Materials and Methods and Results sections.
2.2 MITOCHONDRIAL DNA AS A TARGET FOR MUTATIONAL SPECTROMETRY
2.2.1 Introduction
Mitochondrial DNA in humans is a 16 kb circular genome that encodes 13 of the
approximately 70 protein subunits in the energy production system, 22 tRNAs and 2
rRNAs. The other subunits of the respiratory chain are encoded by the nuclear genome.
The respiratory chain catalyzes the phosphorylation of ADP to ATP to store as an energy
source. Five protein complexes located in the mitochondrial inner membrane are required.
Complexes I-IV take electrons from reduced electron carriers generated by the citric acid
cycle, including NADH and FADH2, and transfers them in a stepwise process to molecular
oxygen. These complexes generate an electrochemical gradient by pumping protons across
the inner mitochondrial membrane. Energy released by permitting protons to return to the
mitochondrial matrix is coupled to the phosphorylation of ADP to ATP by ATP synthase
(complex V).
Complex I (NADH dehydrogenase) and complex IV (cytochrome-c-oxidase)
contain the largest number of mitochondrial subunits. Seven of approximately 40 subunits
of complex I are mtDNA encoded and three of 13 subunits of complex IV are encoded by
mtDNA. Complex II (succinate dehydrogenase) is completely nuclearly encoded, while
complex III (ubiquinol cytochrome-c-reductase) has only one subunit encoded by mtDNA
among its 10 proteins. Two subunits of complex V are also mitochondrially encoded.
2.2.2 Advantages
2.2.2.1 Technical development: high copy number
The goal of developing an unselected approach to mutational spectrometry led to a
copy number problem. Given that 100 copies of a particular mutant is desirable for
statistical significance, in order to reproducibly detect point mutants present at 10-7 , which
would be the expected value for a mutant that represented 1% of all 6-thioguanine resistant
mutants (Grist et al., 1992; Robinson et al., 1994), 109 copies would be required for
analysis. For a single copy gene, this implies that 109 cells are required, which closely
approximates the total number of bronchial epithelial cells present in the upper airways of
the lung. Clearly, an alternative approach was warranted.
The alternative selected was to analyze a mitochondrial DNA target sequence.
Mitochondrial DNA was previously shown to be present at a few hundred to thousands of
copies per cell (Robin et al., 1988). We have estimated about 1000 copies per cell for TK6
cells (Khrapko et al., 1997), about 400 copies per cell for bronchial epithelial cells, and
more than a thousand copies per cell for brain and heart tissue. Use of a mitochondrial
DNA target consequently reduces the size of the tissue sample and the amount of total DNA
that must be handled to obtain statistically reproducible observations. In the experiments
described herein, reproducible detection of rare mutants in mitochondrial DNA was
possible from the small number of cells (approximately 105-106) obtainable from brush
biopsies.
2.2.2.2 Expected high mutation rate
Prior to these experiments, accurate assessments of the point mutant fractions of
mitochondrial DNA in human tissue were not available. There was, however, reason for
cautious optimism that the mutant fractions would be higher than observed for nuclear
sequences. Mitochondrial sequences have been reported to evolve approximately 10-times
faster than nuclear sequences (Brown et al., 1979; Wallace et al., 1987). Further,
mitochondrial DNA is selectively adducted by exogenous compounds (Wilkinson et al.,
1975; Wunderlich et al., 1970). As will be shown in the Results section, the mutant
fractions observed in mitochondrial DNA were indeed higher than the corresponding
mutant fractions in nuclear DNA, which was fortuitous in that signals were easily
detectable above the background noise generated by PCR, adducts, or other artifacts of the
procedure.
2.2.3 Differences from nuclear DNA
While a mitochondrial target sequence is advantageous in that fewer cells are
required and, as we later discovered, high mutant fractions are observed, which further
decreases the number of cells needed, the choice of a mitochondrial target sequence also
poses significant disadvantages. Most importantly, all known oncogenes and tumor
suppressors are encoded in nuclear DNA. Since the ultimate goal of these experiments is to
determine the most likely mutagenic agents that contribute to cancer, determining the
mutational spectra of a tumor suppressor or oncogene, mutation of which represents the
initiating event in cancer, would be ideal. Recognizing that the most important source of
mutations in mitochondrial DNA is not necessarily the same as the most important mutagen
for nuclear sequences, the use of a mitochondrial DNA target makes it inappropriate to
draw conclusions about tumor suppressors or oncogenes. Experiments are currently being
performed to adapt this procedure to nuclear sequences. Several of the most important
differences between mitochondrial DNA and nuclear DNA that could contribute to
differences in the most important mutational pathways are discussed below:
2.2.3.1 Intracellular state
Mitochondrial DNA is supercoiled and is not protected by histones as nuclear DNA.
2.2.3.2 Intracellular microenvironment
It has been estimated that 2% of the oxygen consumed by mitochondria is converted
to superoxide free radicals (02-) as a result of electrons in the oxidative phosphorylation
chain reacting with oxygen (Chance et al., 1979). Superoxide can react directly with DNA,
or may be converted into hydrogen peroxide (H202), which can form highly reactive
hydroxyl free radicals (OH'-). These reactive species are generated within the
mitochondrial membrane, and thus are physically close to mitochondrial DNA, which is
attached to the mitochondrial inner membrane. This could theoretically make mitochondrial
DNA more susceptible to adduction by reactive oxygen species, such as superoxide, H202
and hydroxyl radicals.
In 1988, Richter and colleagues reported levels of 8-hydroxydeoxyguanine (8-OH-
dG), an adduct formed by reaction of hydroxyl with deoxyguanine, in rat liver (Richter et
al., 1988). 8-OH-dG was reported at a level of 1 per 130,000 bases in nuclear DNA and 1
per 8000 bases in mtDNA based on high performance liquid chromatography elution
profiles. These levels are not incompatible with those reported in humans. Estimates of the
abundance of 8-OH-dG include an average of 0.03% of total deoxyguanosine content in the
temporal cortex of individuals from 42 to 97 years of age (Mecocci et al., 1993), 0.5% in
the diaphragm of an 85 year old man (Hayakawa et al., 1991) and 1.5% in a 97 year old
heart (Hayakawa et al., 1991).
Experiments by other groups, however, have reported a lower amount of oxidative
damage in mitochondrial DNA than reported in these studies. One of these studies, in
which the authors were careful to minimize adduction during the isolation procedure,
suggested a significantly lower level of 8-OH-dG in mitochondrial DNA in HeLa cells.
The ratio of 8-OH-dG to total guanines was approximately 3 x 10-7 (Higuchi et al., 1995).
In another study, specific repair endonucleases were used to measure oxidative
modifications in mtDNA from rat liver (Hegler et al., 1993). The number of modifications
sensitive to formamidopyrimidine-DNA glycosylase, which include 8-OH-dG adducts,
was only 8 x 10-6 per bp in mitochondrial DNA.
2.2.3.3 Adduction by exogenous agents
Higher levels of adduction to mitochondrial than to nuclear DNA have been
reported for several compounds. Preferential alkylation of mitochondrial DNA after
incubation of isolated mitochondria or cell nuclei with N-methyl-N-nitrosourea (NMU) has
been reported (Wunderlich et al., 1970). The specific radioactivity of the mitochondrial
DNA was 3-7 times that of the nuclear DNA. In vivo, treating rats with 50 mg
[14 C]NMU per kg led to greater incorporation of radioactivity into mitochondrial versus
nuclear DNA with ratios ranging from 3 to 17 in different experiments (Murphy et al.,
1990). An approximately two-fold increase in alkylation of mitochondrial as opposed to
nuclear DNA was discovered for N7 -methylguanine adducts in rat liver DNA when
dimethylnitrosamine was used to treat rats (Wilkinson et al., 1975). In this experiment,
increased alkylation levels in mitochondrial versus nuclear DNA were observed at three
different dose regimens. For the weak alkylating agent, methyl methane sulphonate,
however, mitochondrial and nuclear DNA were alkylated to a similar extent.
Preferential binding to mitochondrial DNA has been observed for bulky adducts as
well. Measurement of the amount of [3 H]aflatoxin B 1 bound to nuclear and mitochondrial
DNA in treated rats revealed that the levels were three to four times higher in mitochondrial
than nuclear DNA (Niranjan et al., 1981). Further, many lipophilic mutagens including
polycyclic aromatic hydrocarbons tend to accumulate in mitochondria (Schapira, 1992),
possibly as a result of their high lipid content.
2.2.3.4 Repair: Nucleotide excision, base excision, mismatch
The set of enzymes available for repair of mitochondrial DNA is apparently
different from that available to nuclear DNA. The lack of nucleotide excision repair for
mitochondrial DNA was first documented in 1974, when Clayton and colleagues reported
the absence of pyrimidine dimer repair mechanisms in mammalian mitochondrial DNA
based on the ability of the phage T4 UV endonuclease to nick covalently closed
mitochondrial DNA containing pyrimidine dimers (Clayton et al., 1974).
By generating single strand breaks at the site of specific DNA lesions followed by
Southern blot, the formation and removal of adducts has been monitored (Pettepher et al.,
1991). Pyrimidine dimers and complex alkylation damage induced by bifunctional agents
were not repaired in mitochondrial DNA, and there was minimal repair of cisplatin
intrastrand crosslinks (LeDoux et al., 1992). These findings are in concordance with the
absence of nucleotide excision repair. In contrast, there is efficient repair of cisplatin
interstrand crosslinks and of N-methylpurines. For both of these types of lesions, about
70% of the adducts were removed by 24 hours. Several other authors have also
demonstrated repair in mitochondrial DNA of alkylated purines (Meyers et al., 1988; Satoh
et al., 1988) and oxidative damage (Driggers et al., 1993). A process similar to the base
excision mechanism for nuclear DNA therefore apparently exists for mitochondrial DNA.
0 6 -alkyl guanines, which are repaired by 0 6 -methylguanine methyl transferase in nuclear
DNA in E. coli (Samson et al., 1977) have also been observed to be repaired in the
mitochondrial DNA of rat liver and kidney, although nearly no removal was observed from
the DNA of brain mitochondria, suggesting tissue-specific repair (Satoh et al., 1988).
Several enzymes involved in repair of mitochondrial DNA damage in mammalian
cells have been identified. Among the enzymes that have been reported include uracil DNA
glycosylases from rat liver (Domena et al., 1985; Gupta et al., 1981), a mouse
plasmacytoma line (Tomkinson et al., 1990) and humans (Nilsen et al., 1997); an
endonuclease specific for apurinic and apyrimidinic sites from mouse cells (Tomkinson et
al., 1988); a UV endonuclease from a mouse plasmacytoma cell line (Tomkinson et al.,
1990); and a repair enzyme for alkali-labile sites from rat insulinoma cells (Pettepher et al.,
1991). A 23 kd methyltransferase protein, similar to the one found in the nucleus, has
been isolated from rat liver mitochondria (Myers et al., 1988).
Whether human mitochondrial DNA is repaired postreplication by mismatch repair
enzymes is unknown as no specific enzymes have been identified. There is evidence for
mismatch repair of mitochondrial DNA in yeast. The yeast MSH1 gene is a homologue of
mutS, the protein that binds to DNA containing a mismatch during mismatch repair (Su et
al., 1986), and is targeted to mitochondria (Reenan et al., 1992b). Mutations in mshl
result in large-scale rearrangement of mitochondrial DNA (Reenan et al., 1992a). Since the
fidelity of DNA synthesis in the nucleus has been reported to decrease 60-fold (Kat et al.,
1993), 85-fold (Reenan et al., 1992b), and 340-fold (Fishel et al., 1993) when a mismatch
repair protein is mutated, depending upon the species and the specific protein affected, a
higher rate of spontaneous mutagenesis could be observed in mitochondrial DNA than in
nuclear DNA if human mtDNA lacks this error correction mechanism.
2.2.3.5 Replication
Mitochondrial DNA is replicated by DNA polymerase-y, a distinct polymerase from
the ones that replicate the nuclear genome. The gamma polymerase was recently cloned
(Ropp et al., 1996). The gene coding for the enzyme was discovered to contain a CAG
trinucleotide repeat encoding polyglutamine in the first exon. This sequence shows limited
instability in some mismatch-repair deficient cell lines, varying in size from 12 to 16 repeat
units.
This DNA polymerase contains an associated 3'->5' exonuclease activity. In a
forward mutation assay with porcine liver DNA polymerase-y, the enzyme was discovered
to have a high fidelity (misincorporation of less than one error for each million detectable
nucleotides polymerized) for certain mispairs, similar to that of other exonuclease-
containing DNA polymerases (Kunkel et al., 1989). In another study, the average
mutation frequency of chick embryo polymerase-y was estimated as 46 x 10-4 , while for
calf liver polymerase-y the estimated mutation frequency was 27 x 10-4 (Kunkel, 1985).
These frequencies were lower than observed for purified pol-a and pol-3 (nuclear
polymerases), and pol-y was notable in the low level of frameshifts produced.
2.2.3.6 Multiple copies per cell
Each cell contains several hundred to thousands of copies of mitochondrial DNA.
If one of the mitochondrial DNA copies in a cell were mutated, this would not be expected
to produce a phenotypic change in the cell because wild-type mtDNA would compensate
for the mutated mtDNA. Thus, for most cases of low-frequency mitochondrial mutants
phenotypic changes are not predicted to occur. In one model system, phenotypic change in
terms of decreased oxidative phosphorylation capacity was not observed for cells in culture
until as much as 90% of the mitochondrial DNA copies contained a mutation in
tRNALeu(UUR) at bp 3243 (Attardi et al., 1995).
The presence of multiple copies raises questions about the possibility that not all
mitochondrial DNA copies are replicated. In one study in which this question was
specifically addressed, mitochondrial DNA copies were labeled with [3 H]thymidine,
chased, and then labeled again with 5-bromodeoxyuridine (Bogenhagen et al., 1977). The
results were consistent with mitochondrial DNA replication occurring throughout the cell
cycle. Further, the copies selected for replication in the second round appeared to be
random with respect to those selected in the first round. This argues against both extreme
models, on the one hand, that a "queen bee molecule" is replicated repeatedly and on the
other hand, that each mitochondrial DNA copy is replicated once and only once for each
cell division. Not inconsistent with this result are the findings of Davis and Clayton
suggesting that mtDNA replication first occurs in the vicinity of nuclear-provided materials
and then distributes throughout a cellular mitochondrial network (Davis et al., 1996).
Pertinent to the studies described herein is the possibility that occasional mitochondrial
copies, possibly preferentially those containing adducts or premutagenic lesions, could be
left unreplicated without serious consequences for the cell.
2.2.4 Mitochondrial DNA and human disease
The mitochondrial encephalomyopthies are a heterogeneous group of disorders in
which a defect in mitochondrial metabolism is thought to be the primary cause of disease.
These diseases are generally characterized by tissue-specific manifestation of clinical
symptoms, including blindness, deafness, dementia, movement disorders, weakness,
cardiac failure, diabetes, renal dysfunction and liver disease (Lombes et al., 1989; Peterson
et al., 1991; Zeviani et al., 1989a). Mitochondrial disorders can be divided into two broad
classes based on the type of mutation: large-scale rearrangements (deletions) and point
mutations.
2.2.4.1 Deletions
Deletions of mitochondrial DNA have been frequently detected in patients with
mitochondrial myopathies (Holt et al., 1989a; Holt et al., 1988; Lestienne et al., 1988;
Moraes et al., 1989; Zeviani et al., 1988), especially in cases where ocular myopathy is a
key feature, for example, Kearns-Sayre syndrome and progressive external
ophthalmoplegia. In patients, a large fraction of the total population of skeletal muscle
mtDNA molecules (up to 90%) contains large-scale deletions (Holt et al., 1989a; Holt et
al., 1988; Lestienne et al., 1988; Moraes et al., 1989; Zeviani et al., 1988). A
characteristic feature of these diseases is the presence of large numbers of structurally
abnormal mitochondria in muscle fiber segments referred to as "ragged red" based on their
appearance with Gomori trichrome stain (Byrne et al., 1985; Johnson et al., 1983).
Mitochondrial diseases involving large scale deletions are nearly always sporadic,
suggesting that the mtDNA deletions arise as a clonal event in the egg or early in
development.
In one report of a patient with Kearns-Sayre syndrome, for instance, the patient's
symptoms included bilateral drooping eyelids, weakness of the muscles that move the eyes,
decreased hearing progressing to deafness, generalized muscle weakness, and defects in
atrioventricular signaling in the heart (Bresolin et al., 1987). Although cytochrome-c-
oxidase was present, enzyme activity declined as the disease progressed. In a first muscle
biopsy at age 31, 3% of muscle fibers appeared as ragged red. In a second muscle biopsy
seven years later, 20% of muscles stained as ragged red and 60% were completely absent
for cytochrome-c-oxidase activity.
Reported deletions in patients with mitochondrial myopathies range in size from
1.3-7.6 kb (Holt et al., 1989a; Moraes et al., 1989). Although the particular species of
deleted mtDNA varies among patients, approximately one-third of all patients harbor the
same deletion, called the "common deletion" (Mita et al., 1990; Schon et al., 1989;
Shoffner et al., 1989). This deletion eliminates 4,977 bases of mtDNA flanked by a 13 bp
direct repeat.
The frequency of the most prominent deletion varies among the tissues of
mitochondrial myopathy patients. In one Kearns-Sayre patient, the "common deletion"
represented 60% of the copies in skeletal muscle, 15% in heart muscle and kidney, and less
than 5% in the liver (Obermaier-Kusser et al., 1990).
Autosomal dominant inheritance of a disease characterized by multiple deletions of
mtDNA has also been reported (Suomalainen et al., 1992; Zeviani et al., 1989a). In this
case, the cause must be a defective nuclear gene coding, for example, for an enzyme
involved in maintaining the mitochondrial genome.
2.2.4.2 Point mutations
More than 40 pathogenetic point mutations in mitochondrial DNA have been
identified to date, including mutations associated with MELAS (mitochondrial
encephalomyopathy, lactic acidosis, and stroke-like episodes), MERRF (myoclonus
epilepsy with ragged-red fibers), NARP (neuropathy, ataxia, and retinitis pigmentosa), and
LHON (Leber's hereditary optic neuropathy). In all of these disorders, the quantity of
mutated mtDNA molecules is high in selected tissues (usually between 5 and 100% of total
mtDNA) and can be detected easily by restriction fragment length polymorphism analysis.
Mitochondrial mutations that have been identified in mitochondrial diseases are summarized
in Figure 5.
MERRF was among the first diseases clearly demonstrated to originate with a
mitochondrial DNA mutation. Wallace and colleagues demonstrated that a mtDNA
mutation must be pathogenetic by proving maternal inheritance in a large family, and by
identifying specific deficiencies in mitochondrial respiratory complexes I and IV (Wallace et
al., 1988). Respiratory capacity of different patients was correlated with the nature and
severity of the patients' clinical manifestations. Tissues were affected in the order of the
extent to which they rely on mitochondrial energy production (first central nervous system,
then type I oxidative skeletal muscle fibers, then heart). The causative mutation was
subsequently identified as an AT->GC transition at nucleotide pair 8344 which alters the
TNC loop of the tRNALys gene (Shoffner et al., 1990). All MERRF patients and their
less-affected maternal relatives had between 83% and 98% mutated mtDNA and showed an
age-related association between genotype and phenotype.
Leber's hereditary optic neuropathy (LHON) is another disease caused by mtDNA
mutations. It is characterized by bilateral loss of central vision. At least five mtDNA point
Fig. 5: Pathogenic point mutations in mtDNA.
Point mutations of mitochondrial DNA which have been related to human mitochondrial
diseases. *This mutation might be a Japanese polymorphism (Goto et al., 1994). ADPD:
Alzheimer's disease and Parkinson's disease; CIPO: chronic intestinal pseudo-obstruction
with myopathy and ophthalmoplegia; CPEO: chronic progressive external ophthalmoplegia;
DEAF: maternally inherited sensorineural deafness; DMDF: diabetes mellitus and deafness;
FICM: fatal infantile cardiomyopathy minus; FICP: fatal infantile cardiomyopathy plus;
HCM: hypertrophic cardiomyopathy and myopathy; Leigh: Leigh's subacute necrotizing
encephalomyelopathy; LIMM: lethal infantile mitochondrial myopathy; LHON: Leber's
hereditary optic neuropathy; MELAS: mitochondrial encephalomyopathy, lactic acidosis
and stroke-like symptoms; MERRF: myoclonic epilepsy and ragged-red fiber disease;
MILS: maternally inherited Leigh's syndrome; MM, mitochondrial myopathy; NARP:
neuropathy, ataxia and retinitis pigmentosa; PEO: progressive external ophthalmoplegia.
Source: Kadenbach et al., 1995 (see Kadenbach et al., 1995 for references)
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mutations, all of which alter evolutionarily conserved amino acids in the subunits of the
electron-transport chain, appear sufficient in themselves to cause the disease. The most
prevalent mutation, accounting for over 50% of cases, is a GC->AT transition at mtDNA
bp 11778 located in subunit IV of the NADH dehydrogenase complex (I). The mutation
converts a conserved arginine to a histidine (Poulton et al., 1991; Vilkki et al., 1989;
Wallace et al., 1988). LHON can also result from another class of base substitutions that
are not sufficient to induce the disease in themselves, but act synergistically to increase the
risk for optic atrophy. These secondary polymorphisms are also found in control
individuals, though at a much lower frequency, and they alter less conserved amino acids
(Savontaus, 1995).
As opposed to almost all other mitochondrial diseases which are characterized by
heteroplasmy, i.e., mutant molecules coexisting with wild-type mtDNA, LHON is an
example of a mitochondrial disorder which usually harbors primary mutations usually in a
homoplasmic state (Stone et al., 1992; Wallace et al., 1988), although persistent low-level
heteroplasmy accounts for approximately 14% of cases (Holt et al., 1989b; Sweeney et al.,
1992; Newman et al., 1991).
Another example of a disease that can result from a point mutation in mitochondrial
DNA is diabetes. Diabetes-like symptoms have been associated with mitochondrial DNA
deletions, duplications, and mutations in the tRNALeu(UUR) gene and missense mutations
in the NADH dehydrogenase subunit genes (Gerbitz et al., 1995). The most common is an
AT->GC transition mutation in the tRNALeu(UUR) gene at bp 3243 which, in
homoplasmic form, is associated with diabetes in about 1.5% of the diabetic population in
different countries and races (Kadowaki et al., 1994; Reardon et al., 1992).
Tissue specificity in the proportion of mtDNA containing a mutant has been
observed for point mutations as well as deletions. In a case report of a 34 year old man
with recurrent strokes, Chinnery and colleagues discovered that the proportion of an AT-
>GC transition at bp 3243, which has been associated with MELAS, was 85% in the
individual's skeletal muscle but only 4% in the blood (Chinnery et al., 1997).
2.2.5 Low-frequency somatic mitochondrial DNA alterations
The accumulation of point mutations and deletions in mitochondrial DNA has been
suggested as an important contributor to human diseases, including cancer (Shay et al.,
1987; Warburg, 1956; Yamamoto et al., 1992) and aging (Bandy et al., 1990; Corral-
Debrinski et al., 1992; Cortopassi et al., 1990; Mtinscher et al., 1993). Central to the
finding of deletions in mitochondrial DNA of normal tissue has been the observation that
deletion frequency increases with age in a tissue-specific manner.
2.2.5.1 Deletions
Large deletions of mitochondrial DNA have been found to increase with donor age
in multiple human tissues (Cortopassi et al., 1990; Linnane et al., 1990; Simonetti et al.,
1992; Yen et al., 1991). While most studies have focused on the "common deletion," the 5
kb deletion discovered frequently in patients with mitochondrial diseases, several other
deletions have also been shown to increase with age (Katayama et al., 1991; Yen et al.,
1992). In one study, a 7.4 kb deletion was observed in myocardial mitochondrial DNA
from all subjects over 70 years of age (Sugiyama et al., 1991). The proportion of mtDNA
copies containing this deletion increased supralinearly with age. The mtDNA deletion was
present at 0.025% in a 36 year old; at 1.4% in a 85 year old; and at 6.7% in a 97 year old.
An example of the increase in the frequency of deleted mitochondrial DNA copies with age
observed in one study is shown in Figure 6.
Several studies have identified multiple mtDNA deletions with advancing age.
Zhang and colleagues detected 10 different deletions in the heart, brain and skeletal muscle
Fig. 6: Increase in the ratio of deleted to total mtDNA with age.
The ratio of deleted mtDNA to the total mtDNA plotted against the age of subjects. The
amounts of the total and deleted mtDNA in autopsied myocardium of various ages were
determined by kinetic PCR. The ratio increases exponentially with age.
Source: Ozawa, 1995
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of a 69 year old female (Zhang et al., 1992). Ozawa and colleagues developed a method
based on PCR with 180 different primer pairs that permits detection of all deletions in
mtDNA (Katsumata et al., 1994). In the heart mtDNA of a 28 year old normal female, 67
different types of mitochondrial DNA minicircles were observed and they are reported to
represent 23% of mitochondrial DNA copies (Ozawa, 1995). Heart mtDNA of a patient
with a mutation in the tRNAAsp gene who died of heart failure at age 19 was also
investigated. In this patient, 235 different types of deletions were detected and mtDNA
minicircles represented 84% of the mtDNA copies.
Multiple deletions that increase with age have been detected in other species,
including rhesus monkeys (Lee et al., 1993), mice (Wang et al., 1997) and rats (Van Tuyle
et al., 1996).
2.2.5.2 Tissue specificity of mtDNA alterations
Large deletions of mitochondrial DNA have been discovered to show tissue-specific
differences in frequency (Simonetti et al., 1992; Yen et al., 1991). In one report, the
fraction of mitochondrial DNA that was deleted was 5.5 x 10-4 in muscle, 1 x 10-4 in
heart, 0.5 x 10-4 in spleen, and much lower levels in liver, kidney and lung in an 84 year
old man (Simonetti et al., 1992). Indeed, deletions are generally rare in blood cells (Yen et
al., 1991) and splenic lymphocytes (Cortopassi et al., 1992). Even within an organ,
tissue-specificity has been observed in the levels of the "common deletion:" among the
different regions of brain, striatum has been found to contain an approximately 200-fold
higher level of deleted mitochondrial DNA than cerebellum (Corral-Debrinski et al., 1992;
Soong et al., 1992). This has been suggested to be related to the higher density of
dopaminergic neurons because dopaminergic neurotransmitters are degraded by
monoamine oxidase within the outer mitochondrial membrane, a process that is
accompanied by hydrogen peroxide production (Corral-Debrinski et al., 1992; Cortopassi
et al., 1992).
Tissue-specific selection for different mtDNA haplotypes has been observed in
heteroplasmic mice containing two different mtDNA genotypes (BALB and NZB). The
haplotypes contain 106 point mutational differences and are assumed to be neutral to
selection (Jenuth et al., 1997). In these mice, the mean frequency of the BALB haplotype
in a female was the same as the mean frequency in all her offspring, and further the relative
proportion of the BALB haplotype was very similar among tissues in the neonates. With
time, however, the frequencies of the BALB haplotype in different tissues changed
significantly. Without exception (n=37 mice), the proportion of the BALB mtDNA
genotype increased in blood and spleen while that of the NZB genotype increased in liver
and kidney. In the liver, the NZB genotype was estimated to have a 50% selective
advantage over the BALB genotype in each cell generation (see Figure 7).
2.2.5.3 Point mutations
Low-frequency mitochondrial DNA point mutations associated with pathologic
conditions have also been found in several undiseased organs. Using PCR/RFLP analysis
with mispairing primers, Miinscher and colleagues found an AT->GC transition at mtDNA
bp 8344 [a mutation associated with MERRF (Shoffner et al., 1990)] in extraocular muscle
in 11 of 14 normal older adults, and calculated that a maximum of 2.4% of this specific
mutation was present in the oldest samples (Minscher et al., 1993).
A mutation at bp 10,006 in tRNAgly(TCC) was observed in all patients over 67
years old but not in patients 30 and under (Mtinscher et al., 1993). This age-related
difference was not discovered for mutations at either bp 5692 (in tRNAAsn) or bp 12246
[in tRNASer(AGY)]. Mutations at bp 10,006, 8344 and 3243 were observed in most
elderly individuals while mutations at 5692 and 12,246 occurred only occasionally.
Fig. 7: Tissue specific selection for mitochondrial haplotypes.
Selection for alternative mtDNA genotypes in spleen vs. liver and kidney of heteroplasmic
animals with increasing age. Each point corresponds to the value obtained in an individual
animal. Panels A and B refer to mice with BALB (A) and mixed BALB/NZB (B) nuclear
backgrounds
Source: Jenuth et al., 1997.
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Miinscher and colleagues concluded that certain nucleotides of mtDNA represent "hot
spots" for somatic point mutations and suggested that these may contribute to aging.
Kadenbach and colleagues performed nonquantitative allele-specific PCR for five
point mutations in tRNA sequences on samples from individuals of various ages
(Kadenbach et al., 1995). Mutations were below detectable levels in all individuals for
four of the five point mutations. A mutation at bp 12,220 was detected in two of five
elderly (>80 years old) individuals and not in two younger individuals. The same authors
also performed quantitative PCR for the mutations associated with MERRF (bp 8344) and
MELAS (bp 3243). Levels were not detectable for 20 year olds for either mutation.
Among subjects >60 years old, the MERRF mutation was observed at frequencies up to
2% of all wild-type copies and the MELAS mutation was observed at frequencies up to
1%. The authors' claims of an "exponential" increase with time for these two mutations are
not supported by the data.
In two other studies of an AT->GC transition at bp 3243 associated with MELAS,
the reported frequencies were 0.1% using allele-specific PCR (Zhang et al., 1993), and
from an undetectable level to 0.7% using an approach based on restriction digestion of the
wild-type (Pallotti et al., 1996). Zhang and colleagues reported that this mutation was
present at higher levels in adults than infants. While seven out of 38 adult heart tissues
tested were found to contain this mutation at an estimated 0.1%, the mutation was not
detected in any of the 16 infant tissues analyzed. Pallotti and colleagues used restriction
digestion to enrich for mutant copies, followed by PCR to detect mitochondrial mutants, in
the 5 bp region between bp 8991 and 8995, and in the 4 bp region between bps 3242 and
3246 (Pallotti et al., 1996). The restriction digestion/PCR approach was used to detect
spontaneous point mutations in DNA isolated from skeletal muscle from normal individuals
of various ages. Low levels of somatic mutations were observed above background in
both regions, but there was no correlation between the amount of mutation detected and the
age of the subject. These results contrasted with the age-related increase in the amount of
the mtDNA "common deletion" in these samples. They therefore concluded that there is no
preferential amplification or accumulation of specific point mutations in skeletal muscle
over the course of a human lifespan.
Using an approach based on high efficiency restriction digestion followed by
denaturing gradient gel electrophoresis (Fischer et al., 1983) to separate mutants from wild-
type DNA and from each other, hotspot mutations were detected in the 16S rRNA region of
mitochondrial DNA. In this assay, the DNA is restriction digested to eliminate
approximately 99% of wild-type sequences. The sample is amplified, restriction digested
again, reamplified and analyzed using denaturing electrophoresis. Application of this
method to two lung samples and a colon sample revealed a common GC->AT hotspot in
the restriction enzyme recognition sites of the 16S rRNA region (G. Hu, H. C., X.-C. Li
and 0. Kostas, unpublished results). This hotspot was estimated to have a frequency of
10-6 to 10-4.
Attempts have also been made to characterize mitochondrial point mutations by
direct sequencing. Gadaleta and colleagues sequenced 16,000 bases from two different
regions of the genome and did not find any sequence differences between adult and
senescent rat brain mtDNA (Gadaleta et al., 1992). Similarly Bodenteich and colleagues
detected only one heteroplasmic mutation out of 32,000 bases sequenced from two
different regions of mtDNA from the retina of a 71 year old individual (Bodenteich et al.,
1991).
2.2.6 Distribution of mitochondrial mutants
The distribution of mitochondrial mutants among cells has been investigated both
by histochemical staining and by in situ hybridization. Histochemistry has generally
involved staining for lack of cytochrome-c-oxidase activity. Cytochrome-c-oxidase is the
terminal enzyme in the respiratory chain that irreversibly transfers electrons of the
respiratory chain to molecular oxygen. Lack of cytochrome-c-oxidase activity implies that
no oxidative phosphorylation-based ATP synthesis is occurring in mitochondria.
Human aging has been associated with focal accumulation of respiratory deficient
cells in various tissues like heart (Miiller-Hticker, 1989), skeletal muscle (Miller-Hicker,
1990), extraocular muscle (Miller-Hicker et al., 1992) and diaphragm (Miiller-H6cker,
1990). In one study, cytochrome-c-oxidase staining was studied in 140 hearts from men
obtained at autopsy (Miller-Hicker, 1989). Randomly distributed individual
cardiomyocytes lacking enzyme activity were observed independent of heart disease. The
proportion of hearts with cytochrome-c-oxidase deficient cardiomyocytes increased with
age from 0/7 hearts aged 0-7 years to 21/21 hearts aged 81-97. The density of the defects
also increased with age from 2 to 3 defects per cm 2 in the second and third decade to about
50 defects per cm 2 in advanced age. In most cases there was a complete loss of activity
and the defect always involved all the mitochondria of a cell.
In situ hybridization with oligonucleotides has also been used to determine the
distribution of mitochondrial mutants among cells. Mita and colleagues performed a
semiquantitative in situ hybridization analysis and found that mutant and wild-type
mtDNAs were inversely distributed in the muscle fibers of a Kearns-Sayre patient (Mita et
al., 1989). High levels of deleted mtDNAs were found in oxidatively defective fiber
segments, and fiber segments with high levels of wild-type mtDNA had normal
cytochrome oxidase activity, suggesting that deleted and wild-type mtDNAs are
functionally independent.
Shoubridge and colleagues also used in situ hybridization to determine the
distribution of deleted mitochondrial DNA copies in muscle fiber segments (Shoubridge et
al., 1990). In four patients with mitochondrial myopathies, they discovered that individual
ragged red fiber segments contained an unusually large number of total mitochondrial DNA
copies. Most of these were deleted mitochondrial copies (6- to 7- times normal); in
addition, the normal number of wild-type copies were also present. These fibers were
negative for cytochrome-c-oxidase activity. Other unaffected muscle fibers contained only
the normal amount of wild-type copies. This suggested that loss of cytochrome-c-oxidase
function was a result not of lack of wild-type mtDNA but of interference from deleted
mtDNAs.
Fiber bundle analysis has also been employed to investigate the distribution of
mitochondrial mutants. Defined numbers of fibers were dissected from a large muscle of
the rhesus monkey (Schwarze et al., 1995). The number of different deletions observed
declined when the number of fibers examined decreased from 75 to 10. The frequency of
specific deletions from the same samples, however, increased in abundance from
approximately 1% to between 5 and 13% of total mitochondrial genomes when the cell
number decreased. These findings are in concordance with evidence above that
mitochondrial deletions accumulate within cells.
2.2.7 Mitochondrial DNA and aging
As described previously, the levels of deleted mtDNA increase significantly with
age in humans and other species. This observation has suggested that mitochondrial DNA
mutations may be involved in aging. Evidence for this assertion is described below.
Muscle, heart and brain function, as well as electron transport activity decline with age,
while the number of cytochrome-c-oxidase deficient fibers and oxidative free radicals
increases. Further, caloric restriction, the only mechanism that has been proven to increase
longevity in many species, also results in lower levels of mtDNA alterations. Finally, it is
interesting to note that metabolic rate and longevity are inversely correlated among species.
2.2.7.1 Organ dysfunction
Aging is associated with loss of muscle mass and strength, and loss of neurons.
Such changes could be associated with mitochondrial DNA alterations either because cells
with mitochondrial alterations can no longer function due to a decline in oxidative
phosphorylation ability, or because mitochondrial defects promote a sequence of events
resulting in neuronal apoptosis.
A decline in mitochondrial activity with aging has been documented. In addition to
histological studies described previously that demonstrate an increase in cytochrome-c-
oxidase deficient cells with age, biochemical analyses have also been performed to
determine the function of the electron transport complexes of humans, rhesus monkeys,
rats, and mice (Boffoli et al., 1994; Bowling et al., 1993; Desai et al., 1996; Sugiyama et
al., 1993). Age-associated decreases in the activities of complexes I and IV have been
observed in nonproliferating tissues such as skeletal muscle, heart, and brain, but usually
not in proliferating organs like liver or kidney. In one study, the activities of complexes I
and IV of heart mitochondria of rats aged 100 weeks decreased significantly, by 31% and
22%, respectively, compared with those of rats aged 7 weeks (Takasawa et al., 1993). No
significant decline with age was observed in complexes II and III (Sugiyama et al., 1993).
Since complexes I and IV contain the most mitochondrial DNA encoded subunits, this
finding supports the involvement of mitochondrial DNA alterations in the decline of
oxidative phosphorylation.
Mitochondrial dysfunction has also been associated with apoptosis (Cortopassi et
al., 1995; Polyak, 1997; Sheehan, 1997). Death of dopaminergic neurons (Oertel et al.,
1993) and sensorineural hair cells of the inner ear are characteristic features of aging.
Further, the dementia associated with Alzheimer's disease results from apoptosis of
cholinergic neurons, and late-onset diabetes may reflect apoptosis of pancreatic islet cells.
These correlations raise the possibility that mitochondrial DNA alterations may play a role
in the aging process through this mechanism as well. Indeed, deafness, dementia, ataxia
and diabetes are symptoms of mitochondrially encoded diseases.
2.2.7.2 Oxidative damage
Levels of the adducted base 8-hydroxydeoxyguanine (8-OH-dG), which results
from interaction of free radicals with deoxyguanine, have been extensively examined
because the compound can be detected with high performance liquid chromatography.
Several laboratories have reported that this particular adduct increases with age in several
species (Agarwal et al., 1994; Hayakawa et al., 1991; Sohal et al., 1994). Mecocci and
colleagues, for instance, determined the levels of 8-OH-dG in DNA isolated from 3 brain
regions from 10 normal humans aged 42 to 97 years, and discovered that the levels of
adducted nucleotide increased with age (Mecocci et al., 1993). Such findings have also
been extended to rodents. The levels of 8-OH-dG increased by 130% in rats aged 100
weeks compared with levels in rats aged 7 weeks in one study (Takasawa et al., 1993).
In addition, overexpression of two major antioxidant enzymes, dismutase and
catalase, has been shown to bestow longevity upon Drosophila melanogaster (Orr et al.,
1994).
2.2.7.3 Caloric restriction
Another pertinent observation is that caloric-restricted animals age less. Caloric
restriction extends the lifespan of rats by 33%, from less than three to four years of age.
The long-lived rats stay youthful longer and suffer fewer late-life diseases than their
normally-fed counterparts (Weindruch, 1996). Caloric restriction increases the maximum
(as opposed to the average) lifespan, thereby demonstrating that the effect is not simply due
to prevention of premature death but actually a slowing of the rate of aging. Increased
lifespans from dietary restriction have been observed in protozoa (Rudzinska, 1952),
guppies (Comfort, 1963), and rodents (Sohal et al., 1996). Further, dietary-restricted mice
show less decline in learning and motor performance with age (Ingram et al., 1987).
The explanation for the health benefits resulting from caloric-restricted diets that has
the most experimental support is that caloric restriction limits damage to mitochondria by
free radicals (Weindruch, 1996). Mitochondria harvested from the brain, heart and kidney
of dietary-restricted mice reveal that levels of the superoxide radical and of hydrogen
peroxide were markedly lower in animals subjected to long-term caloric restriction than in
normally-fed controls (Sohal et al., 1996). In a recent study, muscle fibers from aged
caloric-restricted rats were shown to contain significantly fewer cells deficient in
cytochrome-c-oxidase activity, fewer cells that stained as ragged red, and a significantly
lower number of mtDNA deletion products in two (adductor longus and soleus) of the four
muscles examined (Aspnes et al., 1997).
2.2.7.4 Metabolic rate and lifespan
One possible explanation for the beneficial effects of caloric restriction is that such
treatment reduces resting energy expenditure (Ramsey et al., 1997). Supporting this
hypothesis is the finding that metabolic rates and lifespans correlate. When the metabolic
rate, defined by ml of 02 consumed per kg per hour, is compared with the generation time
(in days) for 8 species of primates, the correlation coefficient of -0.75 supports a purported
association between the factors (Martin et al., 1993). Further, rates of mitochondrial
oxygen consumption and 02'- and H202 production in the kidney and heart, were shown
to be inversely correlated with maximum lifespan in seven mammalian species: mouse,
hamster, rat, guinea pig, rabbit, pig, and cow (Ku et al., 1993). This correlation suggests
that accumulated damage to mitochondrial DNA may represent the limiting factor in
generation time. Also supporting this hypothesis is the observation that mice accumulate
significantly higher levels of mitochondrial deletions than humans. Using nested PCR, the
absolute frequency and rate of increase of mitochondrial deletion mutations was determined
(Wang et al., 1997). Deletion frequencies rose by 2.5 x 105 , 6300- and 4000-fold in
heart, brain, and kidney, respectively, from young to old mice. The deletion frequencies
rose 40-fold faster in mouse than human mtDNA per unit time, a difference that is similar
to the difference in lifespan, supporting the hypothesis that death from old age occurs as a
result of an accumulation of deleterious mitochondrial mutations.
2.2.8 Target sequence and melting map
The previous sections have described the recent explosion of information about the
role of mutations in mitochondrial DNA in acute diseases and possibly also in aging. For
these studies, a section of the mitochondrial genome was selected for analysis based on its
adaptability to separation by constant denaturing electrophoresis. The target sequence of
mitochondrial DNA used for this study was a 100 bp low melting domain of a 200 base
pair region of mitochondrial DNA bps 10011 to 10217. This sequence was selected
because of its suitability for constant denaturant electrophoresis, which can separate DNA
containing mutations in the low melting domain of a sequence with a biphasic melting
profile. As can be observed from Figure 8, the selected target sequence contains a 100 bp
low melting domain that will be in a rapid equilibrium between open and closed
conformations while the high melting domain remains double stranded and serves as a
"clamp."
The target sequence codes for two genes: tRNAgly(TCC) and NADH
dehydrogenase subunit III. The proposed clover leaf structure of mitochondrial
tRNAgly(TCC) is shown in Figure 9. Mutations present within the tRNAgly(TCC) but
Fig. 8: Melting map of the mitochondrial target sequence used in these studies.
Melting map of the wild-type DNA fragment calculated according to the algorithm of
Lerman and Silverstein, 1987. CW7, J3 and CW7(mut) indicate the positions of the
primers used for PCR and the primer used to generate the artificial mutant used as a low
Tm internal standard (CW7(mut)). The vertical arrow indicates the position of the artificial
mutant mutation. Base pair one on the map corresponds to bp 10,011 of the human
mitochondrial genome.
Source: Khrapko et al., 1994.
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Fig. 9: Clover leaf of tRNAgly in mtDNA.
Proposed clover leaf structures of the mitochondrial tRNA gene for glycine (TCC). The
substitution at bp 10006, together with two other mutations was mutated in a patient with
chronic intestinal pseudo-obstruction with myopathy and ophthalmoplegia. The circled
nucleotide at bp 9997 was found mutated in a patient with cardiomyopathy. Also indicated
are the positions of mutations observed as hotspot point mutations in human tissue
samples. The number designation for each are as follows: p13.5, AT->GC at bp 10042;
p5.5, GC->AT at bp 10056; p11, TA->CG at bp 10057; p1 1.5 AT->GC at bp 10058.
Source: Miinscher et al., 1993.
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outside of our target sequence have been associated with chronic intestinal pseudo-
obstruction with myopathy and opthalmoplegia [bp 10006, (Lauber et al., 1991)] and
cardiomyopathy [bp 9997, (Merante et al., 1994)].
The target sequence also includes a portion of the NADH dehydrogenase subunit
III, which encodes one of 25 polypeptides that compose complex I of the respiratory chain.
This enzyme complex contains a flavin mononucleotide as a tightly bound prosthetic group.
The flavin oxidizes reduced NADH, and then the complex transfers electrons from reduced
flavin to iron-sulfur centers and ultimately to coenzyme Q. Complex III and IV then carry
electrons from coenzyme Q to cytochrome c and ultimately to oxygen to generate water.
The drug 1-methyl-4-phenyl- 1,2,5,6-tetrahydropyridine (MPTP) is a specific
inhibitor of complex I (Nicklas et al., 1985) and provides some information about the
possible effects of mutations in genes encoding complex I subunits. MPTP administration
to animals can simulate the symptoms of Parkinson's disease (Oertel et al., 1993; Schapira,
1992), a common, late-onset neurodegenerative disorder that results in part from the
gradual loss of dopaminergic neurons in the substantia nigra region of the brain. MPTP
may induce Parkinson's-like symptoms by causing apoptosis of substantia nigra neurons
(Sheehan et al., 1997). That MPTP-induced apoptosis is mediated through superoxide is
suggested by findings that mice with deficiencies in the mitochondrial superoxide
dismutase, MnSOD, are hypersensitive to MPTP (Cortopassi et al., 1995). MnSOD-
deficient mice exhibit massive brain toxicity when treated with MPTP.
2.3 BRONCHIAL EPITHELIAL CELLS AND TISSUE KINETICS
The bronchial epithelial cells of the airways are organized as a pseudostratified layer
of cells in which the majority are ciliated (Burkitt et al., 1993). Pseudostratification results
even though all cells touch the basement membrane because differences in cell size make
the nuclei appear to be present at different levels, thus creating the illusion of stratification.
2.3.1 Cell types
The epithelium is composed of five to six major cell types lying on a common
basement membrane. The most important cells in the upper airways are basal cells,
mucous secreting cells, and ciliated cells. The mucous secreting cells include goblet cells,
serous cells, small mucous granule cells and the Clara cells, the last of which is present
only in the bronchioles, the smaller, distal airways of the lung. Less frequently observed
are neuroendocrine cells (also called Kulchitsky cells).
2.3.2 Stem cells
There is clear evidence that there are cells in the lung capable of acting as stem cells,
i.e., cells having extensive self-renewal capacity and the ability to generate differentiated
progeny. Clusters of cells arising from the same stem cell have been visualized in a model
system in which human bronchial epithelial cells are seeded into a denuded rat trachea and
implanted into athymic mice (Zepeda et al., 1995). In this experiment, the human bronchial
epithelial cells were transfected with recombinant retroviruses expressing reporter genes
prior to seeding. Clonal expansion of individual retrovirus-marked cells was observed,
with the largest clones comprising 103-104 cells.
Which of the cell types in the lung acts as stem cells is still a source of controversy.
Ciliated cells are generally considered to be terminally differentiated and therefore are not
candidates as stem cells. The other cell types are not terminally differentiated, do not
contain cilia, and are capable of cell division to replace lost or damaged cells. There are
two views reported in the literature about which cells of the tracheobronchial epithelium
constitute stem cells. One model postulates that the basal cells act as the principle stem cell
in the conducting airways, giving rise to the various secretory cells and ciliated cells
(Blenkinsopp, 1967; Reid et al., 1979). This conclusion is largely based on cell turnover
studies of normal respiratory epithelium using [3 H]-thymidine as a marker of cell
proliferation (Donelly et al., 1982). Support for basal cells as stem cells is also derived
from an in vivo culture system for testing proliferation. Tracheal grafts were stripped of
their own epithelium and then inoculated with basal cells and transplanted subcutaneously
into nude mice (Terzaghi et al., 1978). Basal cells were discovered to be capable of
reconstituting an epithelium containing basal cells, secretory cells and ciliated cells, as
determined by light and electron microscopy (Nettesheim et al., 1990).
An alternative model postulates that the secretory cells are the pivotal cells from
which other cells develop. This model is based on studies of regeneration of chemically or
physically injured epithelium which suggest that basal cells only generate basal cells and
that the secretory cells of the trachea and bronchus are responsible for regeneration of the
rest of the epithelium (Evans et al., 1986; Keenan et al., 1982a; Keenan et al., 1982b;
McDowell et al., 1982).
Clara cells which occur exclusively in the bronchioles in mammalian species
(Jeffery et al., 1977; Kuhn et al., 1974) are rich in enzymes involved in drug metabolism
(Boyd, 1977). These cells were observed to be capable of reconstituting an epithelium in
the tracheal graft model described above (Nettesheim et al., 1990). Clara cells have also
been shown to serve as the progenitors both for themselves and for ciliated cells during the
bronchiolar epithelial differentiation in the fetus in rabbits (Plopper et al., 1991).
2.3.3 Cell kinetics
The mitotic activity of bronchial epithelium in steady-state conditions is extremely
low (Kauffman, 1980; Plopper et al., 1987). This has made routine use of the mitotic
index to estimate cell turnover difficult because there are too few mitoses for this method to
yield statistically reliable results. An estimate of human bronchial epithelial cell turnover is
possible, however. In a recent study of human lung epithelium in which over 250 lungs
were analyzed at autopsy, while no mitoses were observed, labeling with an antibody
against Ki-67 antigen permitted determination of the fraction of cells actively synthesizing
DNA (Boers et al., 1996). The proliferating fraction of all epithelial cells was
0.76±0.53%.
This number has led to some speculation about the organization of cells in the
epithelial layer. Since 0.0076 is approximately 1/128, the proliferation rate is consistent
with a model in which one cell of a "turnover unit" of 128 cells divides once per day, and
one cell in the turnover unit dies each day. This also suggests that each cell divides
approximately 3 times per year, which correlates well with the rate observed by Dr. E.
Furth (University of Pennsylvania) for colon epithelium, as described further below in the
Discussion (Alternatives to mutagenesis: Cell kinetics).
In rodents, the labeling index for bronchial epithelial cells has been determined by
injecting radioactive tracer such as [3 H]-thymidine to label cells in S phase. The results of
a number of studies are summarized in Figure 10. In general, about 1 in 1000 cells is
undergoing mitosis at any time.
2.3.4 Cells and lung cancer
Mucous secreting cells and basal cells, because they are actively dividing and
incorporate tritiated thymidine (Blenkinsopp, 1967; Evans et al., 1986), represent the most
important cells of origin for lung cancer. In one study in which one hundred human
primary lung carcinomas were classified based on the cell of origin (McDowell et al.,
1978), basal and/or mucous cells were the cells of origin for 88% of the tumors, 7% were
Fig. 10: Proliferative indices for bronchial epithelial tissues.
Results from multiple experiments to determine proliferative indices of various cell types in
the bronchial epithelium of a number of species are summarized.
Source: Shami and Evans, 1992 (for references, see Shami and Evans, 1992)
Intrapulmonary Basal Cells Proliferative Indices (%) (Trachea and Bronchi)
Cell Tissue
Animal Age Mitotic Labeling Mitotic Labeling Authors
Hamster 1 day 0.2 Blenkinsopp, 1967
3 months 0.04-0.05 0.3-1.1 Boldue and Reed, 1976
Boron and Paradise, 1978
Monkey 4-9 year 0.7 Donnelly et al., 1982
Rat 1 month 2.3 7.0 2.2 1.4 Keenon et al., 1982
3 months 0.18 Lane and Gordon, 1974
McDowell et al., 1984, 1985
Wells, 1970
Wilson, 1984
Intrapulmonary Basal Cells Proliferative Indices (%) (Bronchi)
Cell Tissue
Animal Age Mitotic Labeling Mitotic Labeling Authors
Hamster 3 month 1.5 Bolduc and Reed, 1976
Breuer et al., 1990
Rat 1 month 0.003-0.15 0.44 Evans et al., 1986
3 months 0.25
Extrapulmonary Nonciliated Cells Proliferative Indices (%) (Trachea and Bronchi)
Cell Tissue
Animal Age Mitotic Labeling Mitotic Labeling Authors
Hamster 1 day 0.2 Blenkensopp, 1967
3 month 0 02-0.1 Bolduc and Reid, 1967
Boron and Paradise, 1978
Rat 1 month 0.9 0.9 Dennelly et al., 1982
3 months 0.1
Intrapulmonary Nonciliated Cells Proliferative Indices (%) (Bronchi)
Cell Tissue
Animal Age Mitotic Labeling Mitotic Labeling Authors
Hamster 3 months 1.0 Bolduc and Reid, 1967
Breuer et al., 1990
Rat 1 month 0.05-0.07 Evans et al., 1986
3 months 0.05
Intrapulmonary Bronchiolar Cells Proliferative Indices (%) (Clara Cells)
Cell Tissue
Animal Age Mitotic Labeling Mitotic Labeling Authors
Hamster 12 months 0.16 Castleman et al., 1980
Eustis et al., 1981
Monkey 2-7 years 0.1 Evans et al., (1976, 1977, 1978, 1982)
Hacket (1979, 1983)
Mouse 3 months 0.3 Lum et al., 1978
Shami et al., 1982, 1986
Rat 1 month 0 2-1.1
3 months 0.1-1 1
11 months 0.1
19 months 0.2
25 months 0.8
derived from neurosecretory cells, 1 tumor (1%) was attributed to Clara cell origin, and 4%
were unclassified.
2.4 SMOKING
2.4.1 Age-specific lung cancer rates
A close association between cigarette smoking and lung cancer has been thoroughly
documented (Doll et al., 1976; General, 1989; Hammond, 1966; IARC, 1986; Wynder et
al., 1950). In order to better understand the relationship between smoking and lung
cancer, P. Herrero of the W. Thilly laboratory has compiled the probability of lung cancer
death for individuals residing in the United States since 1900 as published in Mortality
Statistics (1900-1936) and Vital Statistics of the United States (1937-1992). Lung cancer
incidence was plotted by year of birth. Shown in Figure 11A and 11B are the number of
cases of lung cancer death per 100,000 persons per year for both European American males
and females by birth year. A significant increase in the incidence of lung cancer is apparent
among those born in more recent cohorts for both males and females, a shift that is
hypothesized to reflect the widespread influence of smoking. Further, the rise in male
deaths occurred in earlier birth cohorts than in females, which may mirror the earlier rise in
smoking prevalence among men than women. These hypotheses are substantiated by
Figures 11C and 11D. Figure 11C provides the probability of death by lung cancer in men
and women between 60 and 64 years of age as a function of birth year. Figure 11D
represents the fraction of each birth year cohort which reported substantial cigarette
smoking. The relationship between cigarette use and lung cancer death is supported by the
similarity of the curves. For both lung cancer mortality and cigarette smoking prevalence,
there is an approximately 30 year difference between the increase in men and in women.
2.4.2 Smoking and lung cancer
The public health significance of lung cancer is clear: lung cancer is currently the
leading cause of cancer death in the United States. Lung cancer is also the most common
cause of death from cancer worldwide. In 1994, there were an estimated 400,000 deaths
from lung cancer in the U.S. alone, which represented 30% of all cancer deaths (Boring et
al., 1994). The total national cost of smoking in 1994 was $20.8 billion in direct health
care costs, $6.9 billion in premature disability and $40.3 billion in premature death
(McFarling, 1994). In 1912, before widespread use of cigarettes, only 374 cases of lung
cancer had ever been reported in the medical literature. Overall survival statistics for lung
cancer are exceedingly poor: fewer than 8% of patients are alive 5 years after diagnosis.
In the 1950s the British Doctors' Study demonstrated that an increased risk of death
from lung cancer is associated with smoking, a finding fully substantiated in the 1979
Report of the Surgeon General on Smoking and Health. The study's conclusions included
the following observations: Cigarette smokers taken as a whole are at an approximately 10-
fold greater risk of lung cancer than nonsmokers. A close correlation exists between the
risk of lung cancer and the number of cigarettes smoked per day. The increase in relative
risk is 20-fold for those who smoke two packs or more per day. In addition to the Surgeon
General's report, several large epidemiological studies demonstrated a clear dose-response
relationship between smoking and lung cancer; these results are summarized in Figure 12.
Lung cancer is comprised of three major histological types: squamous cell
(epidermoid) carcinoma, small cell carcinoma, and adenocarcinoma. Kreyberg and Doll
hypothesized in the 1950's that squamous and small cell tumors were related to smoking
while adenocarcinomas were not as closely associated (Doll et al., 1957; Kreyberg, 1955).
More recent studies have reported that adenocarcinomas are also associated with smoking
(Weiss et al., 1972).
Fig. 11: Age-specific lung cancer rates.
Number of cases of lung cancer death per 100,000 people for European American males
(A) and European American females (B) by birth year. (C) Number of lung cancer deaths
per 100,000 individuals for 60-64 year old male and females by birth year. (D) Fraction of
US cigarette smokers by birth year.
Source: Pablo Herrero compiled from Mortality Statistics (1900-1936) and Vital Statistics
of the United States (1937-1992) and Harris, 1983.
600
500
S400
-4(
300
r 200
0 100
0
180
0 150
120
0 90
60v 60
O
30
00 25 50 75 100
Age (years)
-- 1830s --o--1840s ---e 1850s ---- 1860s
- 1870s x 1880s - -- 1890s -- a--1900s
--4-- 1910s ---a-- 1920s ---A-- 1930s ---o-- 1940s
-- *-- 1950s
'I
a' Au
'I
25 50 75 100
Age (years)
Birth Years
300 - Males 60-64
| Females 60-64i
o 250 -
0200
r-4
150 -
100
O 50
1860 1880 1900
Birth Year
1920
i 0.8
S0.6
n 0.4
S0.2
1860 1880 1900 1920
Birth Year
1940
Fig. 12: Correlation between smoking and lung cancer risk.
Results of four large epidemiological studies are summarized with respect to lung cancer
risk as a function of cigarette dose. In the accompanying table, the methods used in each of
the studies is summarized.
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Lung tumors originate from bronchial epithelial cells of the upper airways,
generally within the first few generations of airways, however the location depends upon
the tumor type. Adenocarcinomas tend to occur at approximately the third generation of the
airway while squamous and small cell carcinomas tend to occur within the first and second
(Kvale et al., 1976). Bronchoalveolar carcinomas, a distinct tumor type, occur very
peripherally, and are thought not to be related to smoking. Ashley and Davies (1967) found
that smoking was as closely associated with adenocarcinomas as with other types of lung
cancer and concluded that a tumor's histological type depended entirely upon which part of
the respiratory tract was affected (Ashley et al., 1967).
2.4.3 Mutagenicity of selected components of cigarette smoke
2.4.3.1 Benzo[a]pyrene (BaP)
Benzo[a]pyrene is a ubiquitous polycyclic aromatic hydrocarbon mutagen and
carcinogen found in cigarette smoke, atmospheric pollution and a variety of foods (IARC,
1986). The estimated daily exposure to BaP from different sources is 400-800 ng/day for
20 cigarettes; 10,000 ng per charcoal-broiled steak; 9-40 ng/day from ambient air; and 1
ng/day from drinking water (El-Bayoumy, 1992; Agency for Toxic Substances and Disease
Registry, 1993)
BaP is metabolized in vivo into chemically reactive intermediates which can then
react with cellular macromolecules including DNA (Brookes et al., 1964; Gelboin, 1969).
The 7,8-diol-9,10-epoxide (BPDE) is the most active metabolite of benzo[a]pyrene in terms
of binding to DNA (Ivanovic et al., 1976; Meehan et al., 1976; Sims et al., 1974),
mutagenicity in Chinese hamster ovary cells (Wood et al., 1977), and tumorigenic activity
in mice (Buening et al., 1978; Kapitulnik et al., 1977). Newborn mice treated with the
most active diastereomer of the diol epoxide developed an average of 4.42 pulmonary
adenomas per mouse, as compared with an average of 0.13 lung tumors per mouse in
vehicle-treated controls (Kapitulnik et al., 1978).
The major adduct formed when BPDE reacts with DNA in vitro is the adduct at the
N2 position of guanine (Straub et al., 1977; Weinstein et al., 1976), although adduction at
the N7 position of guanine and the N2 position of adenine also occur at a considerable
frequency.
When 185 nonsense mutations in the lacI gene of E. coli induced by BPDE were
investigated, GC->TA transversions were the most frequently observed type of mutation
(Eisenstadt et al., 1982). This led to the suggestion that an abasic intermediate may be
important in BaP-induced mutagenesis, or that rotation of a modified N2 -guanine around
its glycosylic bond could result in mispairing. In addition to studies of the lacI gene,
several subsequent studies have concluded that GC->TA mutations are induced by
benzo[a]pyrene diol epoxide. These studies used as targets a shuttle vector replicated in
either human cells (Yang et al., 1987) or in monkey cells (Roilides et al., 1988), and
BPDE-treated plasmids replicated in bacteria (Chakrabarti et al., 1984). BPDE-induced
mutations have also been analyzed in the endogenous aprt gene in Chinese hamster ovary
cells (Mazur et al., 1988) and the hprt gene in human cells (Chen et al., 1990; Yang et al.,
1991). The mutants analyzed in all of these studies were predominantly GC->TA
transversions.
Benzo[a]pyrene has been used as a model compound in an experiment designed to
determine the effect of dose rate on mutational spectra (Chen et al., 1996). Using a
combination of en masse treatment with benzo[a]pyrene, selection for hprt mutants with 6-
thioguanine, PCR and denaturing gradient gel electrophoresis (DGGE), the mutational
spectrum induced by benzo[a]pyrene treatment of a human cell line containing the
metabolizing enzyme aryl hydrocarbon hydroxylase (although not the epoxide hydrolase)
was determined. Duplicate cultures were treated with a single toxic exposure of 30 gM for
28 hours, a nontoxic exposure of 0.5 gM for 6 days, and an exposure approximating
estimates of BaP concentration in the human lung of 20 nM for 20 days. The mutational
spectra were critically dependent upon the conditions of exposure. While the long-term,
low-dose and toxic dose treatments induced mainly GC->TA mutations, the intermediate
dose treatment induced two AT->TA mutations and a 7 bp deletion.
2.4.3.2 Tobacco-specific nitrosamines
Another class of potent mutagenic compounds in tobacco smoke are the tobacco-
specific nitrosamines which are formed by nitrosation of nicotine during tobacco
processing (Burton et al., 1989). The amount of several N-nitroso compounds in
cigarettes has been measured. In main stream cigarette smoked, there is 0.08-0.77 ng per
cigarette of N-(methylnitrosamino)- 1-(3-pyridyl)- 1-butanone (NNK), 0.2-3.7 ng/cigarette
of N-nitrosonornicotine (NNN), and 0-0.15 ng/cig of NAB (N'-nitrosoanabasine) (IARC,
1986).
N-nitroso compounds produce tumors in up to 40 animal species (Bogovski et al.,
1981). They display unusual species, organ and cell specificity and a wide variety of
genetic effects. NNK is a highly potent carcinogen in mice, rats and hamsters, and is
specific for lung tissues (Hecht et al., 1988). The compound requires activation by
cytochrome p-450 to exhibit its mutagenic and carcinogenic properties (Crespi et al., 1991;
Hecht et al., 1988). The initial and crucial step of this activation is a-hydroxylation of the
two carbons bound to the N-nitroso group to form reactive electrophilic species (see Figure
13). Several cytochrome P-450 isozymes have been associated with the metabolic
activation of NNK including P-450 2B1, 1Al, 1A2, 2D6 and 2E1 (Crespi et al., 1991;
Devereux et al., 1988).
The compound 4-(methylnitrosamino)- 1-(3-pyridyl-N-oxide)- 1-butanol- (NNAL-)
glucoronide, a metabolic byproduct, has been detected in the urine of all of the over 100
smokers analyzed to date, but not in nonsmokers who have not been exposed to passive
environmental tobacco smoke. In one study, amounts of NNAL-glucuronide ranged from
0.16 to 19.0 pmol/mg creatinine, levels consistent with the amounts of NNK reported in
mainstream cigarette smoke (Carmella et al., 1995).
Activated NNK can methylate and pyridyloxobutylate purine bases of DNA (Hecht
et al., 1980; Murphy et al., 1990). Methyl and pyridyloxobutyl adducts have been detected
in DNA of tissues from animals treated with NNK (Belinsky et al., 1986; Hechts et al.,
1988). Analysis of mutations in the K-ras gene isolated from tumors in A/J mice treated
with NNK showed a high prevalence of GC->AT transitions in the second base of codon
12 (GGT->GAT), which is consistent with the expected mutation induced by 0 6 -
methylguanine (Belinsky et al., 1992; Belinsky et al., 1989; Ronai et al., 1993). Activated
K-ras genes with mutations in codon 12 have been detected in 16% of human lung tumors
and in 24% of adenocarcinomas of the lung (Rodenhuis et al., 1992). However, the types
of K-ras mutation observed most frequently in human lungs is GGT->TGT (58%), which
is not the specific mutation observed in NNK-treated mice. The NNK-induced GGT-
>GAT mutation represents is observed in 19% of the tumors with K-ras codon 12
mutations.
The mutational specificity of NNK has also been investigated in a mammalian cell
system expressing a human cytochrome p450 2A6 and containing the guanine
phosphoribosyl transferase gene as a target for mutagenesis (Tiano et al., 1994). A dose-
dependent increase in cytotoxicity and mutant frequency was observed upon treatment with
NNK, but only in a cell line containing the p450 2A6 enzyme. At the highest NNK dose
(1200 gg/ml), the mutant fraction (339 x 10-6) was 14-fold greater than the spontaneous
mutant fraction (24 x 10-6). Among 98 mutant clones analyzed by PCR, 21 contained
deletions/rearrangements and 77 were putative point mutants. Sequencing showed that
81% of the point mutants were GC->AT transitions and four of the six most frequently
Fig. 13: NNK metabolism
NNK metabolism pathways, as determined in rodents and primates. Compounds in
brackets are postulated intermediates.
Source: Hecht, 1996.
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mutated positions were at the second G of a GGT motif, which is the type of mutation and
the sequence context of the mutation discovered in codon 12 of K-ras in treated mice.
2.4.3.3 Cigarette smoke condensate
The first report of in vitro genotoxic activity caused by an aqueous fraction of
cigarette smoke particulate matter, cigarette smoke condensate (CSC), was in onion root-
tips (Venema, 1959). A 0.04 ppm fraction induced chromosome lagging, "sticky"
chromosomes, and acentric fragments after only two hours, the severity of which increased
after four hours. Leuchtenberger and Leuchtenberger later extended these observations to
the gaseous phase of cigarette smoke (Leuchtenberger et al., 1970). Kier and colleagues
were the first to demonstrate the ability of CSC to induce point mutations. In the
Salmonella typhimurium microsomal test, the condensates from several types of cigarettes
induced frameshifts in the presence of liver or lung microsomal enzymes (Kier et al.,
1974). The CSC from just one-hundredth of one cigarette per plate produced detectable
mutagenicity.
There are two reports in the literature of increased mutant fractions in mammalian
cells after treatment with cigarette smoke condensate. Both Clive and colleagues and
Mitchell and colleagues reported dose-response relationships between mutagenicity and
exposure to cigarette smoke condensate in L5178/TK+ / - mouse lymphoma cells.
However, the cloning efficiency of the cells declined as the mutant fraction increased, so
that the product of survival and mutant fraction was similar at different doses. Such
findings suggest that the induced mutant fractions may be an artifactual result of decreased
cloning efficiency because, as discussed previously, the presence of wild-type cells may
suppress the recovery of mutants in the HPRT assay and the effect is heightened in samples
with high cloning efficiency (Khaidakov et al., 1996). The short period of time elapsed
between treatment with Aroclor stimulated rat liver homogenate and plating (just 2 hours)
suggests that the cells may not have retained the cloning efficiency of control cells as would
be necessary in such an experiment.
In a more recent experiment Charles Crespi and Bruce Penman of Gentest
Corporation (Waltham, MA) treated a number of cell lines expressing different cytochrome
p450s with cigarette smoke condensate and did not observe a statistically significant
increase in mutant fraction in any of the lines (B. Penman, personal communication).
2.4.4 Smoking and DNA adducts
2.4.4.1 Smoking-induced adducts
Several studies have reported an increase in the level of aromatic DNA adducts in
lung tissue from human surgical specimens or autopsy material based on the 3 2 p
postlabeling assay (Cuzick et al., 1990; Phillips et al., 1990; Randerath et al., 1989;
Wiencke et al., 1995). In one study by Philips and colleagues, the significance level
reached p<0.01 and the values were 5.53±2.13 adducts per 108 nucleotides for smokers
versus 3.45±1.62 adducts per 108 nucleotides for nonsmokers (Phillips et al., 1990). In a
separate study, purified DNA from human lung and several other organs was analyzed for
DNA adducts using the nuclease P1 modification of the 32 P postlabeling technique (Cuzick
et al., 1990). Lung was the only organ for which a statistically significant increase in
adduct levels in smokers was observed. Adduct levels in lungs of current smokers were
9.3±6.5 adducts per 108 nucleotides; in ex-smokers, 6.0±4.2 adducts per 108 nucleotides
and in non-smokers, 2.5±2.3 adducts per 108 nucleotides.
DNA adduct profiles have also been examined from bronchial biopsies obtained
from 78 individuals undergoing routine diagnostic bronchoscopy (Dunn et al., 1991).
Lung cancer was present in 37 (47%) of the patients. 3 2 P postlabeling chromatograms
from all of the smokers (n=28) showed a distinctive diagonal adduct zone which was
present in 24 of 40 ex-smokers and 4 of 10 lifetime non-smokers. Adduct levels and
chromatographic patterns were similar in bronchial tissue from different lobes of the lung,
and in tumor and nontumor tissue taken from the same patient. Adduct levels were not
correlated with cancer independent of smoking.
A different conclusion about regional variability within the lung was reached by
Weston and Bowman (Weston et al., 1991). BPDE-adducted nucleotides were purified by
immunoaffinity chromatography and the major product was detected by fluorescence
spectroscopy. Levels of BPDE-DNA adducts in the range of 1-40 in 108 nucleotides were
detected in 6 out of 25 samples. Adduct levels varied significantly among different parts of
the same lung. In one particularly extreme case, BPDE adduct levels were 35 attamole
BPDE/Rg DNA in one section of the lung and 1215 attamoles BPDE/gg DNA in another
section.
Studies of adduct levels in smokers and nonsmokers have also been performed in
peripheral blood. Several studies of leukocyte DNA have shown an association between
polycyclic aromatic hydrocarbon (PAH)-DNA adduct levels and smoking measured by
ELISA (Kriek et al., 1993; Liou et al., 1989). Other studies have not demonstrated a
statistically significant relationship between adducts and smoking by either ELISA or 3 2 p
postlabeling (Jahnke et al., 1990; Perera et al., 1989; Van Schooten et al., 1992). An
association between smoking and PAH adducts was observed with both ELISA and 3 2 p
postlabeling using the longer-lived lymphocyte/monocyte fraction of white blood cells
(Santella et al., 1992; Savela et al., 1991). In another study, a significant reduction in
mean PAH-DNA adduct levels in leukocytes was observed after 8 months of smoking
cessation (p<.05) (Mooney et al., 1995). The mean PAH-DNA adducts for all 40 subjects
was 2-fold higher while smoking [8.3±8.8 adducts/10 8 nucleotides (n=40)] than 8 months
after cessation [4.0±4.1 adducts/10 8 nucleotides (n=35)].
Increased levels of adducts other than polycyclics have also been reported in
smokers. Two studies have reported significant differences between smokers and non-
smokers in levels of the alkylated base N7 -methylguanine. In one report, mean levels of
N7 -methylguanine were 6.9 per 107 nucleotides in total white blood cells, 4.7 per 107
nucleotides in granulocytes and 23.6 per 107 nucleotides in lymphocytes of smokers,
compared with values of 3.4, 2.8 and 13.5 per 107 nucleotides in nonsmokers (Mustonen
et al., 1992). A second study analyzed N7 -methylguanine in bronchial DNA samples and
found mean levels of 17.3 adducts per 107 nucleotides in smokers and 4.7 adducts per 107
nucleotides in nonsmokers (Mustonen et al., 1993). It has also been reported that smoking
induces oxidative adducts based on an observed 50% increase in 8-OH-dG lesions in
sperm DNA samples from smokers (Fraga et al., 1996).
As discussed in the section on DNA repair in mitochondrial DNA, repair of these
adducts is expected to differ between mitochondrial and nuclear DNA. While adducts
recognized by base excision repair machinery including oxidative damage (Driggers et al.,
1993) and alkylation are expected to be repaired (LeDoux et al., 1992), large, bulky
adducts including aromatic amines and polycyclic aromatic hydrocarbons would not be
expected to be repaired (Clayton et al., 1974).
2.4.4.2 Smoking and adducts in mitochondrial DNA
The extent of DNA damage in mitochondrial DNA has also been reported to be
significantly higher in bronchoalveolar lavage tissues from smokers as compared with
nonsmokers (Ballinger et al., 1996). In this study, DNA damage was assessed by
measuring the amount of PCR product created when defined amounts of template were
used for long template PCR (16,262 bp for mitochondrial DNA and 13,458 bp for nuclear
DNA). The absence of PCR product was interpreted to reflect damage to the template DNA
that inhibited synthesis by the polymerase. A significant increase was observed in the level
of DNA damage in smokers as compared with nonsmokers for a nuclear gene (p=0.0056),
and an even larger difference between smokers and nonsmokers was observed for long
template PCR on the mitochondrial genome (p=0.00072). In another study employing
synchronous fluorescence spectrophotometry, Balansky and colleagues detected increased
levels of DNA adducts in mitochondrial DNA of lung tissue in rats exposed to mainstream
cigarette smoke (Balansky et al., 1996)
2.4.5 Smoking and mutations
2.4.5.1 Smoking-induced mutational spectra
A smoking-related increase in the frequency of peripheral T lymphocytes containing
mutations in the hypoxanthine-guanine phosphoribosyl transferase (hprt) gene has been
demonstrated by several laboratories (Albertini et al., 1988; Ammenheuser et al., 1994;
Cole et al., 1988; Jones et al., 1993). Cole and colleagues, for example, have carefully
analyzed experimental factors and donor attributes that affect hprt mutant fractions in blood
(Cole et al., 1988). In this study, smoking (range: 5 to >30 cigarettes per day) caused an
estimated 56% increase in mutant frequency (p<0.001). Jones and colleagues also found
that years smoked was an important determinant of hprt mutant fraction in T-lymphocytes
from 62 smokers and 58 nonsmokers (Jones et al., 1993). In a study of 11 smokers and
12 non-smokers, Htittner and colleagues observed that the mean variant frequency in
smokers was significantly higher (70%) than that in non-smokers (Hiittner et al., 1990).
Tates and colleagues reported that the mean mutant fraction for smokers was 36% higher
than for nonsmokers (Tates et al., 1991). This difference was statistically significant only
if mutant fractions were adjusted for cloning efficiency. Other studies have not reported an
increased mutant fraction in smokers [for instance, (Davies et al., 1992)].
The influence of smoking on mutant fraction has also been studied for the
glycophorin A (GPA) gene, which codes for the M and N blood group erythrocyte cell
surface antigens (Langlois et al., 1993). The 50% of the population with a MN blood
phenotype are suitable for analysis. This phenotype results from codominant allelic
expression at the GPA locus, thus permitting independent detection of nonlethal null
mutations in either the M or the N allele. Using this approach, a small, not statistically
significant smoking effect of a 20% increase in the fraction of singly labeled cells was
reported in one study (Bigbee et al., 1989), while no correlation of mutant fraction with
smoking was observed in another study (Jensen et al., 1995).
In addition to testing for effects on mutant fraction, it is also possible to sequence
individual hprt clones to determine whether smoking affects the specific mutations present.
In one study, T-lymphoctyes from nine adult smokers (2 15 cigarettes per day) and 12 age-
matched controls were plated. 6TG r clones were isolated, and hprt mutations were
identified by reverse transcriptase-PCR and sequencing. Vrieling and colleagues
discovered an elevated mutant fraction in the smokers but did not discern a difference in the
relative frequency of mutation types in the smokers and nonsmokers (Vrieling et al., 1992).
In both smokers and nonsmokers, transitions accounted for approximately 15% of the total
mutations; transversions for about 20%; exon skipping for approximately 45%; and
deletions and frameshifts for almost 20%. GC->TA transversions, the mutations frequently
observed among benzo[a]pyrene diol epoxide-induced mutations in human cell culture
(Keohavong et al., 1992), was not detected in smokers.
Burkhart-Schultz and colleagues reported the sequences of 28 mutations in the hprt
gene from smokers and nonsmokers. They concluded that there was a suggestion (p=0.2
by chi-squared analysis) of more mutations at AT base pairs in smokers (6/14) than
nonsmokers (2/14) (Burkhart-Schultz et al., 1993).
A. Tomita of the W. Thilly laboratory has analyzed a database of all reported hprt
mutations (Cariello, 1996) in order to discover whether smokers' hprt mutations differ
significantly from those of nonsmokers. She compared the set of smokers' somatic
mutations to the set of nonsmokers' somatic mutations divided into three categories:
deletions, other alterations and insertions. The smokers were significantly different from
the nonsmokers based on a chi-squared analysis at the level of p<0.01, due largely to an
increase in the relative number of point mutations (126/205 for smokers versus 107/212 for
nonsmokers). When the types of point mutations were considered separately, the
frequency of GC->TA mutations were elevated significantly in smokers compared with
nonsmokers at the level of p<0.05 but not p<0.01 (15/97 mutations in smokers and 8/88
mutations in nonsmokers). In conclusion, there is some evidence that smoking leads to an
increase in mutant fraction of approximately two-fold in nuclear sequences but a smoking-
induced mutational spectra has not been characterized.
2.4.5.2 Smoking-induced deletions of mitochondrial and nuclear DNA
The ability of cigarette smoking to cause deletions has also been investigated. One
study utilized mouse embryos homozygous for the pink-eyed unstable (pun) mutation
which is the result of duplication of a 70 kb internal fragment of the mouse p gene.
Spontaneous reversion events occur through recombination-mediated deletion of one copy
of a duplicated sequence. Reversion events in premelanocytes in the mouse embryo give
rise to black spots on the gray fur of the offspring. Both whole body exposures of
pregnant pun mice to cigarette smoke for 4 hours and treatment with a 15 mg per kg dose
of cigarette smoke condensate during their 10th day of gestation led to a significant increase
in the number of DNA deletions in the embryos as evidenced by spotted offspring (Jalili et
al., submitted). A concentration of 31±2 mg per m3 of total particulate matter raised the
spotting frequency from the control value of 12.6% to 23.3% (p_0.05), while exposures at
96±15 mg/m 3 resulted in 28% of offspring showing spots (p_0.05).
Whether smoking induces mitochondrial deletions has also been directly addressed.
Ballinger and colleagues (1996) examined the levels of the 4.9 kb common deletion in
alveolar macrophages. Smokers contained almost 7 times the level of the common deletion
as compared with nonsmokers (0.016 versus 0.0023%), although the differences were not
statistically significant because interindividual values were large.
In another study, the levels of the 4.9 kb common deletion, a 7.4 kb deletion and
tandem duplication in the D-loop region were investigated in hair follicles from 213 male
nonsmokers and 74 male smokers (Liu et al., 1997). Current smokers had a 3.1-fold
higher average incidence of the 4.9 kb deletion as compared with nonsmokers (p<0.001).
No dose-response relationship was observed with the amount of smoking; the heaviest
smokers had lower levels of deletions than light smokers (see Figure 14). No statistically
significant relationship was observed between the incidence of the 7.4 kb deletion or
duplicated mtDNA and the smoking index. Intriguingly, a significant difference between
lung cancer patients and controls was observed for the proportion of the 4.9 kb deletion.
In lung cancer patients with high smoking indices, the deleted mtDNA represented 1.2% of
hair follicle mtDNA while among healthy subjects with the same smoking index, the
proportion was 0.15%.
2.4.5.3 p53 mutations in lung tumors
Sequencing the p53 gene in human lung tumors has provided some evidence that
smoking may induce mutations in human lungs. As opposed to most tumors, for which
GC->AT transitions, mainly at CpG sites, predominate, GC->TA transversions are the
mutation type most frequently observed in lung tumors of smoking subjects (Husgafvel-
Pursiainen et al., 1996; Jones et al., 1992). The difference between the types of mutations
Fig. 14: Proportions of the common deletion with age, smoking index, and lung cancer
status
Comparison of the proportion of the 4,977 bp deleted mtDNA in the hair follicles of
subjects in three age groups (A, B, and C) with different grades of smoking index. Bars
reflect the proportion (mean ± S.E.M.) of the 4,977 bp deleted mtDNA. Smoking index =
(cigarettes smoked per day) x (years of smoking). (D) Comparison of the proportion of the
4,977 bp deleted mtDNA in the hair follicles of mild (smoking index within 400) and heavy
(smoking index greater than 400) smokers in normal subjects and lung cancer patients,
aged between 40 and 70 years.
Source: Liu et al., 1997
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in smokers' lung tumors and those observed in other organs suggests that tobacco smoke
may be specifically inducing the GC->TA mutations observed. While there are many
mutagenic compounds in tobacco smoke, it is worth noting that, as described previously,
GC->TA mutations are the predominant type induced by certain polycyclic aromatic
hydrocarbons, including metabolically activated benzo[a]pyrene (Chen et al., 1990;
Eisenstadt et al., 1982; Keohavong et al., 1992; Mazur et al., 1988).
A recent report on the formation of benzo[a]pyrene adducts in the p53 gene of HeLa
and bronchial epithelial cells also provides evidence that supports the hypothesis that
benzo[a]pyrene induces the mutations observed in the p53 gene in smokers' lung tumors
(Denissenko et al., 1996). Denissenko and colleagues treated bronchial epithelial cells with
4 mM benzo[a]pyrene diol epoxide (BPDE) for 30 minutes. The distribution of adducts in
p53 was determined by cleavage with an enzyme complex that digests specifically at
adducted sites, the UvrABC nuclease, followed by ligase mediated PCR. The hotspots for
BPDE-induced adducts were at the same positions that represent hotspots for p53
mutations in human lung tumors. While adduct spectra are not necessarily synonymous
with mutational spectra [see for instance (Fuchs, 1984)], the dose of BPDE was
significantly higher than the biologically relevant dose (Chen et al., 1996), and mutations in
p53 have not been demonstrated to be the initiating mutations in lung tumors, nevertheless,
the study does put forth a plausible mechanism by which smoking could induce lung
tumors via mutations.
3. MATERIALS AND METHODS
3.1 HUMAN CELLS AND TISSUES
3.1.1 TK6 cells
TK6 cells (Skopek et al., 1978) and MT-1 cells (Goldmacher et al., 1986), a
derivative of TK6 deficient in mismatch repair (Kat et al., 1993), were maintained in
exponential growth as spinner cultures by daily dilution with RPMI-1640 media (Gibco
BRL, Grand Island, NY) supplemented with 10% horse serum (Gibco BRL) at densities
not exceeding 106 cells/ml. TK6 cells were grown for more than 400 generations.
3.1.2 Human Samples
Brush biopsies obtained through bronchoscopy were collected from 8 healthy
volunteers who gave informed consent. The protocol was approved by the Research
Subjects Review Board at the University of Rochester and the Committee on Use of
Humans as Experimental Subjects at MIT. Procedures were performed at the University of
Rochester. Subjects were free of significant respiratory or cardiovascular disease
determined by medical history and physical examination.
Among the volunteers were 3 pairs of monozygotic twins recruited from the
Minnesota Twins Registry (Lykken et al., 1990) who were discordant for smoking. For
each pair of twins, one was a lifelong nonsmoker while the other had a >10 pack-years
smoking history. Twins were all females, 46-54 years old. The other bronchoscopy
volunteers were a 28 year old male and a 24 year old female, both of whom were smokers.
Whole lungs were harvested from organ donors at the University of Rochester
Medical Center or Brigham and Women's Hospital. Procedures were approved by the
Research Subjects Review Board at the University of Rochester, the Committee on Use of
Humans as Experimental Subjects at MIT and the Institutional Review Board of Brigham
and Women's Hospital. Informed consent was obtained from the next of kin. Lungs were
obtained immediately post-mortem and were free of diseases affecting the upper respiratory
tree. Two smokers' lungs (one 47 year old female and one 58 year old male), each of
whom smoked two packs per day at the time of death, and one nonsmoker's lung (an 84
year old male) were available.
The lungs of an infant who died of sudden infant death syndrome (SIDS) were
harvested and dissected by Dr. James Willey and his colleagues at the Medical College of
Ohio (Toledo, OH).
3.1.3 Biopsies obtained via brush bronchoscopy
Subjects were premedicated with 0.75 mg of atropine intravenously prior to the
procedure. The oropharynx was topically anesthetized with atomized lidocaine. A
fiberoptic bronchoscope (PVA-1000 Pentax, Tokyo) with video capability was inserted
orally. The vocal cords were topically anesthetized with lidocaine. The bronchoscope was
then advanced to the airways. After gently wedging the bronchoscope in a subsegment of
the lingula, four 50 ml aliquots of sterile normal saline were instilled and withdrawn under
gentle suction. Brush biopsies were then obtained from eight positions within the first
three bifurcations of airway: the right main carina, the first bifurcation of the right upper
lobe, the first bifurcation of the right lower lobe, the second bifurcation of the right lower
lobe, and the corresponding positions on the left side. After each biopsy, the brush was
gently shaken in 3 ml of sterile phosphate buffered saline (PBS) on ice. Each position was
brushed twice. Cells were pelleted and resuspended in 10 gl PBS. Each brush yielded 3 x
105 to 2 x 106 cells, of which about 95% were epithelial cells based on differential counts
performed on cytospin slides.
3.1.4 Lung dissection
For each lung, the airways were dissected intact from the surrounding parenchyma.
The bronchial tree was preserved from the trachea to approximately the sixth bifurcation of
airway. The airways of the bronchial tree were divided into sections at each bifurcation.
Each sample was rinsed with media [(LHC-8 (Biofluids, Rockville, MD) or RPMI 1640
(Gibco BRL, Grand Island, NY)] in a petri dish. Epithelial cells were obtained from each
section by slicing the segment to open the lumen, then gently scraping the lumenal surface
with a scalpel. Cells were pelleted by gentle centrifugation at 4000 x g for 3 minutes, and
then resuspended in a small volume suitable for DNA isolation. Microscopic verification
confirmed that the cells obtained in this manner were indeed epithelial in origin. The
number of cells obtained from each section ranged from 105 to 107.
3.1.5 Other organs
Surgical discard samples of colon and muscle were generously provided by Dr. S.
Singer of the Brigham and Women's Hospital. Brain tissue genomic DNA from a 100 year
old man and heart muscle genomic DNA from a 77 year old individual were generously
provided through a collaboration with Drs. J. Wei and J. Vijg (Harvard Medical School
and Beth Israel Hospital).
3.2 MUTATIONAL SPECTRA
3.2.1 DNA isolation and restriction digestion
DNA was isolated from suspended cells or macerated tissue by digestion with
proteinase K (1 mg/ml) and RNAse A (0.1 mg/ml) in 0.5% SDS followed by ethanol
precipitation of DNA. DNA prepared from bronchial epithelial cells in this way was easily
restricted and amplified. The method provided high DNA yields from 105 to 109 cultured
cells or from milligrams to grams of tissue. DNA was digested with RsaI, which
recognizes base pairs 10,009-10,012 of the mitochondrial genome, and DdeI, which
recognizes base pairs 10,227-10,231 (New England Biolabs, Beverly, MA) at 2 units/tg
DNA, overnight.
3.2.2 Constant denaturant gel electrophoresis
Constant denaturant gel electrophoresis (CDGE) can be used to separate DNA
sequences containing a high melting domain adjacent to a low melting domain based on the
sequence of the low melting domain (Hovig et al., 1991). Due to the cooperative melting
of DNA as melting domains (Fischer et al., 1983; Poland, 1974), sequences with even a
single base pair substitution in the low melting domain will have a higher or lower melting
temperature as compared with wild-type, and therefore will be separable on a CDGE. DNA
sequences containing mutations that convert AT base pairs present in the low melting
domain into GC base pairs will have a higher melting temperature (Tm) than wild-type, and
will consequently migrate more rapidly through a gel under partially denaturing conditions.
Sequences with mutations that convert GC base pairs to AT base pairs will have a lower
melting temperature than wild-type and will migrate more slowly under partially denaturing
conditions.
The electrophoretic mobility of a DNA fragment with a biphasic melting profile
decreases with increased temperature following a sigmoid curve (see Figure 15). The
temperature near the midpoint of the sigmoid curve of the wild-type fragment is desirable
for CDGE separations as it will ensure separation of high and low Tm mutants.
CDGE gels were cast as 8% acrylamide, 1/40 bis-acrylamide, TAE (40 mM Tris
Acetate, 1 mM EDTA), 0.4 mm thick. During separation, the gels were submerged in a
tank containing TAE heated to a temperature around 700 C that was precisely selected based
on test gels to optimize separation. Samples of 4-6 tgl of a restriction digestion were loaded
and separated for 2 hours at 10 V/cm.
Fluorescein-labeled markers and samples were separated in alternating parallel
lanes. The markers were a mixture of PCR amplified hprt exon 3 wild-type and mutant
homoduplexes and heteroduplexes with melting temperatures similar to those of the
mitochondrial DNA mutants to be detected. One lane of each gel contained a second marker
which was the wild-type target mitochondrial sequence with an altered high melting domain
primer (J50). The melting behavior of this sequence was indistinguishable from that of the
normal wild-type sequence, but it could not be amplified with the primers used for
subsequent PCR. This primer was designed as such to avoid contamination of the tissue
samples (the number of target sequence copies in a marker lane is three orders of magnitude
higher than in the sample lane). The marker bands were visualized by illuminating the gel
with a 488 nm argon laser (Idaho Technology, Salt Lake City, UT) and marked while
viewing the gel through a 520 nm low pass glass filter (Oriel, Stratford, CT). The relative
positions of the markers provide information on the exact position to which the desired
mitochondrial mutants migrated in the gel.
Homoduplexes with higher and lower melting temperatures than wild-type were
excised from the gel from positions below and above the wild-type, respectively. High Tm
mutants were enriched by this procedure approximately 100 to 200-fold and low Tm
mutants about 5 to 10-fold.
The gel slices were finely ground between two glass slides and transferred into 1.5
ml test tubes containing 200 pl of 200 mM NaCl. DNA was eluted by shaking for 20
minutes at 500 C, 1300 min-1. Gel particles were spun down, and the supernatant was
collected. The DNA was precipitated with two volumes of ethanol and dissolved in about
15 gl of water.
3.2.3 High-fidelity PCR
PCR was performed in 10 gl capillaries in an air thermocycler (Idaho Technology,
Idaho Falls, ID) with native Pfu thermostable DNA polymerase (Stratagene, La Jolla, CA).
The PCR mix included 10 mM KC1, 6 mM (NH4)2SO4, 20 mM Tris-HCl (pH 8.0), 2 mM
MgC12, 0.1% Triton X-100, 100 gg/ml BSA, 0.2 gM each primer, 0.1 mM dNTPs, and
0.1 units/gl of Pfu. Denaturation at 950 C, annealing at 570C and extension at 720 C, each for
approximately 10 second intervals, constituted the amplification cycle. After the desired
number of cycles, samples were incubated at 72 0 C for 2 minutes and then at 45'C for 30
minutes. The primers used were CW7 [(ACC GTT AAC TTC CAA TTA AC) identical to
base pairs 10011-10031 of human mitochondrial genome] and J3 [(GCG GGC GCA GGG
AAA GAG GT) complementary to base pairs 10196-10215]. The altered high melting
domain primer used to generate CDGE markers (J50) was [(GAA GAA TTT TAT GGA
GAA AGG GTG CGC CCG GGG GGA TAT AGG GTC GAA GC)]. For fluorescently-
labeled primers, a fluorescein moiety was linked to a cyanoethyl phosphoramidite by a nine
atom spacer arm. This species was coupled to the 5' end of the oligonucleotide during
commercial synthesis (Ransom Hill Bioscience, Inc., Ramona, CA). The
tetramethylrhodamine (TMR) dye was coupled to the oligonucleotide via an amino C6
linker also during commercial synthesis (Biosynthesis, Louisville, TX).
Fig. 15: Velocity of DNA migration through the heated zone of the capillary vs. separation
temperature.
The target DNA fragment used in these experiments was electrophoresed through a
capillary with a 10 cm heated jacket at temperatures ranging from 450C to 51 0 C. The
electric field was approximately 300 V/cm. Buffer conditions in the gel and the running
buffer were 0.1X TBE. The full peak width at half-height is plotted. The mobility is
highest when the DNA is in a double-stranded form at lower temperatures up to 470 C, and
declines along a sigmoid curve to a lower mobility in the partially melted form at 51 OC.
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3.2.4 Constant denaturant capillary electrophoresis
Constant denaturant capillary electrophoresis (CDCE) is an adaptation of the
separation principles of CDGE to a capillary electrophoresis format. PCR products
containing mutations in their low melting domains are separated based on differences in
their velocity as they migrate through a heated section of the capillary. An important
advance required for reproducible separation by CDCE was a replaceable linear
polyacrylamide matrix. The procedure for synthesizing the matrix was adapted from Ruiz-
Martinez and colleagues (1993). A 5% acrylamide solution in TBE was deoxygenated by
argon bubbling in an ice bath for 10 minutes and any contact of the solution with air was
avoided until polymerization was complete. TEMED and ammonium persulfate were added
to 0.03% and 0.003%, respectively. The polymerizing solution was immediately dispensed
into 10 ml glass syringes and left at 20C for several days. The matrix was dispensed from
the 10 ml syringes into 100 gl high pressure U6K syringes (Rainin, Emeryville, CA),
which were used to replace the matrix in capillaries through home-made teflon tube fittings.
In order to reduce adsorption of the matrix to the capillary and electroendosmosis,
the capillary was coated with linear polyacrylamide chains in an adaptation of the method of
Hjert6n (Hjert6n, 1985). Capillaries were treated with IM NaOH for 2 hours, washed
sequentially with IM HCI and methanol, treated overnight with 7-
methacryloxypropyltrimethoxysilane (Sigma, St Louis, MO) and washed with methanol.
The capillaries were then filled with a polymerizing solution of 6% acrylamide in TBE
(89mM Tris, 89 mM borate, ImM EDTA, pH 8.4), 0.1% TEMED and 0.025% ammonium
persulfate, and left for several hours to polymerize.
For CDCE separations, electrophoresis was generally performed in 75 gm I.D.
capillaries approximately 30 cm in length. About 108 total copies were electroinjected into
a capillary and run at about 200 V per cm. A portion of the capillary was heated by a water
jacket connected to a constant temperature circulator. For high-resolution runs, a
temperature circulator with precision to 0.01 C and an external probe was used (Neslab,
Portsmouth, NH). The jacket was positioned 5 cm from the injection end of the capillary.
The length of the jacket was 5 cm for the enrichment of heteroduplexes and 15 cm for high-
resolution CDCE. The temperature of the water jacket was about 65 0 C for IX TBE
conditions and approximately 70 0 C for high-resolution conditions described in the next
section. The precise temperature to be used in a particular experiment and the time of
fraction collection was determined in test runs with appropriate standards.
The CDCE instrument used for identification of mutants included a dual dye
detection system. To detect DNA, the capillary was illuminated by a 515 nm argon laser
and emitted light was collected and split. Light was directed into two detectors through
appropriate sets of filters. For fluorescein, a combination of a 540 nm bandpass and a 530
nm long pass filter was used; for tetramethylrhodamine (TMR), a single 580 nm bandpass
filter was employed. Instruments were also used in a single wavelength detection mode, in
which a 488 nm laser was used and filters for fluorescein detection were two 520 nm
filters. The signal from the photomultipliers was amplified (108 V/A) by a current
preamplifier (Oriel, Stanford, CT) and recorded by a MP100 data acquisition system
(Biopac Systems, Goleta, CA). DNA fragments are observed in the output as peaks, each
of which represents a different sequence, and the area under the peak is proportional to the
number of copies of the specific molecule.
At a specific temperature, all heteroduplexes migrate through the heated zone within
a definable range of mobilities which is differentiable from that of the wild-type
homoduplex. Heteroduplexes in the amplified PCR product could therefore be collected
separate from the wild-type homoduplex, thus allowing enrichment of mutants. For
heteroduplex collections, samples were electroeluted from the anode end of the capillary
into 0.5 ml Eppendorf tubes with 5 pl of 0. 1X TBE and 0.1 mg/ml bovine serum albumin.
3.2.5 High-resolution CDCE
High-resolution CDCE runs were performed at approximately 100 V/cm using gel
and running buffers containing 30 mM Na + (30 mM sodium borate, pH 8), in addition to
TBE. Gels for high-resolution CDCE were prepared using a lower amount of ammonium
persulfate (0.0015%). The higher salt concentrations in these gels necessitated higher
water bath temperatures of approximately 700 C.
In the initial experiments performed to detect mitochondrial mutants in human tissue
samples, the mutants observed were isolated and sequenced. As further samples were
examined, the same mutants were observed to be present repeatedly in multiple samples.
In order to determine whether a peak in a given sample was the same as a previously
sequenced peak or if it represented a new mutant, the dual dye detection system described
in the previous section was used to identify sample mutants based on comigration during a
single capillary run with a panel of previously sequenced mutants. Fluorescein-labeled
samples were coinjected into the capillary with authentic standard mutant peaks amplified
with PCR primers labeled with tetramethylrhodamine (TMR). Using a dual-channel
instrument it was possible to preliminarily identify and measure sample peaks that
comigrated with known standards.
3.2.6 Capillary hybridization
In order to identify the sequence change associated with individual peaks more
rigorously, capillary hybridization was developed as a test for peak identity. The CDCE
instrument used for identification by hybridization included consecutive heating jackets
each bathed by a separate water bath. The fluorescein-labeled sample and a panel of TMR-
labeled standards were co-separated in the first jacket at the appropriate temperature
(-71.5 0 C) under high-resolution conditions. Approximately 3 x 108 copies of each
standard mutant and about 107 copies of fluorescein-labeled sample, in which each mutant
represented approximately 10% of the copies, was injected. After the mutants were
separated from each other as homoduplexes, the run was stopped. The temperature in the
second jacket was increased to denature the DNA (800 C), then decreased to 550 C and
maintained for 10 minutes to permit reannealing of single strands. The sample was then
electrophoresed to the detector at a temperature that separates homoduplexes from
heteroduplexes (-700 C). Peak identity was verified when individual fluorescein-labeled
peaks were observed as homoduplexes reflecting that they had reannealed. Sample peaks
that formed heteroduplexes migrated differently from the standards with which they
coseparated and consequently "disappeared".
3.2.7 Test for asymmetric species
A test was designed to distinguish between signals that resulted from true, double
stranded mutants present in cells versus those that originated from cellular pre-mutagenic
species, like adducts and heteroduplexes, that were converted to mutants during in vitro
PCR based on linear preamplification with one or the other primer. For these experiments,
DNA eluted from a CDGE was linearly amplified with either the upstream or downstream
primer for 20 cycles. Eluted DNA was also amplified with both primers for 5 cycles.
Exonuclease-deficient Pfu DNA polymerase was used for this first amplification for all
three samples in order to avoid exonuclease digestion of the single strand products, and
conditions were otherwise the same as for other PCR reactions. In some cases, a
heteroduplex was added to the sample prior to linear amplification to serve as an
asymmetrical control expected to yield different mutant fractions depending on the primer
used for preamplification. Samples were then subjected to exponential amplification with
75
exonuclease-proficient Pfu DNA polymerase. Heteroduplexes were collected on CDCE
and reamplified to create homoduplexes. Homoduplexes were visualized on high-
resolution CDCE as described above. Mutant fractions in the resulting homoduplexes were
compared to an internal standard to determine whether each signal was significantly
different depending upon the primer used for preamplification.
4. RESULTS
4.1 MUTATIONAL SPECTRA METHODOLOGY
4.1.1 Overview
Our approach to measuring mutational spectra is based on sequential enrichment of
mutants that lie within a 100 bp target sequence (see Fig. 8 in Literature Review for melting
map of target sequence). The target sequence comprises the low melting domain of a 200
bp DNA fragment with a biphasic melting profile suitable for separation of point mutants
by partially denaturing gel electrophoresis, i.e., a low melting domain adjacent to a melting
domain requiring a higher temperature for denaturation. Mutations in the low melting
domain of such a sequence affect the rapid equilibrium between the partially-denatured and
double stranded forms of the molecule that coexist in a given temperature range, and
therefore alter the mobility of the DNA through a gel matrix. The enrichment of mutants is
based on separation of all of the mutant sequences present in a sample from the large excess
of wild-type sequences.
The mutational spectra methodology involves two separation methods, both of
which are based on the principles of cooperative melting equilibria (Lerman et al., 1987):
slab gel (CDGE) (Hovig et al., 1991) and capillary (CDCE) (Khrapko et al., 1994b) (see
Figure 16 for an overview of the procedure). Enrichment of mutants prior to subjecting the
DNA to PCR is essential to avoid PCR noise generated by amplifying the wild-type from
obscuring visualization of low-frequency mutants. CDGE was used as the pre-PCR
enrichment step to permit separations of samples containing jg amounts of total DNA.
Such samples cannot be conveniently separated on capillaries with a 75 gim inner diameter.
CDCE, which permits rapid and precise collection of mutants, was used for post-PCR
mutant enrichment, at which point the total DNA loaded was negligible.
Prior to CDGE separation, DNA was digested with a pair of restriction
endonucleases that excise the 200 bp target fragment. The samples were doped with small
known fractions of particular mutants which served as internal standards. The internal
standards permit monitoring of the enrichment efficiency at each step, and determination of
the absolute mutant fractions of mutants in a sample. The samples were run on CDGE, and
mutant-enriched DNA fractions located above and below the wild-type were eluted.
Enriched fractions were subjected to high-fidelity PCR which eliminated interference from
non-target DNA and also added a fluorescent label to the target sequence.
After PCR, the mutants were further enriched by CDCE separation. The pooled
fraction containing all of the mutants, but not the wild-type DNA peak, was collected from
the capillary and further amplified by PCR. Enriched samples in which mutants were
clearly visible were run on high-resolution CDCE capable of separating the mutants from
each other and displaying them as individual peaks suitable for identification and isolation
for sequencing.
4.1.2 Copy number measurement and internal standard
It is critical for measurement of mutant fractions that the number of copies of target
sequence in each DNA sample is measured accurately. Since measurements of mutant
fractions are based on comparisons with internal standards, knowledge of the total number
of initial copies of the target sequence is essential for accurately introducing internal
standards at the desired initial fraction. Further, the number of mutant copies in the sample
must be known to ensure that it is sufficient for the desired statistical power.
To measure the initial number of copies available for PCR in a DNA sample, the
sample was doped with a PCR amplified target sequence containing an AT->GC mutation
at bp 10072 (p13, see Figure 27 in Results) to serve as an internal standard. The number of
mutant copies in the stock dilutions of internal standard was inferred from the amount of
Fig. 16: Overview of the procedure.
Flow diagram of the sample handling steps showing the total number of target copies and
the number of copies of a mutant initially present in the sample at a fraction of 10-6 at each
step.
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primer used in PCR and observation on CDCE that the primer was completely exhausted.
The sample DNA and a known amount of internal standard were subjected to PCR
followed by CDCE. The areas of the wild-type and mutant peaks were determined. The
ratio of these areas was used to calculate the initial number of copies.
Critical to this calculation is the demonstration that wild-type and internal standard
amplify with the same efficiency. Comparison of the p13 to wild-type ratio before and after
20 doublings revealed that the amplification efficiency of the internal standard was equal to
that of the wild-type (0.6 per cycle) within fl%.
This method for measuring copy number is robust; the sample can be doped at any
ratio of mutant to wild-type from 0.01 to 100 with good results. It has also shown good
reproducibility. Estimated copy numbers from independent copy number experiments were
generally within a factor of two of each other.
4.1.3 Pre-PCR enrichment by CDGE
Prior to enrichment for mutant sequences, samples are represented by about 2.5 gg
restriction digested cellular DNA containing approximately 4 x 108 copies of the unlabeled
target sequence. The small fraction of target sequences that contain mutations must be
separated from the vast excess of wild-type sequences and non-target DNA. This task
could be simplified by PCR amplification of the sample followed by CDCE separation.
However, to achieve low backgrounds and, hence, low detection limits, it is important to
significantly enrich for mutants before PCR is applied to the sample (see Figure 20 in
Reconstruction experiments for an illustration of the improvement gained by CDGE).
Slab gel CDGE separation (Hovig et al., 1991) was used for the necessary initial
enrichment. Under the partially denaturing conditions used for separation, high Tm mutants
and low Tm mutants were excised from the portions of the gel below and above the wild-
type band, respectively. CDGE rather than CDCE was used at this stage because the large
amount of non-target DNA and impurities in the samples create a high-resistance zone in
the capillary which prevents separation. An alternative approach has since been developed,
in which CDGE is replaced by CDCE in wide-bore capillaries (Li et al., 1996).
The efficiency of CDGE enrichment of mutants was estimated using a sample
doped with a high Tm and a low Tm mutant as internal standards at fractions of 10-2 each.
Mutants at this fraction can be easily and reliably observed on CDCE after PCR. (The
samples used for mutational analysis are usually doped at 10- 5 - 10 - 4 , fractions that are too
low to be observed without further enrichment). The ratio of mutant fractions after CDGE
to the initial fraction represents the enrichment efficiency. The enrichment was typically
100-200 for high Tm mutants and 5-10 for low Tm mutants.
Elution from the CDGE gel slices and the first PCR represents the statistical
"bottleneck" in the procedure since the number of mutant copies is at a minimum. Any
mutant to be measured with adequate precision (that is, not worse than ± 20%, 95%
confidence limits) should be represented by at least 100 copies at this point in the
procedure. Thus, if one began with 4 x 108 mitochondrial DNA copies, a mutant with a
mutant fraction of 10-6 would be present as 400 copies. Losses in DNA isolation and
enrichment steps would reduce this number to about 200, and an estimated efficiency of the
first cycle of PCR of 0.5 would mean the bottleneck number would be 100 mutant copies,
the minimum necessary to give the desired lower limit of statistical uncertainty.
4.1.4 High-fidelity PCR
After enrichment by CDGE, the samples were subjected to PCR, which generated
1012 copies of the target sequence, reduced the relative amount of non-target DNA to an
insignificant level and provided for fluorescent labeling of the target. In essence, PCR
made the samples suitable for CDCE separations.
PCR introduces "noise" into the analysis. It is important to amplify with a DNA
polymerase of sufficiently high fidelity so that errors created by copying excess wild-type
strands do not interfere with observation of mutants in the samples. Pfu DNA polymerase
was used in this work because it is thermostable and was reported to have a high fidelity
(Lundberg et al., 1991). P. Andre and colleagues determined the fidelity of Pfu on this
target sequence, and discovered an unusually low error rate, 6.5 x 10- 7 errors per base
pair doubling (Andre et al., 1997). This is significantly lower than other DNA polymerases
screened for fidelity (Keohavong et al., 1989).
Pfu does, however, share with other DNA polymerases the ability to convert wild-
type sequences into byproducts that have lower melting temperatures than the wild-type
homoduplex. These byproducts can interfere with the mutant enrichment step on CDCE.
Among these byproducts are incomplete or exonucleolytically processed products missing
from one to several nucleotides. The fractions of these byproducts can be as high as 50%
of the total in some PCR preparations. The problem has been reduced but not eliminated by
use of an increased Pfu concentration (four-fold higher than the manufacturer's
suggestion), and a 30 minute post-PCR incubation at 450 C. Under these conditions, the
CDCE enrichment is approximately 30-fold, limited by collection of 3% of the wild-type as
tail on the main peak and low melting temperature wild-type byproducts.
During PCR, the mutants were converted into heteroduplexes with the excess of
wild-type strands by continuing to subject the sample to temperature cycles even after the
point where the primers were exhausted. All such heteroduplexes have significantly lower
melting temperatures than the parent wild-type homoduplex, a fact which allows collection
of all of the heterodouplexes as a single fraction greatly reduced in the number of wild-type
strands by DGGE, CDGE, or CDCE.
4.1.5 Post-PCR enrichment by CDCE
A post-PCR CDCE separation is shown in Fig. 17. A sample of TK6 cellular DNA
from cells grown 400 generations is shown. The sample contains two prominent low Tm
mutants with initial fractions of about 4 x 10-4 and 3 x 10-4 , in addition to the internal
standard at 10-4 , and was selected for demonstration purposes. In an initial CDCE (Figure
17A), the four heteroduplexes of the two mutants (marked by X's) are about 0.2% of the
wild-type peak (which implies 5-fold CDGE enrichment) and are hardly distinguishable
among the wild-type variants (noise) which are present at a similar fraction (marked by
asterisks).
The heteroduplex fraction of the first CDCE was collected, amplified and run on a
second CDCE (Fig. 17B). On the second CDCE, the four heteroduplex peaks of the two
major mutants are clearly visible above the background and constitute more than 5% of the
wild-type peak each, which implies a more than 25-fold enrichment by CDCE. In addition
to these prominent peaks, smaller mutant peaks that were not visible on the first CDCE are
visible on the second CDCE.
The combined size of all mutant heteroduplex peaks in the separation shown in Fig.
17B is comparable to the size of the wild-type peak. In this situation, another collection of
the heteroduplex fraction will not significantly enrich against the wild-type because each
heteroduplex contains one wild-type strand. If the initial frequency of mutants in the sample
were lower, as is usually the case, the combined size of heteroduplexes at this stage would
be smaller and additional CDCE separations would provide further enrichment.
Fig. 17: Post-PCR enrichment of mutants by CDCE.
A. TK6 cellular DNA eluted from the low Tm region after CDGE was subjected to 35 cycles
of PCR and separated by CDCE. Mutant heteroduplex peaks marked by "x" are not clearly
visible above background peaks marked by "*". The x axis reflects the time since the
beginning of the run at which the peak reaches the detector and the y axis marks the relative
intensity of fluorescence.
B. The heteroduplex fraction of the first CDCE shown above was collected, subjected to 35
additional cycles of PCR and run on a second CDCE. A set of mutant heteroduplex peaks
is clearly distinguishable from the background.
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4.1.6 High-resolution CDCE
Once the mutants have been enriched, individual mutants are then separated,
measured, isolated and sequenced. These procedures are most easily performed with the
mutants in homoduplex form. Mutant heteroduplexes were converted into homoduplexes
by stopping PCR when the molar amount of unused primers still exceeded that of the
products. Homoduplexes were then separated via CDCE under "high-resolution separation
conditions" that include increasing the time the sample spends in the heated zone. This was
achieved by increasing the length of the zone and decreasing the running voltage. High-
resolution conditions also involved increasing the salt concentration in the electrophoretic
buffer. The improvement in resolution with these modifications results from increasing the
average number of partial meltings and reannealings a molecule undergoes while in the
heated zone of the capillary (Khrapko et al., 1996).
Fig. 18 (upper curve) shows a high resolution separation of the same sample as the
one shown in Fig. 17 after it was converted to homoduplex form. The reason that the two
separations look dissimilar is that each pair of heteroduplexes which in Fig. 17 were
represented as two peaks yielded a single homoduplex peak in Fig. 18.
4.1.7 Identification of mutants
In our first studies of mitochondrial hotspot mutants, each mutant peak was
isolated, amplified and sequenced. It became clear soon thereafter that the same mutants
appeared in multiple samples and that a more efficient mode of mutant identification was
possible. All sequenced mutants were labeled with tetramethylrhodamine (TMR) and
combined together to form a "standard set" of markers. This TMR-labeled "standard set"
could then be coinjected with an aliquot of fluorescein-labeled sample under study and both
signals could be observed on a single CDCE separation by means of a two-wavelength
detector. In this way, mutants in the fluorescein-labeled sample could be identified based
on comigration with the TMR-labeled previously isolated hotspot mutants. Further, any
novel mutants could be identified for subsequent isolation and sequencing. The fluorescein
and TMR labeled homoduplexes are shown for TK6 cells grown 400 generations in Fig.
18.
Development of a dual-dye detection method significantly facilitated mutant
identification. The results supported the preliminary conclusion that the same specific
mutants appear repeatedly in all samples tested. However, comigration is not proof of
identity. Two distinct mutants could theoretically comigrate under a specific set of
conditions. In order to test more rigorously the identity of specific peaks, an identification
procedure based on capillary hybridization of sample peaks with the panel of previously
isolated mutants was developed. The CDCE instrument used for identification by
hybridization included two consecutive heating jackets. The sample and the standards were
co-separated in the first jacket as performed for identification by co-migration, and the
resulting set of peaks was stopped inside the second jacket. The temperature in the second
jacket was increased to denature the DNA, then decreased to permit reannealing of single
strands, and finally the sample was electrophoresed through the rest of the second jacket to
the detector.
If a sample peak were identical to the standard with which it comigrated, then its
reannealing to homoduplexes was forced by the high concentration of the "driver" in the
reaction, that is, the standard mutants labeled with TMR. In this case, the position of the
fluorescein-labeled peak with respect to the TMR-labeled homoduplexes, which reanneal
efficiently due to their high concentration, is retained. In contrast, if the peak is different
from the standard mutant with which it co-migrates during the pre-hybridization part of the
CDCE separation, the hybridization procedure will convert the sample mutant into two
heteroduplexes with the standard mutant present in excess. Such heteroduplexes are
always less stable than the homoduplexes from which they are derived, and move to a
Fig. 18: Mutant identification by comigration with authentic standards.
A sample of fluorescein-labeled low Tm mutants isolated from TK6 cells in the form of
homoduplexes (A) was coinjected with a tetramethylrhodamine (TMR)-labeled set of
known low Tm mutants (B). Standard mutants identified as pl, p1.5, A (internal
standard), p3, p5, p5 .5 and p7 represent GC->AT transitions at base pairs 10068, 10085,
10040, 10038, 10098, 10056 and 10126, respectively. p6 represents a GC->TA
transversion at base pair 10070. Based on a comparison of the mobilities, mutants pl, p1.5
and p3 were determined to be present in the sample. Comparison with the internal standard
added to the sample at a mutant fraction of 10-4 permits assignment of mutant fractions of
other mutants.
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different position during the post-hybridization portion of CDCE separation. This results
in the "disappearance" of the sample peak from its original position in the spectrum.
Capillary hybridization was performed for high Tm mutants from 16 twins'
bronchoscopy samples, 3 dissected lung samples, TK6, muscle and colon samples. The
specific mutants tested by capillary hybridization were 1, 3, 5, 5.5, 6, 7, 11, 11.3, 11.5,
13, 13.5, 14, 15.5, 16, 18, 18.5, and 19. Approximately 90% of peaks identified by
comigration were confirmed as present by capillary hybridization. In most cases, the
mutant fractions estimated by measurement of homoduplex runs and capillary hybridization
were very similar (within 2- to 3-fold). In cases where a significant difference was
observed, the mutant was often difficult to measure in the homoduplex run due to the
presence of other closely-spaced peaks.
An example of the mutational spectra observed before and after capillary
hybridization is shown in Fig. 19. In the top panel, the high Tm mutational spectra of a
sample biopsied from a nonsmoking twin's left lower lobe is shown. The lower curve of
the top panel represents several TMR-labeled mutants that were electrophoresed
simultaneously with the sample. In the lower panel of Fig. 19, the same sample is shown
after capillary hybridization. Peaks that remain are identical to the standard with which they
comigrate, and are numbered. All sample peaks that were not identical to one of the TMR-
labeled mutants injected in this run were converted to single stranded DNA or
heteroduplexes. Such species were retarded during migration through the second water
jacket and hence passed the detector later, after the hybridized homoduplexes. These
species consequently "disappeared" from the spectrum. As an example, the peak between
mutant 11 and mutant 11.5 labeled "x" in Fig. 19 was not identical to any of the TMR-
labeled standards and was consequently not observed in the spectrum after capillary
hybridization. This particular peak represents mutant 11.3 which was not included in the
standards for this particular hybridization run.
4.1.8 Quantification of mutants.
Peak measurement is illustrated in Fig. 18. The area under each peak is
proportional to the initial mutant fraction in this sample. The initial mutant fraction of
mutant peaks p3, p1.5 and p can be determined by comparison of the areas under these
peaks to the peak representing the 10-4 internal standard. In this sample, the original
fractions of mutants represented by p3, pl.5 and pl are estimated to be 5 x 10-5 , 4 x 10-4
and 3 x 10-4 , respectively.
4.2 TESTS FOR VALIDITY
4.2.1 Reconstruction experiments
The mutants that we detect with this method are represented in our initial samples
by as few as four hundred molecules. Consequently, an obvious problem is the potential
for contamination from purified PCR preparations of these mutant sequences. In order to
minimize contamination, DNA isolation, CDGE, and preparing aliquots for PCR were
performed in a clean lab equipped with high-throughput air filters. No PCR products of
purified mutant sequences entered this laboratory except for very dilute stocks used to
introduce internal standards.
In order to determine whether any of the mutant peaks observed were caused by
contamination, Pfu polymerization errors or by replicative bypass of DNA adducts created
during our procedures, CDGE-purified wild-type homoduplex was doped with known
amounts of internal standards containing a single point mutation and subjected to all of the
steps of our procedure. Shown in Fig. 20 are the results when wild-type PCR fragments
Fig. 19: Capillary hybridization to confirm peak identification.
The high Tm homoduplex mutational spectra was determined for the left lower lobe
bronchoscopy sample of a nonsmoking twin. (A) The set of homoduplexes observed as
the mutational spectra, and several TMR-labeled mutants from the standard set, specifically
11, 11.5, 13, 16, 18 and 19, that were used for capillary hybridization. (B) The same
sample after capillary hybridization. Individual peaks that are still present in the sample are
considered to be confirmed as representing specific mutants and are numbered. The peak
designated with an "x" is peak 11.3. This mutant disappeared after hybridization because
there was no excess 11.3 TMR-labeled mutant with which it could reanneal.
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purified from possible mutants by CDGE were doped with a low Tm mutant at 10-4 and
with a high Tm mutant at 10-5, mixed with non-amplifiable herring carrier DNA, and
subjected to all the procedures described above except for the initial DNA isolation.
Importantly, no prominent mutants were observed in this control sample besides the
internal standards. In this experiment, the peaks representing both of the reference mutants
are about ten times larger than the largest peaks of the background. Thus, the limit of
detection, defined as the frequency of a mutant that yields a peak comparable to the largest
background peaks, at least for purified wild-type DNA, should be considered 10- 5 for low
Tm mutants and 10-6 for high Tm mutants. In a variation on this control, to test whether
detectable levels of DNA adducts leading to noise "mutants" were generated during cell
lysis, the target human mitochondrial fragment was mixed with rat cells and subjected to
the entire procedure. No interfering signals were observed in this control experiment
either.
Since the limit of detection depends on the size of background peaks it is important
to know the sources of background mutants. Most of the background peaks do not co-
migrate with mutants originating from Pfu replication errors (Andre et al., 1997) as
described further subsequently. The most likely source of the background may be adducts
present in mitochondrial DNA that were converted to mutations during in vitro PCR. As
can be seen from a comparison of Fig. 20A and 20B, CDGE substantially eliminates some
of this background. Panel B displays the results from the same experiments as A without
CDGE enrichment. The difference in detection limits between high and low Tm mutants
could reflect that more of these lesions co-migrate with low Tm mutants than with high Tm
mutants.
In order to further investigate the possibility that adducts of mitochondrial DNA
contribute to background mutations in the mutational spectra procedure, the amount of
enrichment of a low Tm artificial mutant PCR product spiked into genomic DNA during
CDGE was determined for DNA isolated from various sources. Mutant PCR product
added to TK6 genomic DNA was enriched more efficiently in two independent experiments
than PCR product added to genomic DNA from tissue samples. Further, when artificial
mutant was added to genomic DNA isolated from lung tissue of an 84 year old man, the
enrichment was particularly poor. In one experiment, the enrichment for TK6 cells was
14-fold; for lung parenchyma, 6.4-fold and for lung epithelial cells from the 84 year old
man, 1.8-fold. No difference was observed, however, in the extent of enrichment between
smoking and nonsmoking twins. These findings suggest that modifications of
mitochondrial DNA that lead to altered mobility on a CDGE may represent important
contributors to the background in our mutational spectra determination of low Tm mutants.
Further, these results suggest that there is modification of mitochondrial DNA at a level
such that several percent of the copies contain a modification somewhere in the 100 bp low
melting target. Finally, these experiments suggest that the extent of modification may differ
for cultured cells, human tissues and tissues of the elderly. These observations are
supported by measurements of 8-OH-dG in mitochondrial DNA from cell and tissue
samples described in the Literature Review (Intracellular milieu).
4.2.2 Spectra differ from each other
The limit of detection available with the mitochondrial mutational spectra
methodology was shown to be sufficient to observe mitochondrial hotspot mutations in
human tissue samples. Fig. 21 provides high resolution CDCE runs of the following
samples: (A) CDGE-purified wild-type DNA with internal standards added; (B) a sample
derived from a culture of TK6 cells grown 400 generations; and (C) a sample of human
bronchial epithelial cells. The cell and tissue samples in panels B and C contain a series of
Fig. 20: Limit of detection: Reconstruction experiment.
A: A sample of wild-type PCR fragment that was depleted of mutants by CDGE was mixed
with nonamplifiable carrier DNA. The sample was spiked with a high Tm mutant (10-5 ) and
a low Tm mutant (10-4 ) as internal standards, and subjected to the mutant isolation procedure
(panel A, "CDGE+"). The left panel includes mutants with melting temperatures higher than
wild type and the right panel depicts mutants with melting temperatures lower than wild type.
B: To demonstrate the role of pre-PCR CDGE, the same experiment was carried out with
the CDGE enrichment omitted (panel B, "CDGE-").
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Fig. 21: Examples of mitochondrial mutational spectra.
A: Negative control. Sonicated herring DNA was mixed with CDGE-purified wild-type and
internal standards and subjected to mutational spectra analysis.
B: A spectrum derived from a culture of TK6 human lymphoblastoid cells.
C: A spectrum of a human lung epithelium sample. For sequences of mutants, see Figure
27.
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peaks that are not present in the negative control in panel A. The fractions of high Tm
mutants in the TK6 sample (Fig. 21B) are on the order of 10-6. The low Tm mutants are
as high as 4 x 10- 4 . The bronchial epithelium sample (Fig. 21C) displays significant
peaks in both the high and low Tm sets. In the low Tm set, the bronchial tissue displays
some of the same hotspot mutants as are found in the TK6 cells (p and p3). In the high
Tm region of the bronchial epithelium sample, several peaks are seen with mutant fractions
on the order of 10-4 . Five peaks are identified by number (see Figure 27 in Results:
Hotspots, for sequence changes).
Both the cell and tissue samples contain hotspot mutants detectable significantly
above the background generated by the procedure itself. Further the pattern observed in
DNA isolated from TK6 cells was substantially different from the pattern observed from
this bronchial epithelial cell sample, a finding that supports the conclusion that the
mutations observed do not result from any of the procedures used, as this process would
be expected to induce the same type and frequency of mutants in all samples.
4.2.3 Reproducibility
The reproducibility of the procedure is demonstrated in Figure 22. A single DNA
sample taken from TK6 cells was split in two, and internal standards were added separately
to each aliquot. Duplicate samples were analyzed independently on a constant denaturing
gradient gel, followed by further enrichment via CDCE and visualization of mutants. As
can be observed, the reproducibility is excellent. Samples were routinely analyzed in
duplicate and the reproducibility was generally very good. When mutant fractions are
measured, the ratio of mutant fractions between duplicates is generally less than two-fold.
This is in sharp contrast with the much more large difference in the mutant fraction of
particular peaks between samples, where the mutant fractions can vary by 30-fold or more,
as discussed in Results: Variability of Mutant Fractions.
4.2.4 Pfu noise characterization
An important potential source of error in these procedures is to misinterpret mutants
created by Pfu DNA polymerase in vitro for mutants actually present in tissue samples. In
order to avoid this possibility, P. Andr6 and colleagues characterized the PCR noise
induced by Pfu DNA polymerase in this DNA sequence (Andre et al., 1997). Using
successive rounds of PCR to generate Pfu-induced mutants and CDCE to enrich for the
mutants, the error rate of Pfu was estimated as 6.5 x 10-7 errors/bp-doubling. Five of the
most frequent hot spot mutations were three transversions (GC->TA at bp 10070, mutant
E; AT->TA at bp 10071, mutant D; and AT->CG at bp 10071, mutant A), one transition
(AT->GC at bp 10108, mutant B) and a one base pair deletion in a run of six consecutive
adenines (bps 10048-10053, mutant C) (see Figure 23). Of the peaks in the "standard set"
that were consistently observed in human tissues, only one (p6, mutant E) was found to
arise from the PCR process itself. The others are unlikely to originate from PCR noise.
4.2.5 Test for asymmetric species
The tests for the validity of mutational spectra results discussed to this point are
concerned with systemic bias in which mutants may have been created as a result of
artifacts generated by our procedures themselves. Such errors include contamination of
samples and PCR-created mutants. PCR errors could arise as misincorporation events
during primer extension over a wild-type substrate or as a result of misinsertion during
replicative bypass of DNA adducts formed in our procedures. The errors of this class, as
Fig. 22: Reproducibility of the mutational spectra procedure.
Restriction digested DNA from TK6 cells containing the equivalent of approximately 3 x
108 copies of the mitochondrial target sequence was divided into two samples and each
was doped at 10-4 with the artificial mutant to serve as an internal standard. Panels A and B
are the results of CDCE separations of the duplicate samples.
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Fig. 23: Characterization of Pfu-induced noise on mitochondrial target sequence.
Analysis by CDCE of the purified homoduplex mutant fractions generated by amplifying
wild-type DNA for 14 and 34 doublings using Pfu DNA polymerase. Many small peaks
visible after 14 doublings were observed as significantly larger peaks after 34 doublings.
Of the major peaks for which the mutant sequences were determined, peak A is an AT-
>CG transversion at bp 10071; peak B is an AT->GC transition at bp 10108; peak C is a
deletion occurring in a run of six consecutive adenines at bp 10048-10053; peak D is an
AT->TA transversion at bp 10071; and peak E is a GC->TA transversion at bp 10070.
Source: Andr6 et al., 1997
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discussed above, can be addressed by comparison of a spectrum to the negative control,
such as the one shown in Fig. 21A.
A second type of error could also bias the mutational spectra we observe. The
errors of this class arise when cellular pre-mutagenic sites are converted into mutants by
our procedures. These would include DNA adducts in the original mitochondrial sample
that were misreplicated by the polymerase during PCR to create mutants. Similarly,
mismatch intermediates that were formed during DNA replication but were not yet repaired
at the time of DNA isolation, could be mistaken for true heritable mutations. Note that such
mismatches could exist whether or not there is mismatch repair machinery in human
mitochondrial DNA. In order to discriminate cellular lesions and mismatches from true
mutants, a method was developed that exploits a distinguishing property of these species:
adducts or sequence changes are present in only one of the two DNA strands, while the
other strand is an unadducted wild-type sequence. True mutants, in contrast, contain a
changed sequence at the same base pair in both DNA strands of the original sample.
To preserve this distinguishing information, a modified PCR procedure was
employed which includes asymmetric pre-amplification. Two aliquots of a CDGE-enriched
sample were subjected to repeated primer elongation cycles with only one or the other of
the two PCR primers. During this "linear amplification" stage, only one strand of the
sample DNA was used as a template. Thus after preamplification, one aliquot contained a
vast excess of "Watson" copies while the other contained excess "Crick" copies as single
strands. Then the other primer was added and exponential amplification followed.
Asymmetric pre-amplification of a real double stranded mutant results in equal
fractions of a particular mutant when the samples preamplified with opposite DNA strands
are compared. However, in the case of a mismatch or a pre-mutagenic lesion, the mutant
will arise only from copying the strand which contains the mismatch or premutagenic
lesion. This results in different mutant fractions for a particular mutant between the spectra
obtained from the two aliquots which begin by copying only the Watson or the Crick
strand.
Fig. 24 provides the results of a test for asymmetric species as applied to low Tm
mutants isolated from a lung epithelium sample. The sample was preamplified to achieve a
5.7-fold for the J3 primer (Fig. 24A), 10-fold for both primers (Fig. 24B), and 8.8-fold
enrichment for the CW7 primer (Fig. 24C). The sample contains the peaks for p and p3.
The results show that pl yields the same mutant fraction regardless of the strand used in
linear amplification. We regard this finding as strong evidence that the p signal arises from
a true mutant in this sample. Other experiments in which TK6 cells were examined,
however, have suggested that pl may have slight (<1/3) adduct characteristics. The signal
designated p3 shows a significantly larger mutant fraction when linear amplification was
performed to copy the Watson as opposed to the Crick strand. These results suggest that a
significant portion of the signal designated p3 arose either as a mismatch intermediate or as
an adduct located in the Watson strand that was converted into a mutant by Pfu polymerase.
Another mutant, that was not sequenced, designated X in Fig. 24, demonstrates the
opposite distribution, which suggests that it originates in significant part from a mismatch
or a lesion located on the Crick strand.
Figure 25 reveals the results when high Tm mutants from a bronchial epithelial cell
sample were tested for symmetry. In this experiment, the optimal enrichment (13-fold)
was obtained for CW7 (Fig. 25A) and an enrichment of 7-fold was achieved for J3 (Fig.
25C). A separate aliquot was amplified with both primers CW7 and J16 for 5 cycles,
which generated an enrichment of 10-fold (Fig. 25B). The pattern was essentially constant
whether the sample was preamplified with one primer, the other primer, or both primers.
For each of the peaks in the high Tm standard set, the ratio of the mutant fractions in a
sample preamplified with one primer versus the other was less than two. In contrast, the
ratio of mutant fractions for a heteroduplex introduced prior to preamplification as an
asymmetrical control was six when samples preamplified with one or the other primer were
Fig. 24: Test for asymmetric species: low Tm mutants.
Low Tm mutants from lung epithelium were eluted from a CDGE and linearly preamplified
for 20 cycles either with the J3 primer (A) or the CW7 primer (C). In (B), the sample was
preamplified with both primers for 5 cycles. The amplification was 8.8-fold for the CW7
primer, 5.7-fold for the J3 primer and 10-fold for both primers. Preamplified samples
were then subjected to the remaining protocol for determining mutational spectra and the
results are shown.
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Fig. 25: Test for asymmetric species: high Tm mutants.
DNA was isolated from cells obtained via brush bronchoscopy from the right upper lobe
of a twin with a smoking history. The high Tm homoduplex portion of a CDGE was
eluted and subjected to linear preamplification. An enrichment of 7-fold was achieved for
J3 and the optimal enrichment (13-fold) was obtained for CW7. A separate aliquot was
amplified with both CW7 and J16 for 5 cycles, which generated an enrichment of 10-fold.
After exponential PCR, heteroduplexes were enriched by CDCE, reamplified and converted
to homoduplexes. (A) The sample after preamplification with CW7 along with coseparated
standards, (B) homoduplexes for samples preamplified with both primers and coseparated
standards, and (C) sample after for preamplification with primer J3 and coseparated
standards.
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compared. These results support the conclusion that high Tm signals represent true,
double stranded mutants. Similar results concluding that high Tm signals reflect true
mutants were also observed for samples from other organs besides lung.
4.3 MITOCHONDRIAL MUTATIONAL SPECTRA
The previous section describes some of the experiments performed to determine the
validity of the mitochondrial mutational spectra determined by this method. In this section,
the mutational spectra of a variety of human samples are provided.
4.3.1 Several organs
Figure 26 shows the homoduplex mutational spectra for four samples of normal
tissues: colon, muscle and lung epithelium (2 samples). Each of the tissue samples was
found to contain prominent mutational hotspots that were detectable with our procedure.
Further, the same set of approximately 17 hotspots were observed repeatedly among tissue
samples. These mutants were confirmed by capillary hybridization and are numbered in
Figure 26. The mutant fraction of each particular mutant, however, was discovered to vary
significantly among samples. Among these organs (see heart sample in Mutant Fraction
and Age: Other Tissues for an exception), no specific mutant was discovered to be
particularly prominent in a specific tissue. The example of the two different bronchial
epithelial samples illustrates this point, as some mutants (for instance, p18), vary as much
between the two bronchial epithelial samples (Fig. 26A and B) as they do between different
tissues (Fig. 26A, B, C and D). The similarity in the overall level of mutations observed
for all detectable point mutations in this 100 bp low melting domain region of mitochondrial
DNA contrasts with the tissue specificity observed in the levels of deletions in aged
individuals as discussed in the Literature Review.
4.3.2 Hotspots
Most of the mutants that are observed repeatedly in different tissue samples have
been purified and sequenced. For the mutants in the standard set and the artificial mutant
used as an internal standard, Figure 27 provides the specific type of mutation and the
sequence context. All but two mutations are transitions, with both GC->AT and AT->GC
mutations represented. The predominance of transition mutations is in concordance with
studies of the types of mitochondrial point mutations observed as polymorphisms. Both
GC->AT and AT->GC transitions are observed as polymorphisms of mitochondrial DNA
more frequently than transversions (Aquadro et al., 1983; Horai et al., 1990). Most of the
mutations in the NADH dehydrogenase protein create amino acid substitutions, but p13 and
p19 are silent and p7 creates a stop codon. No differences in the number or kind of
mutations present in the tRNAgly versus the NADH dehydrogenase subunit were
observed. Triplet analysis of nearest neighbors did not reveal any significant deviation
from chance.
4.3.3 Tumor spectra
Figure 28 provides the set of mutant peaks observed for samples derived from
tumors of the colon and muscle. The same set of hotspot mutations as in normal tissues is
observed in these tumors, and the mutant fractions are not significantly different from those
determined for healthy tissue. Such findings suggest that the processes that generate
mutations in healthy tissue also generate mutations in tumors as well.
Fig 26: Mutational spectra of lung, colon and muscle samples.
DNA was isolated from two samples of 106 human bronchial epithelial cells each (A and
B), approximately 1 g epithelial cells from a human colon (C), and 1 g of human muscle
tissue (D). DNA was restriction digested, mixed with internal standards and the mutational
spectra were determined. Depicted are separations of fluorescein-labeled samples along
with the co-separated TMR-labeled authentic standards (lower of each pair of curves). (X)
marks a peak that has not been sequenced.
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Fig. 27: The mitochondrial DNA sequence (bp 10011-10215) used as a target sequence for
these studies.
The high melting and low melting domains, as well as the junction between the tRNAgly
sequence and the beginning of the NADH dehydrogenase subunit III sequence, are
indicated. Also shown are the specific base pair substitutions associated with each mutant
in the standard set, along with the number designation. The base substitution of the
artificial mutant used as an internal standard for low Tm mutants is given and designated
"am". Sequences recognized by DNA primers used for PCR are underlined.
Target Sequence and Isolated Mutants
10011
ACCGTTAACT
primer CW7
TCCAATTAAC TAGTTTTGAC
A T
3 am
10041
AACATTCAAA
G
13.5
-- tRNAgly I NADH
AAAGAGTAAT
ACG C
5.5 11 11.5 11.3
dehydrogenase subIII
AAACTTCGCC
G
18.5
CTA
18 2 6
10071
TTAATTTTAA
CC
16 13
10101
TTACTACTAA
high melting domain
CCACAACTCA
10161
ACCCCTTACG
10191
TCCCCCGCCC
TAATCAACAC
TAATTATTAC
ACGGCTACAT
AGTGCGGCTT
GCGTCCCTTT
CCTCCTAGCC
4- low melting domain
ATTTTGACTA
AGAAAAATCC
CGACCCTATA
CTCCA
complementary to primer J3
Fig. 28: Mutational spectra of colon and muscle tumor samples.
The mutational spectra was determined for colon (A) and muscle (B) tumor samples of 1 g
and 20 mg, respectively. Shown are the CDCE separations of the mutational spectra for
colon and muscle tumor samples as well as the co-separations of the TMR-labeled set
(lower curve of each pair of curves).
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4.3.4 TK6 cells
The mutational spectra present in TK6 cells, as an example of human cells in
culture, was also determined (Fig. 29). The most prominent mutation in these cells was
mutant p1. Other mutants are present at a significantly lower mutant fraction. Examination
of the high Tm mutants, combined with capillary hybridization, revealed that the mutations
present in TK6 cells are in fact the mutants from the standard set observed in human tissues
as well. The ratio of p to other peaks is apparently about 10-fold higher in TK6 cells as
compared with human tissue samples.
An important question to address was whether the point mutant fractions increase
with generations of growth in TK6 cells. While "older" cells might contain more adducts,
as a result of accumulated mutations to oxidative phosphorylation proteins or DNA repair
enzymes, for instance, it would be consistent with the hypothesis that the signals observed
are true mutants if they were found to increase with generations of growth in culture. K.
Khrapko determined the mutational spectra for TK6 cells that were grown for up to 400
generations in culture. The relatively larger size of peak pl made it a good candidate to
study the increase in mutant fraction with cell division. Shown in Figure 29A is the
increase in mutant fraction with cell divisions for pl. Separate data points represent
independent mutant fraction measurements from a single culture. P1 increased almost
linearly relative to the internal standard up to 200 generations. The mutant fraction did not
increase linearly from 200 to 400 generations. After 400 generations of continuous culture,
it is possible that a faster growing subpopulation of cells displaced the other cells in the
culture, thus making mutant fractions no longer reliable. Displacement by a faster growing
subpopulation has been previously documented (Kubitschek, 1970).
Figure 29B shows the set of high Tm mutant peaks for the same TK6 culture at 52
and 400 successive generations. The mutants observed in tissue samples are present in the
cultured cells, as confirmed by capillary hybridization. However, the mutant fractions are
significantly lower in cultured human cells than in tissues (note the change in the size of the
internal standard peak area between Figures 28 and 29). The high Tm mutants, in general,
increased in mutant frequency with cell division, but the increase was not linear with
generations of culture. The nonlinearity of the increase may reflect the low mutant fractions
of these peaks. In a single, relatively small culture from which 2/3 were discarded each
day for dilution, rare mutants, especially if they were not distributed evenly among cells,
would not be expected to show a linear increase in mutant fraction (Oller et al., 1989).
4.3.5 Treated cells
In order to determine whether exogenous compounds are capable of inducing
mutations in mitochondrial DNA, L. Marcelino and colleagues treated a mismatch repair
deficient cell line, MT-i (Goldmacher et al., 1986), with a 4 gM dose of the alkylating
agent N-methyl-N'-nitro-N-nitrosoguanidine (MNNG)(Marcelino et al., in prep). The
induced mutant fraction was 5 x 10- 3 in the hprt gene as determined by plating in the
presence and absence of 6-thioguanine, a 200-fold induction over controls. Using the
methodology for determining mutational spectra in mitochondrial DNA as described in
Materials and Methods, multiple hotspot mutations were observed in duplicate in MNNG-
treated cultures and not in controls (see Figure 30). Sequencing of individual MNNG-
induced mutants revealed that they were all GC->AT mutations, a finding consistent with
MNNG-induced mutations in other systems (Burns et al., 1987; Coulondre et al., 1977;
Kat, 1992). L. Marcelino also treated cells with benzo[a]pyrene diol epoxide. In order to
induce a significant surviving mutant fraction in hprt, she subjected the cells to a series of
eight cycles of treatment and recovery, and a 40-fold induction over the controls resulted.
When these cells were analyzed with the procedures described in Materials and Methods,
no prominent mutants induced by the treatment were observed in the target sequence.
Fig. 29: Mutational spectra of TK6 cells
A. Mutant fraction of p1 (GC->AT, bp 10,068) with generations of human cells grown in
culture. TK6 cells were sampled at the number of generations designated on the horizontal
axis and the mutational spectra determined. The mutant fraction for p1 is plotted on the y
axis.
B. TK6 cells grown for 52 and 400 generations were sampled. DNA was isolated from an
aliquot of cells and subjected to mutational spectrometry. CDCE runs of the mutational
spectra for high Tm mutants are shown.
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Fig. 30: MNNG mutational spectrum in mitochondrial DNA of MT1 cells.
MT-i cells that lack mismatch repair were treated with 4 gM MNNG or left untreated as
controls in duplicate. The mutational spectra of low Tm mutants are shown for (A) 4 pM
MNNG, and (B) 0 gM MNNG. The two curves represent duplicate samples. The
artificial mutant was included as an internal standard at a mutant fraction of 3 x 10-4 .
Induced mutations, labeled with letters, are clearly observed in treated and not untreated
samples. Sequencing the induced mutations revealed that they were GC->AT transitions.
Source: L. Marcelino
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4.3.6 Mutant fractions and mutation rate
The average mutant fraction for each of the 17 mutants of the standard set was
calculated for all bronchial epithelial cell samples and plotted in a histogram along the target
sequence shown in Figure 31. Also provided are the kinds of mutation and the position of
the mutational hotspots in the context of the local DNA sequence. Note that the average
mutant frequencies for these prominent hotspots range from 5.3 x 10-6 for p 1 1.5 to 4.3 x
10- 4 for pl.
Estimating a mutation rate from the mutant fraction determined by this procedure
requires a number of assumptions for several reasons. First, it is not possible to
distinguish between mutants that were generated independently and those that resulted from
expansion of a cell containing the particular mutant. In the case of hprt mutants in T
lymphocytes, the clonality of individual mutant colonies can be determined by
characterizing the T-cell receptor as described in the Literature Review: Phenotypic
Selection. The extent of overestimation for solid tissues has not been determined, but as
demonstrated below, clonal expansion of mutants is likely to play a role in at least a small
fraction of observations.
Another significant drawback in estimating a mutation rate from mutant fractions are
uncertainties about the number of divisions. For this discussion, bronchial epithelial cells
are assumed to divide three times per year by analogy with colon epithelium and the
observations of Dr. E. Furth (Univ. of Pennsylvania), that colon epithelium divides at
approximately this rate. Further, the number of mitochondrial DNA divisions per cell
division is assumed to be one.
With these caveats in mind, a typical, prominent peak in the bronchoscopy samples
based on comparison with an internal standard has a mutant fraction of approximately
10-4. Assume that this mutation occurred after development of the lung when the lung
epithelium was maintaining constant cell number. In order to model an organ with constant
cell number, assume that half the cells die after DNA replication and cell division, along
with half of the mutants. In each generation, Nr mutants are created where N is the number
of cells and r is the mutation rate. Assuming half the cells and mutants die after each
Nr
generation, 2 mutants remain at the end of the generation. The number of mutants
gNr
present at any generation is 2 , where g is the number of generations, while the number
of cells is N. The mutant fraction can therefore be approximated by gr . The number of2
generations is estimated by dividing the number of years of life by the turnover time for
cells in the lung. For a 30 year old individual, assuming three divisions per year, the
number of generations is 90. A mutation rate of 2 x 10- 6 errors/(bp x duplication) for a
prominent hotspot would consequently be predicted.
The calculated mutant frequency for a hotspot mtDNA mutation can be compared
with that estimated for nuclear mutations. Experiments on T-lymphocytes from human
donors suggest a mutation rate of 5 x 10-7 mutations per generation for the entire hprt gene
(Green et al., 1995). Assuming that there are approximately 1000 base pairs at risk in hprt,
an average nuclear mutation rate of approximately 10- 10 mutations/(bp x generation)
results. A nuclear hotspot with a mutation rate 100-fold the average would have a mutation
rate of 1 x 10-8 in the nucleus as compared with 2 x 10-6 for a mitochondrial hotspot.
Consequently, the best available estimate is that the mutation rate in mitochondrial DNA is
apparently several hundred-fold higher than in nuclear DNA.
Fig. 31: Position, type of mutation and frequency of hotspot mutations.
The type of mutation and its position for each of the sequenced mutants is shown. The
target sequence printed along the x axis is staggered for clarity. The positions of the two
genes encoded by this sequence, tRNAgly and NADH dehydrogenase subunit III, are
designated. The height of each peak reflects the average mutant fraction of this peak in all
lung samples analyzed to date (n=39). Note that mutants 1 and 2 are different substitutions
at the same base pair. Also note that mutant 13 (TA->CG, bp 10,072) was used as an
internal standard to measure the size of other peaks.
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4.4 COMPARISON OF SMOKERS AND NONSMOKERS
4.4.1 Twins discordant for smoking
Shown in Fig. 32 are mutational spectra for mutants with a lower melting
temperature than wild-type in two sections of the lungs of a pair of twins. In the top panel
(Fig. 32A) are the results for cells sampled from the right side of the main bifurcation
separating the right and left lungs of the smoking twin. Individual peaks are numbered
based on capillary hybridization with TMR-labeled standards. The artificial mutant
included as an internal standard is identified in each sample and was introduced at 10- 4 .
Panels 32B and 32C provide the results for the same individual when DNA isolated from
cells sampled from the first bifurcation in the right upper lobe was analyzed. The sample
was divided into two at the DNA isolation stage and each portion was independently
subjected to the procedure. The figure demonstrates that the results are almost identical
spectra. Figs. 32D and 32E provide the results when samples from the corresponding
smoking twin were analyzed, including samples from the right side of the first bifurcation
(Fig. 32D) and the right upper lobe (Fig. 32E).
The same low Tm mutants were observed repeatedly in different bronchial epithelial
cell samples. No specific low Tm mutants were present only in smoking samples, and the
overall mutant fractions were similar regardless of smoking history. Further, the amount
of variability was as great between two samples taken from different positions within a
single individual's lung as between samples taken from different individuals. For instance,
in the right main carina of the smoking twin (Fig. 32D), mutant 5.5 is the most prominent
mutant, present at a mutant fraction of 2 x 10-4 . In the right upper lobe sample from the
same individual (Fig. 32E), which was biopsied from just a few centimeters of airway
away, this particular peak did not rise significantly above background levels. This
difference is not attributable to artifacts of the procedure, as it is clearly observed in each
sample in duplicate. Further, intralung variation is as great as any observed between
smokers and nonsmokers.
These findings were in concordance with earlier experiments performed by K.
Khrapko in which a muscle tumor was sliced into several sections with a microtome (see
Figure 33). Mutational spectra were determined for two adjacent slices and a remote slice.
The adjacent slices showed similar mutational spectra while the remote slice had a distinct
spectra. These findings suggest a "clustering" of mitochondrial mutants within solid
tissues.
Fig. 34 provides the mutational spectra, including both low and high Tm mutants,
for a representative sample from each of the six twins. This figure includes the TMR-
labeled "standard set" of previously purified mutants that was coseparated with each sample
and recorded in a separate channel. Similar observations as reported for Fig. 32 are here
extended to the high Tm mutants and other twin pairs. The same mutants were repeatedly
observed as the most prominent mutations in all of the samples, although a particular
mutant may not be detectable in a given sample. Further, an extra mutant not part of the
standard set was occasionally observed at a significant frequency in a particular sample (for
instance, peak x in Fig. 34A). No specific peaks were observed consistently in smokers'
samples and not in nonsmokers. Further, the overall mutant fraction, based on comparison
with internal standards, was not significantly increased in smokers.
4.4.2 Dissected lungs
The brush biopsy samples that were obtainable from twins' lungs were analyzed
through the third generation of airway. In order to test whether smoking-induced
Fig. 32: Sample of low Tm mutational spectra from twins bronchial epithelial cells.
Brush bronchoscopy samples were biopsied from the right main carina and the first
bifurcation of the right upper lobe from smoking and nonsmoking identical twins. Samples
were subjected to the procedure for determining mitochondrial mutational spectra as
described in Materials and Methods, and the low Tm mutants are depicted. Individual
peaks are identified as specific mutants by number based on comigration with TMR-labeled
standards recorded in a separate channel (not shown) and were confirmed by capillary
hybridization. The artificial mutant was added as an internal standard at 10-4 prior to
CDGE. Low Tm mutational spectra were determined from the nonsmoking twin right main
carina (A) and right upper lobe in duplicate (B) and (C). The DNA was split after
restriction digestion and internal standards were added separately. Duplicate samples were
loaded on a CDGE and analyzed independently. The low Tm mutational spectra were also
determined from the smoking twin's right main carina (D) and right upper lobe (E).
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Fig. 33: Mitochondrial mutational spectra of a muscle tumor sample sliced with a
microtome.
Three slices of a muscle tumor, two adjacent to each other (A and B) and one remote (C)
were analyzed to determine the mitochondrial mutational spectra. Samples were run prior
to high resolution gel conditions and were not subjected to capillary hybridization. Mutants
are therefore lettered instead of numbered. Mutants with the same letter in different
samples are likely to represent the same mutant, but capillary hybridization would be
required for confirmation.
Source: K. Khrapko
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Fig. 34: Mutational spectra of bronchial epithelial cell samples from three pairs of twins
discordant for smoking.
Mutation spectra of a representative sample from each of the six twins included in the study
are shown. Both high Tm homoduplexes (left panels) and low Tm homoduplexes (right
panel) are shown. (A) The results from twin pair 1; both samples were biopsied from the
right upper lobe. (B) Samples taken from the second pair of twins. For the smoking twin,
the sample was taken from the right upper lobe and for the nonsmoking twin from the left
lower lobe. (C) Mutational spectra of samples biopsied from the third pair of twins, in
both cases from the right lower lobe. Cells were resuspended in 100 ml PBS and the
mutational spectra were determined for each sample as described in Materials and Methods.
The artificial mutant and p13 were added as internal standards at 10-4 except in the case of
twin pair 3, nonsmoking sample, in which p13 was added at 10-5 . Shown are fluorescein-
labeled homoduplexes and the TMR-labeled standard set with which they were
coseparated. Peak identity was confirmed by capillary hybridization.
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mutations were present in airways distal to the third generation, bronchial epithelial cells
were isolated from dissected whole lungs. Mutational spectra derived from dissected
lungs, including samples from both smokers and nonsmokers, were similar to spectra from
bronchoscopy samples. The same mutants observed in bronchoscopy samples were also
represented in the dissected lungs, and the mutant frequencies were similar as well. No
significant differences were observed in smokers compared to nonsmokers in any of the
airways tested, through the eighth bifurcation.
4.4.3 Average mutant fractions
The previous figures have demonstrated that there are no new, prominent mutants
observed in smokers bronchial epithelial cells and not in nonsmokers' cells. Further, they
also reveal that the overall mutant fraction is not larger in smokers samples. Another
important question was whether any particular one of the mutants commonly observed in
the standard set was present at a significantly higher frequency in the smokers as compared
with the nonsmokers. Shown in Fig. 35 is a summary of the average mutant fraction for
each of the mutants commonly observed among bronchial epithelial cell samples in smokers
and nonsmokers. Smokers' mean mutant fractions represent averages from 13
bronchoscopy samples taken from 4 individuals and 14 samples from dissected lungs of 2
individuals. The nonsmokers' mutant fractions represent the mean from 11 bronchoscopy
samples taken from 4 individuals and 5 samples taken from 1 dissected lung. These data
are not normally distributed and therefore the use of a standard deviation is not strictly
appropriate. However, the standard deviations are included in order to clarify the
conclusion that no specific peak was statistically significantly different between the
smokers and nonsmokers.
The standard deviations on the mean mutant fraction are large as compared with the
mean for many of the specific mutants. The large standard deviations reflect cases in which
individual mutants were substantially overrepresented in particular samples. An example of
such an instance is the large size of mutant 5.5 in the smoking twin, right main carina
sample pictured in Fig. 32D. The same mutant was barely detectable in a sample taken a
few centimeters of airway away as shown in Fig. 32E.
4.5 Variability in mutant fractions
While the same hotspots were observed repeatedly in multiple bronchial epithelial
cell samples from many individuals, the frequency of individual mutants varied
significantly in different samples. This variability could not be attributed to experimental
errors, smoking status, position within the lung, age, gender, or any other variable
measured.
In order to better understand the distribution of mutant fractions among samples,
the mutant fractions were plotted as histograms. Mutant fractions were measured in each
bronchial epithelial sample for 16 mutants that were considered unlikely to be PCR noise
(p6 was eliminated) or adducts (p3 was eliminated). For the samples that were analyzed in
duplicate (about 2/3 of the database), mutant fractions were averaged. In approximately 1/3
to 1/2 of the cases, the mutant fractions were confirmed by capillary hybridization.
Samples likely to represent errors in the introduction of the internal standard, for instance,
in which high Tm or low Tm mutants were consistently over or under represented (4
samples), were discarded from analysis. The final database contained mutant fraction data
for 570 mutants from 39 samples. A table containing the 570 mutant fractions is provided
in the appendix.
Histograms of the number of samples containing a particular range of mutant
fractions were generated for each of the mutant peaks. Examples of three such histograms
are given in Figure 36. The mutant fractions are not normally distributed. There are often
Fig. 35: Mean mutant fractions in smokers and nonsmokers.
Histogram of mean mutant fractions in smokers and nonsmokers. Peak areas were
measured in high resolution homoduplex runs for each of 17 frequently observed mutants.
Smokers were represented by 13 bronchoscopy samples taken from 4 individuals and 14
samples from dissected lungs of 2 individuals. The mean of the nonsmokers represents 11
bronchoscopy samples taken from 4 individuals and 5 samples taken from 1 dissected
lung. Peak areas were converted to mutant fractions based on comparison with the
introduced internal standard. Mutant fractions were measured and the mean and standard
deviations determined. Mean mutant fractions for smokers (speckled bars) and
nonsmokers (white bars) are plotted. The standard deviation is designated by a line
extending from the mean to the position of the mean plus one standard deviation.
Mutant Fractions for Each Mutant in Smokers and Nonsmokers
9.00E-04
8.00E-04
7.00E-04
o 6.00E-04
Lu 5.00E-04 - Smokers
C
-ONonsmokers
S4.00E-04 -
r
2 3.00E-04
2.00E-04
1.00E-04
O.OOE+00 .
, () lO LO (0 - ) lO Cj LO * L. w 00 LO 0)
LO T T- CO LO 00
Mutant
Fig. 36: Examples of mutant fraction histograms.
Mutant fractions were measured in 39 bronchial epithelial cell samples. In some cases, a
particular mutant was difficult to measure and was therefore eliminated from analysis. The
number of samples with a given mutant fraction was plotted and the results are shown for
three mutants, p18, p1 9 and p 11.5.
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one or two samples that contain a significantly larger mutant fraction than other samples
(for instance, the unusually large p18 shown in Fig. 36). These observations are unlikely
to reflect errors in the procedure as they have been observed repeatedly in duplicate.
Further, such mutants can vary as compared with the mean by as much as 5- to 11-fold,
which is considerably larger than the variability observed when a sample is split. Such
mutants are believed to represent the manifestations of clonal expansions of mutant-rich
cells, as described further below.
Another observation is that, with the exception of outliers, the mutant fractions for
each mutant do cluster around a consistent value characteristic of the mutant. Some
mutants are clearly more frequent than others. The largest mean of 4 x 10-4 was observed
for pl, while the smallest mean was for p11.5 with a mean of 5 x 10-6. The mutant
fractions for particular peaks therefore can be considered to reflect average mutant fractions
characteristic of bronchial epithelial cells. Because many samples of bronchial epithelial
cells have been analyzed to date, it is possible to compile a quantitative representation of a
"typical" bronchial epithelial mutational spectrum. These mean mutant fractions are shown
in the histogram in Figure 31.
In order to better represent the variability observed for specific mutants among the
samples analyzed, the histograms for all mutants were superimposed on a single plot.
First, the mean was determined for each mutant. The "q-test" was applied to this
calculation; if a particular mutant increased the range of mutant fractions for the all samples
by more than two-fold, it was not included in the estimation of the mean. The x-axis was
then taken as the fraction of the mean for that mutant and the y axis as the number of
samples with a mutant fraction in that range. This permitted superposition of all mutants to
generate a single histogram (see Figure 37). The vast majority of mutants (551/570) are
present in a particular sample at less than four times the mean for the particular mutant. In
ten cases, a mutant was observed at 5 to 11-fold the mean for that mutant. In two cases,
mutants were observed at a significantly higher frequency than in other samples (>40-fold).
Dilution experiments were also performed in order to investigate the distribution of
mitochondrial mutants among cells. TK6 cells grown for 400 generations contained two
prominent mutants with melting temperatures lower than wild-type, p (GC->AT mutation
at bp 10,068) and p1.5 (GC->AT mutation at bp 10,085). p1 .5 is not generally observed
in tissue samples. The homoduplex spectra for a large sample of these cells is shown in
Fig. 18. Aliquots of these TK6 cells were diluted and their concentration confirmed by cell
counting with a hemacytometer. Defined numbers of cells were subjected to PCR: 5 x 103
cells per PCR reaction, 103 cells per PCR reaction and 102 cells per PCR reaction. The
fraction of cells that were actually amplified was monitored by introduction of an internal
standard. Approximately 1/3 to 1/2 of the cells present were amplified; samples containing
more cells amplified more completely. The PCR products were enriched for mutants
through two iterations of CDCE collection of mutants and PCR with Pfu. Mutant fractions
were measured for pl.5 and pl and their ratios, plotted against the number of cells per
sample, are shown in Figure 38. Note that the ratio of the pl.5 to pl mutant fraction
should not be affected by the PCR efficiency. The variance in the ratios is much higher for
samples with 5000 and fewer cells per sample than for the three samples with 100,000
cells, which showed very similar results. This suggests that the mitochondrial mutants are
clustered among cells, and the number of mutants per cell is likely to vary over a wide
range.
Fig. 37: Histogram of the number of samples versus the fraction of the mean for all peaks.
For each mutant, the mean mutant fraction was calculated and the number of samples with a
given fraction of the mean was plotted. The same data are shown on two plots: (A) all of
the data are included and the x axis values extend to 56, (B) two of the data points are not
included and the fraction of the mean is truncated at 12.
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Fig. 38: Ratio of mutant fractions for p1.5 and p observed in limiting dilution experiments
with TK6 cells grown 400 generations.
For the largest sample (100,000 cells), the mutational spectra was determined as in
Materials and Methods. For smaller samples, known amounts of TK6 cells were diluted
and added directly to a PCR reaction. After amplification, mutants were enriched by two
rounds of CDCE enrichment and Pfu PCR. The ratio of the amount of p1.5 to the amount
of pl was plotted. Each point represents an independent PCR reaction.
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4.6 Mutant fractions and age
4.6.1 Infant
In order to better understand the behavior of mitochondrial point mutational
hotspots as a function of age, bronchial epithelial cell samples from an infant who died of
sudden infant death syndrome were analyzed to determine the mutational spectra. The
mitochondrial point mutation fractions present in these samples were significantly lower
than for adults. An example of a mutational spectra observed for high Tm mutants for
epithelial cells isolated from the left lobe of the infant is shown in Figure 39. Note that the
internal standard was added at 10-5 , which is 10-fold lower than the mutant fraction used
for adult tissue samples. The large peak on the left is assumed to be a nuclear pseudogene
of this sequence, as it is consistently observed in human samples and contains multiple
mutations compared with the wild-type mitochondrial sequence (Hadler et al., 1983; Hu et
al., 1995; Lonsdale et al., 1983; Richter, 1983). Three different sections of the infant's
lung were investigated, and all three contained mutant fractions lower than any observed in
adult lung samples. These findings are consistent with the hypothesis that the mutations
observed in different human adult tissues are somatic mitochondrial mutations that
accumulate over the subject's lifetime.
These observations also make it extremely unlikely that the mutations detected are
polymorphisms. One might argue that the 17 mutational hotspots that were repeatedly
observed were actually inherited as polymorphisms, and that the differences within a single
organ reflect variations due to segregation of the mutants. This would require that all of the
individuals tested to date inherited the same 17 mutants as polymorphisms in this 100 base
pair target. The same level of polymorphisms would be expected for the rest of the
mitochondrial genome of 16.5 kb, implying that each individual should have inherited, on
average, 2805 different polymorphisms according to this logic. Such an argument is
extremely unlikely because, first, it is believed that there is a bottleneck in mitochondrial
DNA copy number in oogenesis (Bolhuis et al., 1990; Hauswirth et al., 1985; Laipis et al.,
1988). One study of mitochondrial DNA copy number during mammalian oogenesis
concluded that only 5 copies are likely to be present as founders in the fertilized zygote
(Hauswirth et al., 1985), while an experiment with heteroplasmic mice carrying two
mtDNA genotypes concluded that the effective number of segregating units for mtDNA is
approximately 200 in mice (Jenuth et al., 1996). Second, because these mutations are so
low as to be essentially undetectable in the infant sample, the argument would require that
coincidentally, the infant is the only one of the individuals tested so far who did not inherit
these mutations.
4.6.2 Bronchial epithelial cells
Analysis of samples from four dissected lungs permitted consideration of the trends
in mitochondrial mutant fractions with age. Shown in Figure 40 are the results when the
sum of all of the mutants in the standard set for each of several different samples taken
from four individuals was plotted against age. The infant samples contained significantly
fewer mutants than samples from adults. The point mutant fractions in the 84 year old and
two middle aged individuals are similar. It is not clear from these data whether the most
appropriate interpretation is that the mutant fraction is increasing modestly but consistently
with age, or whether the mutant fraction increases between infancy and adulthood and then
plateaus. The results suggest that point mutations in human bronchial epithelial cells do not
increase supralinearly with age as has been observed for deletions in post-mitotic tissues
(see Figure 6 in Literature Review: mtDNA and Aging), although analysis of more
individuals is required to draw firm conclusions.
Fig. 39: Mitochondrial mutational spectra of bronchial epithelial cells from an infant.
Lungs of an infant who died of sudden infant death syndrome were harvested and
bronchial epithelial cells were collected from the left lobe. DNA was isolated and the
mitochondrial mutational spectra was determined. Shown are the high Tm mutants that
resulted. Note that the internal standard is present at a mutant fraction of 10-5 , ten-fold
lower than the mutant fraction used for adult tissues.
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Fig. 40: Mitochondrial mutant fractions with age.
Mutant fractions for each of the mutants in the standard set were summed for each
bronchial epithelial sample analyzed from four dissected lungs. The sum of the mutant
fractions in different lung sectors is plotted against the donor's age.
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4.6.3 Other tissues
While studies on bronchial epithelial cells suggest that point mutations do not
increase supralinearly with age, it is important to note that lung tissue is not among the
tissues for which deletions are observed to increase substantially with age. Studies on the
behavior of point mutations with age in different tissues will be performed by K. Khrapko
as faculty of the Division of Aging at Harvard Medical School. As a preliminary
experiment toward this goal, a single experiment was performed in which the mutational
spectra present in the hippocampal region of the brain from a 100 year old man and a heart
muscle sample from a 77 year old man generously provided by J. Wei and J. Vijg (Harvard
Medical School) were determined. While the hippocampal section of the brain did not
show prominent mutants (no mutations larger than the 10-4 internal standards were
observed), the heart sample contained two unusually large mutations. One mutant, which
was more stable than wild-type, was estimated to be present at a mutant fraction of 6 x
10-3 (shown in Figure 41), while a second mutant that was less stable than wild-type was
estimated to be present at a mutant fraction of 1.5 x 10-2. These two mutants are the
largest mutations yet observed with this procedure. Neither of the mutants are members of
the "standard set."
Fig. 41: High Tm mutational spectra of a heart sample from a 77-year old man.
Heart muscle DNA generously provided by Dr. J. Wei (Harvard Medical School) was
analyzed to determine the mitochondrial mutational spectra. Shown are the hi h Tm
mutants. A single high Tm mutation was present at a mutant fraction 6 x 10- . Not shown
is a low Tm mutant also discovered in this sample present at an estimated 1.5 x 10-2.
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5. DISCUSSION
5.1 SUMMARY
A methodology has been developed that permits detection of point mutations
present in a 100 bp mitochondrial DNA target sequence in human tissue samples. The
procedure couples partially denaturing electrophoresis to enrich for mutant over wild-type
sequences with high-fidelity PCR to amplify mutant-enriched samples with minimal
introduction of PCR errors. While other methods are available for detecting and measuring
low frequency point mutations, they are limited to a single known mutation using allele
specific PCR (Cha et al., 1992; Wu et al., 1989a) or the ligase chain reaction (Abravaya et
al., 1995; Barany, 1991; Landegren et al., 1988; Wu et al., 1989b), or mutations present in
<6 base pairs in a naturally occurring or artificially created restriction enzyme recognition
site (Felley-Bosco et al., 1991; Kan et al., 1978; Khrapko et al., 1994a; Kumar et al.,
1990; Pallotti et al., 1996). The ability to determine a mutational spectrum in a 100 bp
target sequence in any human tissue by avoiding a requirement for phenotypic selection is,
to the best of our knowledge, unique.
The technical advances that we have achieved in the course of this work include the
development of CDGE and CDCE conditions that permit enrichment of mutants, conditions
for high-fidelity PCR, accurate use of internal standards, a double dye CDCE detection
system, high-resolution CDCE conditions, capillary hybridization and tests for
asymmetrical species. These methods should prove valuable in future experiments
designed to determine the mutational spectra in nuclear sequences.
The methodology is sufficient to observe the prominent hotspot mutations in
mitochondrial DNA isolated from human tissues. Hotspot mutations were discovered and
were found to be present at a higher mutant fraction than has been detected for nuclear
sequences, with the ratio estimated as several hundred-fold. The same set of approximately
17 hotspot mutants were observed repeatedly in human bronchial epithelial cells from
multiple donors, TK6 cells, colon and colon tumor, muscle and muscle tumor. Specific
mutants were not present as prominent peaks in some samples, while prominent peaks
representing other mutants not part of the "standard set" were observed on occasion as
well. Sequencing revealed that most of these mutations were predominantly transitions,
both GC->AT and AT->GC.
Smokers and nonsmokers contained the same set of mutational hotspots as
observed in other organs. There were no prominent smoking-specific hotspots and the
overall mutant fractions were not larger in the smokers than the nonsmokers. Comparison
of the average mutant fractions for each of the mutants observed repeatedly did not reveal
significant differences between smokers and nonsmokers. There was as much variability
in the fractions observed for individual mutants in a single lung as between smokers and
nonsmokers.
When all of the bronchial epithelial cell samples are considered, most of the mutant
peaks observed were within 4-fold of the mean for the specific peak (551/570). Significant
outliers were also observed. These are interpreted as reflecting the accumulation of
multiple mitochondrial copies containing a specific mutant within a bronchial epithelial stem
cell. In two instances, the mutant fractions were significantly larger than the mean (>40-
fold). Such cases may reflect proliferation of mitochondria in response to lack of oxidative
phosphorylation function.
The results suggest that the most likely sources of mutation in human mitochondrial
DNA are endogenous sources, although the results are not sufficient to distinguish between
replication errors, adduction by endogenous compounds or another pathway.
Left unresolved is the mechanism by which smoking causes cancer. Two of the
important hypotheses are first, that smoking induces prominent mutations in nuclear but not
mitochondrial DNA due to the high spontaneous background in mitochondrial DNA, and
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second, that smoking causes cancer by a mechanism distinct from mutagenesis, for
instance, by altering the kinetics of cell proliferation in bronchial epithelial cells.
5.2 SOURCES OF OBSERVED MUTANTS
5.2.1 Spontaneous
Among the most important questions raised by these results is the source of
mitochondrial mutations in human lung tissue. For several reasons, the most important
source(s) of mutations appears to be endogenous. One of the major findings that supports
this conclusion was the observation that most of the mutational hotspots observed in human
tissue are also observed in human cells grown in culture. Although the mutant fractions are
generally significantly lower in the cultured cells, the same mutants are apparently present
as confirmed by capillary hybridization.
In addition to the observation that the same mutational hotspots are present both in
vivo and in vitro, further evidence is derived from the observation that the same kinds and
positions of hotspot mutations are observed in colon, muscle and lung. Note that the one
heart sample investigated is an exception. Our finding that the same mutations were present
in multiple tissues, which would be expected to be exposed to a very different array of
mutagenic agents but share the possible endogenous sources of mutants, thus supports this
conclusion.
Also critical is the conclusion that the mitochondrial mutational spectra in smokers'
bronchial epithelial cells are indistinguishable from those in nonsmokers. The link between
smoking and lung cancer is among the most clearly demonstrated for exogenous agents to
which humans are routinely exposed. Further, multiple known and potent mutagenic
agents are present in cigarette smoke. Consequently, if smoking is not the most important
contributor to mutagenesis in the bronchial epithelial cells of smokers, then endogenous
mutagenic sources are likely to be the most important contributor to mitochondrial
mutagenesis in general.
The several hundred-fold higher mutant fractions for these mitochondrial hotspots
relative to nuclear hotspots, and to the level of mutagenesis that might be expected to be
induced by environmental factors, provides a reasonable explanation for our finding. As
discussed in Results, L. Marcelino and colleagues (in prep.) demonstrated that a toxic dose
of MNNG would be required to induce mutants of approximately the same frequency as
observed in human tissue samples. Consequently, environmental agents may induce
mitochondrial mutations, but they apparently do so at levels significantly lower than those
that have been induced by endogenous sources.
A critical question in attempting to understand the relationship between exposure to
mutagenic agents, adduction, and mutations in mitochondrial and nuclear DNA is the
response of polymerase-y when it encounters adducted DNA. Since there are many copies
of mitochondrial DNA per cell, it is not necessary for the cell's survival to replicate each
one at every division. In fact, Clayton and colleagues observed that in cells treated with
ultraviolet light, mitochondrial DNA copies with pyrimidine dimers were preferentially not
replicated (Clayton et al., 1974). Further, in an experiment performed in vitro with
synthetic oligonucleotides, tetrahydrofuran, an analog of an abasic site in DNA, was found
to inhibit elongation by DNA polymerase-y (Pinz et al., 1995). The findings of L.
Marcelino and colleagues described in the Results section showing that a large dose of
MNNG induced detectable mitochondrial mutations, while a substantial dose of
benzo[a]pyrene diol epoxide did not (Marcelino et al., in prep), might reflect the gamma
polymerase falling off the molecule when it confronts bulky adducts, including
benzo[a]pyrene diol epoxide. It is also noteworthy that bulky adducts are not repaired in
mitochondrial DNA while alkylating damage is repaired (LeDoux et al., 1992). The
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distributive nature of polymerase-y is unlikely to be sufficient to explain completely the lack
of smoking-induced mutations, however, because there are high levels of alkylating agents
in addition to polycyclic aromatic hydrocarbons in cigarette smoke, and mutations induced
by these agents were also not observed.
5.2.2 Endogenous mutagens or replicative errors?
The two most likely sources of endogenous mutations are errors introduced by the
mitochondrial gamma polymerase during replication, and mutations that result from in vivo
replication past adducts generated by reaction with endogenous compounds. Consideration
of the types of mutations observed, which are mostly transitions, is not sufficient to
support a conclusion. A spectrum dominated by AT->GC and GC->AT transitions is
reminiscent of the spectrum produced by the Klenow fragment of DNA polymerase I from
E. coli (Keohavong et al., 1989). It is also suggestive of the type of spectrum observed in
the lacI gene in E. coli that are defective in mismatch repair (Leong et al., 1986; Schaaper et
al., 1987). While mismatch repair has been reported for yeast mitochondrial DNA (Chi et
al., 1994), it has not been reported for human mitochondrial DNA. The mutational spectra
observed could therefore be plausibly hypothesized to result from errors in DNA replication
in the absence of mismatch repair, which could explain not only the predominance of
transitions but also the higher mutant fractions in mitochondrial than nuclear DNA.
The mutations observed may also result from reactions with endogenous agents, for
instance, reactive oxygen species. Such species would be expected to be more mutagenic
to mitochondrial than nuclear DNA based on their high concentrations in the inner
mitochondrial membrane. The types of mutations induced by oxidative radicals have been
reported in several systems. The hprt exon 3 mutational spectrum of hydrogen peroxide-
treated TK6 cells included a prominent AT->TA transversion and two less prominent GC-
>CG transversions (Oller et al., 1992). As will be described further below, AT->TA and
GC->CG mutations have been missed with the mutational spectra methodology employed.
Grollman and colleagues investigated the types of mutations induced during polymerization
past 8-OH-dG constructed into a synthetic template, and discovered that GC->TA
mutations were predominantly induced (Shibutani et al., 1991), while Kuchino and
colleagues reached a different conclusion, finding that all possible misinsertions across
from the adducted nucleotide were observed and further that pyrimidines adjacent to the
adducted residue were also misread (Kuchino et al., 1987). Finally, in a study that
specifically addressed the behavior of polymerase-y at the site of 8-OH-dG, C was
incorporated into 73% of full length products and A was incorporated into 27%. Insertion
of an adenine would lead to GC->TA transversions (Pinz et al., 1995). It is not well-
established, however, exactly which adducts are expected to result from oxidative damage.
Therefore, although the mutations observed, mainly transitions, are not precisely what
would be expected from reaction with reactive 8-OH-dG, it is not yet possible to resolve
this question.
5.2.3 Comparison with MNNG-induced mutational spectrum
Another interesting finding is that two of the mutations that are frequently observed
in human tissues, p5 and p5.5, were also observed by L. Marcelino and colleagues as
mutations induced by the model alkylating agent N-methyl-N'-nitro-N-nitrosoguanidine
(MNNG) (Marcelino et al., in prep). Both of these mutations are GC->AT transitions at
guanines preceded by adenines, the most frequently mutated site for alkylating agents
(Burns et al., 1987). Such findings raise the interesting possibility that endogenous
alkylating agents may induce these mutations in human tissues.
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5.3 POTENTIAL SOURCES OF ERROR
While the mutational spectra that are produced by the mitochondrial mutational
spectra methodology described are, for reasons discussed above, likely to accurately reflect
the mutations present in tissue samples, there are several important sources of error in these
experiments. Mutant fractions for individual peaks are estimated to be very likely to be
correct within a factor of approximately three. None of the major findings and conclusions
of this thesis would be altered by minor differences in mutant fraction that would result
from the sources of error described below.
5.3.1 Internal standard
Accurate addition of the internal standard requires that the copy number of a given
sample is measured precisely before the CDGE step. The difficulty of measuring small
amounts of viscous material, like concentrated DNA samples, may lead to some
inaccuracies in this measurement. Further, internal standards must be diluted significantly
for use as a reference, a process that can lead to imprecision. It is also significant that
accurate introduction of the internal standard requires complete restriction digestion. If the
restriction digestion is incomplete, then fewer than the expected numbers of copies will
migrate in the high Tm mutant range, and the high Tm internal standard will be
overintroduced. Fortunately, underrestriction digestion (which was observed in one
sample), can be detected when the CDGE gel is stained with ethidium bromide. The
sample is observed as a bright band of high molecular weight instead of a uniform smear,
and such samples can be discarded from analysis. Generally, when the copy number of a
given sample was measured independently, the results were within two-fold, although on
occasion variations of three-fold were observed.
5.3.2 Peak measurement and identification
Peak measurement is another factor that can lead to inaccuracies in estimates of
mutant fractions. Peaks that are well-separated from other peaks during high-resolution
homoduplex runs can be measured accurately, but for peaks that are not well-resolved,
estimates of the area under each of the peaks can be difficult. Capillary hybridization can
be extremely valuable in such cases in determining accurate mutant fractions, although
quantification is better for high Tm than low Tm mutants. Peaks may also be mistaken for
an incorrect mutant sequence if they are not well-resolved. Capillary hybridization can
clarify essentially all such cases.
Another potential source of error involves differences among the mutants in
amplification efficiency. Given that our procedure involves about 109 -fold amplification,
the relative sizes of the peaks observed depends not only on the original mutant fractions,
but also on the relative amplification advantage or disadvantage of a particular mutant
(allelic preference). To discover if the mutant fractions observed deviate significantly from
the original fractions due to allelic preference, the relative amplification efficiencies of most
of the mutants in the standard set were tested. Mutants were mixed together and amplified
1000-fold in the same PCR reaction and the relative sizes of the peaks before and after the
amplification were compared, as suggested by Keohavong and Thilly (Keohavong et al.,
1989). The amplification efficiency of each of the mutants in the standard set was within
±6% of the efficiency of amplification of the wild-type (0.6 per cycle). Given that the
overall amplification of mutants during our procedure is about 109 -fold, these differences
in amplification efficiencies will lead to errors in the measurement of mutants within a
factor of two. Since it is not possible to check the amplification efficiencies of all
theoretically possible mutants, some mutants with a severe amplification disadvantage may
have originally been present in the samples but were not observed. It is important to note,
148
though, that the artificial mutant which was created for use as a low Tm internal standard
and was never observed in human tissue samples, amplified with an efficiency similar to
wild-type.
5.3.3 Missed mutants
Theoretically, constant denaturant electrophoresis should be able to separate all
mutants from each other, especially in heteroduplex form (Borresen et al., 1991; Ridanpiii
et al., 1995). While all heteroduplexes are easily separable from wild-type, some mutants
may be lost during the CDGE homoduplex separation that occurs immediately after
restriction digestion. Two portions of the constant denaturant gel are excised, one above
and one below the wild-type. The area left for the wild-type, approximately 1.2 cm of gel,
is expected to contain some homoduplex mutants that have similar melting behavior to the
wild-type. Reconstruction experiments have been performed to determine which mutations
are likely to be lost because they migrate too close to the wild-type. While all mutations
that convert GC->AT base pairs or vice versa have always been detectable with such
experiments, some mutations were not. An A deletion in a run of six adenines is
represented at about 50% of its original frequency post CDGE under conditions used in
these experiments, because it is present at the border of the high Tm region excised. When
an AT->TA mutation was tested, this particular mutation was discovered to migrate close to
the wild-type and therefore to have been excluded. Mutations that convert a GC base pairs
into AT base pairs or vice versa, for both transition or transversion mutations, therefore,
would be expected to be included in the spectra we observe. Single base pair deletions
might or might not be included. GC->CG and AT->TA transversions have a high
probability of migrating too close to the wild-type for inclusion.
5.4 LACK OF SMOKING-INDUCED SPECTRA
No significant increase was observed in the overall mutant fraction or individual
mutants in bronchial epithelial cells sampled from smokers compared with nonsmokers for
the mitochondrial sequence investigated. Any mutations induced by smoking in lung
epithelial mitochondrial DNA must be small (<10-6) compared to those observed at
frequencies as high as several times 10-4 . Yet, as discussed previously, smoking is clearly
associated with lung cancer (Doll et al., 1976; General, 1989; Hammond, 1966; IARC,
1986; Wynder et al., 1950). Several possible explanations for these findings are offered
and discussed: (1) the sequence is vacant, (2) only a subset of the population is at risk and
no members of this subset were sampled, (3) mitochondrial mutations induced by smoking
are masked by spontaneous mutations in mitochondrial but not nuclear DNA, and (4)
smoking induces lung cancer by a mechanism distinct from mutagenesis.
5.4.1 Sequence is vacant
One possibility is that this particular DNA sequence is "vacant" for smoking-
induced mutations. Existing data suggest two ways in which the probability that a given
100 bp is vacant for a given compound can be estimated for nuclear sequences. Extensive
experience with the hprt gene (Cariello et al., 1990; Chen et al., 1994; Kat, 1992;
Keohavong et al., 1992; Oller et al., 1992), has shown that in approximately 15% of cases,
a particular compound will not induce a prominent hotspot in a given 100 bp region. The
low melting domain of hprt exon 3, for instance, is vacant for MNU (Kinkaid, 1993),
MNNG (Cariello et al., 1990) and ICR-191 (Cariello et al., 1990). An alternative
approach is to determine the frequency of mutations when one compound is used to induce
hotspots across an entire gene. Investigations of the mutational spectra of MNNG in MT- I
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cells revealed 11 point mutational hotspots in 1025 base pairs scanned, or 1 for every 93
base pairs (Kat, 1992).
The low fraction of GC base pairs in our low melting domain (27%) makes it a
relatively poor target for compounds that specifically adduct at guanines. However,
MNNG, a model alkylating agent with a preference for adduction at guanines, induced
eight hotspot mutations in this same sequence.
It remains theoretically possible that smoking-induced hotspots exist in other
regions of mitochondrial DNA, and would be detected by performing similar experiments
on a different mitochondrial sequence.
5.4.2 Subset of population is at risk
A second possibility is that only a fraction of individuals are susceptible to
smoking-induced mutagenesis. Indeed, while a very high fraction of those who develop
lung cancer in industrialized nations are smokers, only a small fraction of all smokers
develop lung cancer. Genetic factors may play a role in determining which smokers
actually develop tumors (Sellers et al., 1990). An inherited predisposition could exert an
influence in any of several aspects of lung cancer susceptibility. Large interindividual
differences in the rate of particle clearance from the lungs have been observed (Albert et al.,
1969; Wilkey et al., 1980), and studies of monozygotic and dizygotic twins indicate that
genetic factors have a major influence on this host defense (Camner et al., 1972). A
fraction of the population may also have inherited increased activity of drug-metabolizing
enzymes that convert tobacco-derived promutagens to their DNA-binding form (Ayesh et
al., 1984; Bartsch et al., 1991; Caporaso et al., 1990), which could affect lung cancer risk.
Indeed, the inducibility of aryl hydrocarbon hydroxylase activity in mitogen-stimulated
lymphocytes has been associated with a higher risk of lung cancer in smokers (Kirki et al.,
1987; Kellerman et al., 1973; Kouri et al., 1982). Further, an increased level of adducts in
human lungs has been correlated with a null genotype for the detoxifying enzyme
glutathione S-transferase (Shields et al., 1993).
The participants in this study were recruited because they were monozygotic twins
discordant for smoking. None of the participants had lung cancer. It could be argued that
smoking-induced mutations would have been observed if the study had included members
of a smaller, at-risk population. In order to test this hypothesis, healthy lung tissue from
smokers who have actually developed lung cancer would need to be tested for smoking-
specific mutational patterns.
5.4.3 High spontaneous mutant fraction
A third possibility is that smoking does induce mutations in mitochondrial and
nuclear DNA but that in mitochondrial DNA, in contrast to nuclear DNA, those mutations
are masked by the generally higher level of spontaneous mutations. Indeed, the mutant
fractions detected in these mitochondrial sequences are several hundred-fold higher than
expected for nuclear sequences, as discussed previously. Possible explanations include
differences in the level of oxidative damage to mitochondrial versus nuclear DNA, or the
absence of nucleotide excision repair or potentially mismatch repair in mitochondrial DNA.
The expected mutant fraction of smoking-induced mutations can be estimated based
on long-term, low-dose treatment of human cells with benzo[a]pyrene (Chen et al., 1996).
Treatment for 20 days with 0.02 pgM BaP, a concentration similar to that achieved by
smoking 10 cigarettes a day, induced a mutation rate of 8.4 x 10-7 hprt deficient mutants
per generation. Assuming an individual's lung cells divide three times a year, 20 years of
smoking 10 cigarettes per day would imply an induced mutant fraction of 5 x 10- for the
entire hprt gene for benzo[a]pyrene. A corresponding "1% hotspot" would be present at 5
x 10-7 . If the induced level per base pair in mitochondrial DNA were similar to that for
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nuclear DNA, then induced mutants at such a level might not have been observed given the
much more prominent mutations that result from endogenous mutagens.
5.4.4 Alternatives to mutagenesis
The final possible explanation for the observations reported herein that will be
discussed is that smoking induces cancer by a mechanism distinct from induction of point
mutations. Two possible pathways are by increasing recombination and by altering cell
kinetics.
5.4.4.1 Recombination
Smoking could theoretically cause cancer not via point mutations but by inducing
larger scale chromosomal damage, for instance recombination events, that would not have
been detected in this assay. As described in the Literature Review: Smoking-induced
deletions, the ability of cigarette smoke to induce homologous recombination in the nuclear
genome of mice has been reported (Jalili et al., submitted).
Until recently, it was assumed that there is no homologous recombination in
mitochondrial DNA. Studies suggest that it is at least an infrequent event. Ohno and
colleagues described a patient with both the MELAS point mutation at bp 3243 and a
mtDNA deletion (Ohno et al., 1996). The deletion was found only in mtDNA molecules
that carried the 3242 mutation and not in those that were wild-type, suggesting that
crossover recombination between the deletion and point mutation is rare. However,
Thyagarajan and colleagues have recently reported that extracts of mitochondria from
human cells contain enzymes that can catalyze the homologous recombination of DNA
plasmids (Thyagarajan et al., 1996). These findings raise the possibility that recombination
may occur in mitochondrial DNA.
It is possible that the deletions of mitochondrial DNA observed in patients and, at a
lower frequency, the elderly (see Literature Review), result from intramitochondrial
homologous recombination events. Indeed, the deletions are often flanked by direct repeats
and have been shown to increase with age (Ashkenas, 1997; Ozawa, 1995). As discussed
previously, these deletions have been reported to be elevated in smokers compared with
nonsmokers (Ballinger et al., 1996; Liu et al., 1997).
5.4.4.2 Cell kinetics
Another possibility is that smoking leads to cancer by increasing cell proliferation
(Ackerknecht, 1953). Histological analysis has documented a significant increase in basal
cell hyperplasia among smokers (Auerbach et al., 1961), and that the extent of hyperplasia
is associated with the number of cigarettes smoked per day. In a study of over 22,000
slides of lungs from autopsy samples, the percentage of slides with 3 or more cell rows
(hyperplasia) was 9.4% for never smokers, 35.5% for those who smoked <0.5 packs per
day, 40.3% for 0.5-1 pack per day smokers, 63.8% for 1-2 packs per day smokers, and
76.2% for 2 or more packs per day smokers. In addition to observed hyperplasia,
increased cell turnover has been documented in rodent cells in response to smoking. [3 H]-
thymidine labeling of hamster epithelial cells exposed to cigarette smoke revealed increased
mitotic activity after exposure (Boren, 1970). These findings support the conclusion that
smoking causes cell proliferation.
Compounds that affect cell turnover can directly affect the probability of developing
cancer. P. Herrero and W. Thilly have been developing mathematical models to describe
cancer development that include explicit terms for the rates of cell division, cell death and
mutation. The model assumes that two mutations are sufficient to create an "initiated" cell
that gives rise to a dysplastic colony, and a third mutation is sufficient for the
transformation to a carcinoma. Cell turnover parameters are critical in determining the
probability that an initiated cell survives stochastic extinction. Cell division and death rates
are also used to model the amount of time necessary for a colony of initiated cells to obtain
a third mutation that would convert it into a carcinoma. The higher the division rate, the
shorter the period of time required for progression.
In conjunction with the mathematical models, W. Thilly and colleagues have
proposed to measure the cell division and death rates in healthy bronchial epithelium of
smokers and nonsmokers. Such experiments have already been performed in normal colon
epithelium, colon adenomas and colon carcinomas by Dr. E. Furth (University of
Pennsylvania). Expressed in rates of division or death per cell year (a and 3,
respectively), normal colonic epithelium has equal death and division rates of 2.92 per stem
cell-year. Adenomas have higher division (a) and death rates (3) of approximately 8.8,
with the division rate being slightly greater than the rate of cell death. Carcinomas do not
have an increased rate of cell death as compared with adenomas, but the rate of cell division
is increased to about 30 per year, which implies substantial growth for a colony. Once
these values were incorporated into the equation describing the probability of cancer at a
given age, the mutation rates for the first two initiating mutations could be estimated and
these were discovered to correlate well with expectations (3 x 10-7 ) (Robinson et al., 1994;
Grist et al., 1992).
P. Herrero and W. Thilly have applied similar reasoning to the data for lung cancer
mortality in smokers and nonsmokers. By assuming that the rate of cell death is the for
lung as colon, and applying the same mathematical model to lung cancer data for cohorts of
individuals born before and after cigarette smoking became widespread (see Figure 11),
they estimated the parameter (a-p), which represents net growth of an "initiated" colony.
For females, the value (a-) increased from 0.12 before widespread introduction of
cigarettes to 0.19 after cigarettes were generally available; for males, the increase was from
0.15 to 0.20. This suggests that smoking may play a role in inducing lung cancer via an
effect on cell kinetics.
If smoking were affecting cell turnover, then two changes actually observed in the
age-specific lung cancer death rates would be predicted. First, by increasing the probability
that an initiated cell survives to become a dysplastic colony, the probability of having
cancer would be greater at any given age. This change is clearly observed as cohorts are
compared progressing to those born most recently. Secondly, an increase in the number of
cell divisions per doubling of the dysplastic colony would be manifested by a shift in the
curve towards having cancer at earlier ages, a change that is also observed. It should be
pointed out, however, that modeling the lung cancer data also led to the conclusion that
smoking increases the mutation rate for the initiating mutation as well (from 1.2 x 10-6
mutations/cell-year in the target gene before cigarettes to 1.8 x 10-6 mutations/cell-year in
the target gene after cigarettes for females, and from 1.1 x 10-6 mutations/cell-year in the
target gene before cigarettes to 1.6 x 10-6 mutations/cell-year in the target gene after
cigarettes for males). Yet, an increase in the mutation rate for initiating mutations could
explain the higher probability of cancer at a given age, but would not be sufficient to
explain the shift in the curve. Experiments to determine empirically the rate of cell division
and death in human bronchial epithelial cells from smokers and nonsmokers will aid in
assessing the contribution, if any, that changes in cell turnover make to lung cancer
incidence.
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5.5 DISTRIBUTION OF MUTANTS
An important observation that resulted from these studies was that a particular
mutant in a given sample could, on occasion, be observed at a mutant fraction significantly
above the mean for that mutant. One possible explanation for these findings is discussed.
5.5.1 Mutant-rich clusters
After determining the mean mutant fraction for each of 16 mutants, the number of
samples containing a particular range of mutant fractions was plotted against the fraction of
the mean mutant fraction for that mutant (see Figure 37 in Results). In the vast majority of
cases (551/570), the mutant fraction for a given sample was within 4-fold of the mean for
that mutant. There were 10 cases (out of 570 observations) in which the mutant fraction
for a given sample was between 5 and 11-fold above the mean. Such cases are unlikely to
be attributable to errors in the introduction of the internal standard or statistical fluctuation
during analysis due to their large size and because they were consistently observed in
duplicate.
Since this variability was observed even within a single organ and could not be
attributed to smoking status, gender, position within the lung, or any other trait, small
samples are likely to be the source of the variability. If mitochondrial mutants were
distributed randomly among cells, it would be extremely unlikely that mutant fractions at 5-
11-fold the mean would be observed simply as a result of sampling. For a mutant with a
mean mutant fraction of 5 x 10-5 , a sample of 106 cells containing 400 mitochondrial DNA
copies per cell with this mutant represented at 8-fold the mean would contain 8 x (5 x 10-5)
x 400 x 106 = 1.6 x 105 copies. The average number of mutants per sample would be 2 x
104 copies. If this were a normal distribution (which it clearly is not), then the standard
deviation would be the square root of 2 x 104 or 141 copies. In such a case, the outlier
sample would be 993 standard deviations above the mean. Clearly, the default hypothesis
of random mutant distribution must be rejected.
Assuming that mitochondrial mutants may be clustered within cells makes such an
outcome more likely. Since fewer mutant-rich cells would be required to have been
sampled in order to generate the elevated mutant fractions observed, the variance would be
expected to be higher.
The accumulation of mitochondrial mutants in a particular cell can be pictured as
follows: Consider a cell containing a mitochondrial DNA mutation in the target sequence in
one of several hundred copies of mitochondrial DNA. When the mitochondrial DNA in
this cell is replicated, on average, a cell containing two mutant mitochondrial DNA copies
will result. When the cell divides, the two copies may separate such that each of the two
daughter cells receives a single copy. Alternatively, one daughter cell may receive both
copies. If this process continues over many generations, by chance, a small number of
cells containing many mitochondrial DNA copies would be expected to accumulate over
time.
It is not possible to estimate the size of such a colony without making assumptions
about the number of mutant copies per mutant-rich cell. Assuming 400 mutant copies per
cell, the size of the colonies for mutants 5- to 11-fold higher than the mean are generally in
the range of several hundred cells, depending upon the mean mutant fraction and the
number of cells used for the DNA isolation. Returning to the example above, if an excess
of cells containing 400 mutant copies were included in one sample of 106 cells causing it to
have a mutant fraction 8-fold times the mean, then this would require an extra 350
completely mutant cells.
We suggest that this could occur if a bronchial epithelial stem cell accumulated
many copies of a particular mitochondrial mutant. Cells derived from such a mutant-rich
cell would be expected also to contain many mitochondrial mutants. Thus, specific DNA
preparations may have been observed to include an unusually large mutant because a
colony of mutant-rich cells was sampled.
Clustering of nuclear mutants in solid tissues has been observed previously and
presumed to result from mutant stem cells. Dr. R. Cha divided mammary gland epithelium
into sections and used allele-specific PCR [the mismatch amplification mutation assay
(MAMA)] to measure the levels of H-ras mutants in DNA from each section (Cha et al.,
1994). Some sectors contained significantly higher levels of the mutant, suggesting the
possibility that a cluster of mutant cells derived from a stem cell containing an H-ras mutant
was sampled. Clustering of mutant cells likely to have derived from a mutant stem cell has
also been observed by immunohistochemical staining for p53 in epidermis (Jonason et al.,
1996). Further, Z.-Y. Chen, H. Zarbl and K. Hong have detected sections of bronchial
epithelial cells from autopsy samples containing unusually high levels of a K-ras mutation
also by allele-specific PCR (MAMA).
Finally, there is evidence for a similar phenomenon from heteroplasmic mice
carrying two mtDNA genotypes that differ from each other at 106 bases (Jenuth et al.,
1997). The mtDNA genotypes in colonic crypts, which are each derived from the clonal
expansion of a single founder cell, were examined. In crypt samples from two
heteroplasmic animals aged 4 and 15 months, the mean proportion of the BALB haplotype
was approximately 4% in the population of crypts from both animals. There were,
however, significant differences in the distribution of frequencies of the two mtDNA
genotypes among individual crypts in the young and old animal (see Figure 42). In
individual crypts from the 4-month-old animal, the proportion of the BALB haplotype
varied from 0 to 25%. In contrast, two distinct populations were observed in the 15-
month-old animal; most crypts had lost the BALB genotype completely (0% BALB), but a
small number of crypts contained predominantly (>50%) BALB mtDNA. These findings
support the following model. A stem cell containing a small number of BALB mtDNA
copies has some chance of losing each BALB copy to the daughter cell that becomes a
transition cell and ultimately a terminally differentiated cell, with each division. While most
stem cells lost all of the lower frequency BALB mtDNA copies by 15 months of life, a
small fraction of stem cells by chance retained the less frequent BALB genotype and
accumulated many mtDNA mutants.
5.5.2 Modeling mutant accumulation
Modeling the expected number of mutant-rich clusters in bronchial epithelial cells
was undertaken by P. Herrero. He assumed that there are 256 cells in a "turnover unit", all
of which derive from a single stem cell. The cells are arranged in a pyramidal structure
such that there is 1 stem cell, and 1 transition cell in the first layer, then 2 cells in the
second layer, 4 cells in the third layer and so on, up to 128 cells in the final layer. One cell
from the 128 cell layer dies each day. When 2 cells from the outermost, 128 cell layer die,
then a cell from the 64 cell layer must divide to replace them. When 2 cells from the 64 cell
layer have divided, a cell from the 32 cell layer must divide to replace them. And so on.
When the stem cell divides, it creates another stem cell and a transition cell. The model
developed by P. Herrero also assumes a mutation rate of 2 x 10-6, that there are 400
mtDNA copies per cell, and that mitochondrial mutants are distributed randomly to cells,
that is, once a cell contains two mitochondrial mutants, there is a 50% chance that one
mutant copy will be transmitted to each daughter cell, and a 50% chance that both mutants
will go to a single daughter cell. Using these assumptions, P. Herrero calculated the
probability that a stem cell contained different amounts of mutants after various generation
times. The results are given in Fig. 43. After 150 generations (approximately 50 years),
the probability that a cell contained greater than 300 mutants (integration of the area under
300 to 400 mutants) under these assumptions is approximately 10-9 .
Fig. 42: Distribution of mtDNA genotypes in colonic crypts.
Frequency histogram of the distribution of mtDNA genotypes in individual colonic crypts
from animals 4 and 15 months of age.
Source: Jenuth et al., 1997.
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Fig. 43. Modeling the accumulation of mitochondrial mutants.
The probability of a cell containing different numbers of mitochondrial mutants was
determined for different numbers of generations. Assumptions included 256 cells per
turnover units, 400 mtDNA copies per cell and random segregation of mutant copies with
cell division.
Source: P. Herrero
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This result can be compared to that observed empirically. Assuming 106 cells per
sample and that there were approximately 106/128 = 8000 stem cells per sample, largely
mutant stem cells were observed in the following fraction of instances: 12 (high mutant
observations)/(570 total observations x 8000 cells x 16 hotspots) = 2 x 10- 7 . This number
is 200-fold higher than the expected value, although it should be recognized that a large
number of assumptions were made.
Two possible explanations for the greater than expected likelihood of a sample
containing a mutant with an unusually large mutant fraction are offered. One possibility is
that the model does not accurately reflect reality because, when a mitochondrial mutant
divides to become two mitochondrial mutants, the probability that both mutants are
transmitted to the same daughter cell upon cell division is greater than 50%. For instance,
if mitochondria as opposed to mitochondrial DNA were the segregating unit, as has been
substantiated experimentally (Attardi et al., 1995), segregation would be significantly more
rapid. Another possibility is that there is some selection for specific mitochondrial mutants
as opposed to wild-type. The data available are not sufficient to distinguish between these
two possibilities. Information about the phenotypic effects of cells containing many copies
of a particular mitochondrial mutant could shed light on which of these mechanisms is
responsible. Selection would only be expected to have an effect on mutants that confer a
phenotypic effect, while all mutants, including silent mutants, would be expected to be
affected by nonrandom segregation during cell division. Mutant p19 is therefore of
particular interest since it is a silent substitution and leads to no change in the amino acid
coding sequence of the NADH dehydrogenase subunit III protein. The histogram for p19
is provided in Figure 36 in Results: Variability in Mutant Fractions. Note that no samples
with unusually large p19 mutant fractions have been observed, thus making either of the
offered explanations possible.
5.5.3 Mitochondrial proliferation?
Among the mutants in the histogram shown in Figure 37 are two samples in which
a particular mutant is present at a value very significantly above the mean for that mutant in
all other samples. Mutant p7 and mutant p16 were each observed in one case at >40-fold
the mean. In both instances, the unusually large frequencies were observed in duplicate
and the identity of the peaks in both samples was confirmed. These mutants are
significantly larger than would be expected from a completely mutant turnover unit and are
therefore hypothesized to result from proliferation of the mitochondria (and consequently
the mutant mitochondrial DNA therein) in a number of cells.
Cells with large numbers of mitochondria have been observed in muscle as ragged
red fibers and often lack cytochrome-c-oxidase activity. These may result when cells
attempt to compensate for reduced oxidative potential by stimulating mitochondrial
proliferation (Tremblay, 1969). In animal models, skeletal muscle mitochondria proliferate
in response to increased oxidative demand (Pette et al., 1985; Salmons et al., 1981;
Williams et al., 1986). Further, Shoubridge and colleagues demonstrated by in situ
hybridization that some of the muscle fibers of two mitochondrial myopathy patients
contained 6- to 7-fold higher levels of deleted mtDNA than observed in adjacent, normal
fibers (Shoubridge et al., 1990). Finally, oncocytes, epithelial cells with a high content of
often abnormal mitochondria, are found in nearly all epithelial organs, especially with
advancing age (Miiller-Hicker, 1992).
A cluster of cells with proliferation of mitochondria in response to lack of oxidative
phosphorylation is one possible explanation for the two cases of outstanding mutants. This
proliferative response would require that the mutations cause a phenotypic change. Mutant
p7 represents the only example of a nonsense mutation, and would lead to a significantly
truncated and presumably nonfunctional NADH dehydrogenase subunit III protein. The
effect on the enzyme complex is unknown. For p1 6, the mutation is a missense mutation
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and its effects on the protein are unknown. It is interesting to note that peak h from Fig.
33, which depicts the mutational spectra in muscle tumor slices, is likely to represent p16
and is very large in the sample in panel C.
5.6 AGING AND MITOCHONDRIAL DNA
5.6.1 Deletions
As described previously, mitochondrial deletions increase in variety and frequency
with age in humans and other species, especially in postmitotic tissues. There are several,
not incompatible, possible mechanisms for this increase with age. One option is that the
deletions are induced independently, and that they are observed to increase supralinearly
with age because the causative factor increases substantially with age. Alternatively,
selection for deleted mitochondrial DNA copies may exist.
Several researchers have suggested that mitochondrial deletions represent a
manifestation of a vicious cycle and that aging is a result of accumulated damage to
mitochondria from free radicals [for example, (Ames et al., 1995)]. The model usually
includes the following argument. Oxidative free radicals, including superoxide and
hydroxyl radicals, react with mitochondrial DNA and induce mutations. The mutations
induced would be expected to adversely affect mitochondrially encoded proteins, either by
causing mutations in the proteins themselves or by affecting their translation via mutations
in mitochondrially encoded tRNA. If a protein in the electron transport pathway is
damaged, then the enzyme complexes upstream of the damage will be in a reduced state,
and more likely to contribute electrons to oxygen to form superoxide (Bandy and
Davidson, 1990). Increased levels of superoxide would produce even more free radicals
and more damage to mitochondrial DNA. Hence, a vicious cycle of increased free radicals
and damage, each accelerating the other, would result. Supporting this argument is the
observation that the levels of free radicals in postmitotic cells increase with age (Mecocci et
al., 1993). Also, caloric restriction decreases the levels of free radicals in muscle tissue
(Dubey et al., 1996; Sohal et al., 1996) and decreases the levels of deleted mitochondrial
DNA molecules (Aspnes et al., 1997), in addition to delaying aging.
A second possibility is that mitochondrial deletions increase with age because there
is a mechanism that selects for these deletions. Critical findings supporting selection for
preexisting mutants rather than the generation of new mutants are that the mitochondria of a
single respiration-deficient muscle fiber carry the same mutation, and different fibers carry
different mutations (Miiller-Hcker et al., 1993). This observation supports a model in
which a single mutant molecule is amplified via selection. It has been suggested that the
selection may occur because deleted copies of mitochondrial DNA have an advantage
during replication due to their shorter length (Wallace, 1989), or that cis-acting elements
within mitochondrial DNA responsible for regulating replication are deleted (Shoubridge et
al., 1990). Both of these hypotheses require deletions for a selective advantage.
Therefore, the observation that 5 of 13 human myoblast cell lines carrying the mtDNA
point mutation responsible for MELAS were discovered to undergo a rapid shift of their
genotype toward the pure mutant type (Yoneda, 1992), while the other 8 cell lines, 6 of
which were almost completely homoplasmic, maintained a stable genotype, argues that the
hypotheses that require the mutation to be a deletion may not be correct.
Another possible explanation for selection of mitochondrial mutants is that loss of
mitochondrial function may confer a selective advantage. Selection could take the form of a
positive selection, for instance, individual organelles that do not have functioning
mitochondria could be replicated more frequently, possibly as a proliferative response as
described in the section in the Discussion on Mitochondrial Proliferation. Alternatively,
there may be selection against wild-type organelles. For instance, de Grey has argued that
mitochondria with reduced respiratory function due to a mutation or deletion affecting the
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respiratory chain may suffer less frequent lysosomal degradation because they inflict free
radical damage more slowly on their own membranes (de Grey, 1997).
5.6.2 Point mutations
As described previously, several authors have attempted to measure the
relationship between the frequency of point mutations in mitochondrial DNA and age (see
Literature Review) (Miinscher et al., 1993; Pallotti et al., 1996), and the results are unclear.
The methodology described herein should be valuable for determining the relationship
between mitochondrial point mutations and aging, given the possibility of measuring
mutations, including silent mutations, at levels as low as 10-6 from any tissue sample.
While the results are very preliminary, multiple samples of the lungs of an 84 year
old showed point mutational spectra in this sequence very similar to those observed in 50-
year olds. While there may be a modest increase with age in point mutational spectra in
bronchial epithelial cells, there does not appear to be a dramatic increase in frequency with
age as observed for deletions in post-mitotic cells. These findings make unlikely a model
in which aging in all tissues is characterized mainly by a vicious cycle of increased free
radicals contributing to increased point mutations in mitochondrial DNA.
The analysis of a single heart sample from a 77 year old provided an unexpected
result: two extremely frequent mutations were seen, neither of which is among those
routinely observed. These mutations may be the result of a selection process in heart tissue
for mitochondrial mutants.
6. CONCLUSIONS
Similar mitochondrial mutations were observed repeatedly in different samples but at
different frequencies.
Mutant frequencies varied considerably even from closely spaced positions within a single
organ.
Smoking did not induce new, prominent mitochondrial mutants.
Smoking did not increase overall mitochondrial mutant fractions in this sequence.
None of the mutants of the that were consistently observed in human tissue samples were
elevated in smokers.
The large variability in the size of individual mutants may reflect the accumulation of
mitochondrial mutants in bronchial epithelial stem cells, and in two extreme cases,
proliferation of mutant mitochondria.
Mitochondrial point mutants do not appear to increase supralinearly with age in human
bronchial epithelial cells, but selection for point mutants may occur in post-mitotic tissues.
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7. SUGGESTIONS FOR FUTURE RESEARCH
7.1 SOURCES OF HUMAN MUTATIONS
The discovery that mitochondrial mutations are likely to result largely from
endogenous agents suggests that one or both of two major pathways may be critical for
mitochondrial mutagenesis: replication errors and endogenous damage. Given that a set of
specific mutants arise as hotspots in human tissues, it is possible to test whether the
mitochondrial DNA polymerase-y induces these same mutations in vitro. W.-M. Zheng in
the W. Thilly laboratory has amplified purified wild-type copies of the mitochondrial target
sequence used in these experiments with a preparation of polymerase-y generously
provided by Dr. William Copeland (National Institute of Environmental Health
Science)[see (Ropp et al., 1996) for cloning of the gene]. Capillary electrophoresis has
been used to enrich for mitochondrial mutants generated during amplification.
Characterization of the mutational spectra induced by polymerase-y on this sequence will be
performed as for Pfu DNA polymerase (Andre et al., 1997). These experiments may
clarify whether the specific mutations observed as mitochondrial hotspots in human tissue
samples are likely to result from DNA polymerase errors.
Further, the suggestion that endogenous factors may be the most important
mutagenic pathway in mitochondrial DNA raises (but certainly does not prove) the
possibility that the most important pathways in nuclear mutagenesis are spontaneous as
well. This assertion is supported by analysis of databases for hprt and adenomatous
polyposis coli (APC), which suggest that polymerase-mediated slippage events (Kunkel,
1990) and mutations at CpG sites (Coulondre et al., 1978) are primary mutagenic
pathways. One approach to assessing this possibility is to test human DNA polymerase-6,
the putative replication polymerase for human nuclear DNA, to determine whether its
replicative hotspots correlate with the mutagenic hotspots observed in vivo. B. Muniappan
of the Thilly laboratory is planning to use this enzyme to amplify the APC gene, which is a
particularly good sequence for such studies, as several prominent hotspot mutations have
been observed in colon cancer. A correlation between the in vivo mutations observed in
APC and the replicative hotspots induced by pol-8 would suggest that pol-5 errors are the
source of such mutations.
Another approach to studying whether spontaneous pathways are responsible for
the mutations that occur in humans is to determine the in vitro mutational spectrum of a
single gene in several different organisms. A group led by A. Tomita of the W. Thilly
laboratory in collaboration with the Demple and Walker laboratories is studying the
spontaneous hotspot mutations observed in hprt exon 3 in cultured human cells, and
bacteria and yeast with hprt exon 3 introduced into their genomes, in order to compare the
spontaneous hotspots observed in the three different model systems. A. Tomita's
determination of the in vitro hprt mutational spectrum can be correlated with the in vivo data
compiled in available databases.
7.2 MITOCHONDRIAL MUTANTS AND AGE IN DIFFERENT TISSUES
The ability to measure point mutations in mitochondrial DNA provides an
opportunity to monitor the frequency of these mutations with age. Also, eliminating
phenotypic selection implies that the mutational spectra can be measured in a variety of
tissues, including post-mitotic tissues. The ability to measure mutants in any tissue is
critical given the many previous observations that different tissues accumulate
mitochondrial mutations at different rates. K. Khrapko has been appointed to the faculty at
the Harvard Medical School Division of Aging and will continue these investigations. He
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will test whether point mutations increase with age in humans, and whether there are
significant differences among tissues. Which specific mutations, if any, increase with age
will be determined to define the implications for the mechanism of their generation. He will
also investigate the mitochondrial mutational spectra of caloric-restricted rats in order to
better understand the effect of the age-lengthening procedures on mitochondrial point
mutations. The ultimate goal will be to differentiate whether an increase in mitochondrial
mutations actually causes aging, or is merely correlated with aging.
7.3 MECHANISM OF SMOKING-INDUCED LUNG CANCER
7.3.1 Nuclear mutational spectra
One of the most important questions left unresolved by this work is how smoking
causes cancer. Direct experimentation to determine whether smoking causes cancer by
inducing mutations in critical nuclear sequences, but does not induce mutations above the
spontaneous level in mitochondrial DNA, would be very valuable. Denissenko and
colleagues showed that the hotspots of the p53 adduct spectra formed when BPDE is
permitted to react with bronchial epithelial cells in culture are the same as the hotspots
observed in the p53 gene of smokers' tumors (Denissenko et al., 1996). Such findings
suggest but do not prove that smoking induces mutations that lead to cancer in critical
tumor suppressors. Further studies determining the mutational spectra in nuclear
sequences of healthy bronchial epithelial cells in smokers and nonsmokers will be
undertaken by K. Hong of the W. Thilly laboratory.
While the methodology described herein is sufficient for identifying and measuring
hotspot point mutations in mitochondrial DNA, further technical improvements are needed
to measure mutational spectra in nuclear DNA, where mutant fractions and the number of
target sequence copies per cell are both lower. X.-C. Li of the W. Thilly laboratory has
developed a method using sequence-specific hybridization coupled with a biotin-
streptavidin capture system on magnetic beads that permits greater than 10,000-fold
enrichment of a target sequence from total genomic DNA with a 70% yield (Li, 1997). The
first enrichment for mutants can then be performed using a wide-bore capillary separation
(Li et al., 1996). A sensitivity of 10-6 has already been demonstrated.
7.3.2 Recombination
The recent discovery that mitochondrial DNA is capable of performing homologous
recombination in cell extracts (Thyagarajan et al., 1996), combined with the observation
that a common mitochondrial deletion may be more prominent in smokers as compared
with nonsmokers (Ballinger et al., 1996; Liu et al., 1997), has raised the possibility that
smoking induces deletions in mitochondrial DNA by stimulating homologous
recombination. A. Kim of the W. Thilly laboratory is planning experiments to investigate
the role of homologous recombination in the development of human tumors. She will
specifically address whether there are hotspots for chromosomal rearrangement throughout
the genome, as there are mutational hotspots.
7.3.3 Cell kinetics
Another possibility is that smoking does not induce cancer via a mutagenic
mechanism but by affecting cell kinetics, that is, the rate of cell division and cell death in
bronchial epithelial cells. As discussed previously, P. Herrero and W. Thilly have
developed a mathematical model that separates the variables of mutation rate, mitotic rate
and apoptotic rate. Computer simulations with the data on age-specific lung cancer rates in
the U.S. prior to and after the widespread introduction of cigarettes suggests that smoking
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has an effect on the factor (a-3), that is, the rate of cell division minus the rate of cell
death. Through a collaboration with Dr. E. Furth (Univ. of Penn.) who has already
measured mitotic and apoptotic rates in colon, the rates of cell division and death will be
measured in vivo in normal human lung epithelium and preneoplastic lesions in smokers
and nonsmokers. This approach may clarify whether smoking affects the probability of
lung cancer by increasing the mutation rate in genes that would lead to cancer by
influencing cell kinetics or both.
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3.37E-04
3.89E-05
5.33E-5
4.33E-5
0.00E+00
3.73E-05
4.73E-05
7.90E-06
7.27E-06
0
1.21 E-05
1.00E-04
1.00E-04
1.00E-05
2.02E-05
1.21 E-05
0.00E+00
3.31E-05
6.00E-05
1.40E-05
3.00E-06
1.10E-05
9.49E-04
0.00E+00
5.24E-05
2.93E-04
0
1.16E-04
0.00E+00
6.84E-05
1.91E-05
3.21E-06
0
1.00E-04
1.00E-04
1.82E-05
2.54E-05
1.39E-05
2.18E-04
1.93E-05
1.68E-05
0
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Subject Sex Age Twin? Smoker? Gel Lobe PeakSample Bifurcation # Number Mutant FractionNumber
Bronch or
Dissected
Lung?
bronchoscopy
bronchoscopy
bronchoscopy
bronchoscopy
bronchoscopy
bronchoscopy
bronchoscopy
bronchoscopy
bronchoscopy
bronchoscopy
bronchoscopy
bronchoscopy
bronchoscopy
bronchoscopy
bronchoscopy
bronchoscopy
bronchoscopy
bronchoscopy
bronchoscopy
bronchoscopy
bronchoscopy
bronchoscopy
bronchoscopy
bronchoscopy
bronchoscopy
bronchoscopy
bronchoscopy
bronchoscopy
bronchoscopy
bronchoscopy
bronchoscopy
bronchoscopy
bronchoscopy
bronchoscopy
bronchoscopy
bronchoscopy
bronchoscopy
bronchoscopy
bronchoscopy
bronchoscopy
bronchoscopy
bronchoscopy
bronchoscopy
bronchoscopy
bronchoscopy
bronchoscopy
bronchoscopy
bronchoscopy
bronchoscopy
bronchoscopy
bronchoscopy
bronchoscopy
bronchoscopy
bronchoscopy
bronchoscopy
bronchoscopy
bronchoscopy
bronchoscopy
BG
B3
B3
BG
BGB3BG
BG
B3
BGa
BG
B;
BG
B3
BG
BG83
BG
BO
BO
BO
BO
BO
BO
BOBO
BO
BO
BO
BO
BO
BO
BO
BO
BO80
BO
BO
B0
BO
BO
BO
BO
BO
BO
BO
BO
BO
BO
BO
BO
BO
BO80
BO
80
BO
51
51
51
51
51
51
51
51
51
51
51
51
51
51
51
51
51
51
51
51
51
51
51
51
51
51
51
51
51
51
51
51
51
51
51
51
51
51
51
51
51
51
51
51
51
51
51
51
51
51
51
51
51
51
51
51
51
51
Yes
Yes
Yes
Yes
Yes
Yes
Yes
Yes
Yes
Yes
Yes
Yes
Yes
Yes
Yes
Yes
Yes
Yes
Yes
Yes
Yes
Yes
Yes
Yes
Yes
Yes
Yes
Yes
Yes
Yes
Yes
Yes
Yes
Yes
Yes
Yes
Yes
Yes
Yes
Yes
Yes
Yes
Yes
Yes
Yes
Yes
Yes
Yes
Yes
Yes
Yes
Yes
Yes
Yes
Yes
Yes
Yes
Yes
Smoker
Smoker
Smoker
Smoker
Smoker
Smoker
Smoker
Smoker
Smoker
Smoker
Smoker
Smoker
Smoker
Smoker
Smoker
Smoker
Smoker
Smoker
Smoker
Smoker
Smoker
Nonsmoker
Nonsmoker
Nonsmoker
Nonsmoker
Nonsmoker
Nonsmoker
Nonsmoker
Nonsmoker
Nonsmoker
Nonsmoker
Nonsmoker
Nonsmoker
Nonsmoker
Nonsmoker
Nonsmoker
Nonsmoker
Nonsmoker
Nonsmoker
Nonsmoker
Nonsmoker
Nonsmoker
Nonsmoker
Nonsmoker
Nonsmoker
Nonsmoker
Nonsmoker
Nonsmoker
Nonsmoker
Nonsmoker
Nonsmoker
Nonsmoker
Nonsmoker
Nonsmoker
Nonsmoker
Nonsmoker
Nonsmoker
Nonsmoker
J24
J24
J24
J24
J24
J24
J24
J24
J24
J24
J24
J24
J24
J24
J24
J24
J24
J24
J24
J24
J24
J17
J17
J17
J17
J17
J17
J17
J19
J19
J19
J19
J19
J19
J19
J24
J24
J24
J24
J24
J26
J24
J26
J26
J26
J26
J26
J26
J26
J26
J26
J26
J26
J26
J26
J24
J24
J24
right lower lobe
left lower lobe
left lower lobe
left lower lobe
left lower lobe
left lower lobe
left lower lobe
left lower lobe
left lower lobe
left lower lobe
left lower lobe
left lower lobe
left lower lobe
left lower lobe
left lower lobe
left lower lobe
left lower lobe
left lower lobe
left lower lobe
left lower lobe
left lower lobe
right main carina
right main carina
right main carina
right main carina
right main carina
right main carina
right main carina
right upper lobe
right upper lobe
right upper lobe
right upper lobe
right upper lobe
right upper lobe
right upper lobe
right lower lobe
right lower lobe
right lower lobe
right lower lobe
right lower lobe
right lower lobe
right lower lobe
right lower lobe
right lower lobe
right lower lobe
right lower lobe
right lower lobe
right lower lobe
right lower lobe
right lower lobe
right lower lobe
right lower lobe
right lower lobe
right lower lobe
right lower lobe
left lower lobe
left lower lobe
left lower lobe
4A
8A
8A
8A
8A
8A
8A
8A
8A
8A
8A
8A
8A
8A
8A
8A
8A
8A
8A
8A
8A
1A
1A
1A
1A
1A
1A
1A
2A
2A
2A
2A
2A
2A
2A
4A
4A
4A
4A
4A
4A
4A
4A
4A
4A
4A
4A
4A
4A
4A
4A
4A
4A
4A
4A
8A
8A
8A
19
1
2
3
5
5.5
6
7
11
11.3
11.5
12
13
13.5
14
15
15.7
16
18
18.5
19
1
2
3
5
5.5
6
7
1
2
3
5
5.5
6
7
1
2
3
5
5.5
6
7
11
11.3
11.5
12
13
13.5
14
15
15.7
16
18
18.5
19
1
2
3
3.81 E-05
4.07E-5
2.03E-6
8.94E-6
3.25E-5
4.47E-6
1.14E-5
0.OOE+0
9.62E-05
7.88E-05
8.46E-06
2.31 E-05
1.00E-04
5.77E-06
7.69E-06
6.73E-06
2.31 E-05
2.40E-05
1.10E-05
1.35E-05
1.50E-05
2.82E-4
5.33E-6
2.23E-5
4.64E-5
4.47E-5
3.36E-5
1.00E-04
5.54E-04
5.88E-05
1.64E-04
3.60E-04
1.03E-04
1.19E-04
1.19E-04
1.34E-3
1.71E-4
1.04E-4
1.83E-4
5.00E-05
6.00E-05
1.07E-03
7.50E-06
4.50E-06
5.30E-06
0
1.00E-05
6.60E-06
7.90E-06
3.90E-06
5.30E-06
8.80E-06
2.80E-06
0.00E+00
2.00E-06
6.30E-04
0
1.00E-4
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Subject Sex Age Twin?
Bronch or
Dissected
Lung?
bronchoscopy
bronchoscopy
bronchoscopy
bronchoscopy
bronchoscopy
bronchoscopy
bronchoscopy
bronchoscopy
bronchoscopy
bronchoscopy
bronchoscopy
bronchoscopy
bronchoscopy
bronchoscopy
bronchoscopy
bronchoscopy
bronchoscopy
bronchoscopy
bronchoscopy
bronchoscopy
bronchoscopy
bronchoscopy
bronchoscopy
bronchoscopy
bronchoscopy
bronchoscopy
bronchoscopy
bronchoscopy
bronchoscopy
bronchoscopy
bronchoscopy
bronchoscopy
bronchoscopy
bronchoscopy
bronchoscopy
bronchoscopy
bronchoscopy
bronchoscopy
bronchoscopy
bronchoscopy
bronchoscopy
bronchoscopy
bronchoscopy
bronchoscopy
bronchoscopy
bronchoscopy
bronchoscopy
bronchoscopy
bronchoscopy
bronchoscopy
bronchoscopy
bronchoscopy
bronchoscopy
bronchoscopy
bronchoscopy
bronchoscopy
bronchoscopy
Smoker? Gel Lobe
51
51
51
51
51
51
51
51
51
51
51
51
51
51
51
51
51
54
54
54
54
54
54
54
54
54
54
54
54
54
54
54
54
54
54
54
54
54
54
54
54
54
54
54
54
54
54
54
54
54
54
54
54
54
54
54
54
Yes
Yes
Yes
Yes
Yes
Yes
Yes
Yes
Yes
Yes
Yes
Yes
Yes
Yes
Yes
Yes
Yes
Yes
Yes
Yes
Yes
Yes
Yes
Yes
Yes
Yes
Yes
Yes
Yes
Yes
Yes
Yes
Yes
Yes
Yes
Yes
Yes
Yes
Yes
Yes
Yes
Yes
Yes
Yes
Yes
Yes
Yes
Yes
Yes
Yes
Yes
Yes
Yes
Yes
Yes
Yes
Yes
bronchoscopy JC F 54 Yes Nonsmoker J26
Nonsmoker
Nonsmoker
Nonsmoker
Nonsmoker
Nonsmoker
Nonsmoker
Nonsmoker
Nonsmoker
Nonsmoker
Nonsmoker
Nonsmoker
Nonsmoker
Nonsmoker
Nonsmoker
Nonsmoker
Nonsmoker
Nonsmoker
Nonsmoker
Nonsmoker
Nonsmoker
Nonsmoker
Nonsmoker
Nonsmoker
Nonsmoker
Nonsmoker
Nonsmoker
Nonsmoker
Nonsmoker
Nonsmoker
Nonsmoker
Nonsmoker
Nonsmoker
Nonsmoker
Nonsmoker
Nonsmoker
Nonsmoker
Nonsmoker
Nonsmoker
Nonsmoker
Nonsmoker
Nonsmoker
Nonsmoker
Nonsmoker
Nonsmoker
Nonsmoker
Nonsmoker
Nonsmoker
Nonsmoker
Nonsmoker
Nonsmoker
Nonsmoker
Nonsmoker
Nonsmoker
Nonsmoker
Nonsmoker
Nonsmoker
Nonsmoker
PeakSample Bifurcation # Number Mutant Fraction
J24
J24
J24
J24
J24
J24
J24
J24
J24
J24
J24
J24
J24
J24
J24
J24
J24
G26
G26
G26
G26
G26
G26
G26
G26
G26
G26
G26
G26
G26
G26
G26
G26
G26
G26
G26
G26
G26
J24
J24
J24
J24
J24
J24
J24
J26
J26
J26
J26
J26
J26
J26
J26
J26
J26
J26
J26
left lower lobe
left lower lobe
left lower lobe
left lower lobe
left lower lobe
left lower lobe
left lower lobe
left lower lobe
left lower lobe
left lower lobe
left lower lobe
left lower lobe
left lower lobe
left lower lobe
left lower lobe
left lower lobe
left lower lobe
right main carina
right main carina
right main carina
right main carina
right main carina
right main carina
right main carina
right main carina
right main carina
right main carina
right main carina
right main carina
right main carina
right main carina
right main carina
right main carina
right main carina
right main carina
right main carina
right main carina
right main carina
right lower lobe
right lower lobe
right lower lobe
right lower lobe
right lower lobe
right lower lobe
right lower lobe
right lower lobe
right lower lobe
right lower lobe
right lower lobe
right lower lobe
right lower lobe
right lower lobe
right lower lobe
right lower lobe
right lower lobe
right lower lobe
right lower lobe
right lower lobe
8A 3 5 3.33E-4
8A 3 5.5 1.00E-4
8A 3 6 1.20E-04
8A 3 7 1.00E-05
8A 3 11 5.10E-05
8A 3 11.3 9.38E-05
8A 3 11.5 3.40E-05
8A 3 12 2.00E-05
8A 3 13 1.00E-04
8A 3 13.5 9.50E-06
8A 3 14 0
8A 3 1 5 3.85E-06
8A 3 15.7 2.46E-05
8A 3 16 1.40E-04
8A 3 1 8 2.90E-05
8A 3 18.5 1.20E-05
8A 3 19 4.30E-06
1A 1 1 7.90E-5
1 A 1 2 5.97E-6
1 A 1 3 3.23E-5
1A 1 5 5.81E-6
1 A 1 5.5 2.74E-5
1A 1 6 1.13E-5
1A 1 7 6.61E-6
1 A 1 1 1 1.20E-05
1A 1 11.3 1.93E-5
1A 1 11.5 0.00E+0
1 A 1 11.7 1.30E-6
1 A 1 12 1.10E-05
1 A 1 13 1.00E-4
1A 1 13.5 3.00E-6
1 A 1 14 1.00E-6
1A 1 15 8.86E-6
1 A 1 15.5 8.50E-7
1 A 1 16 3.64E-5
1 A 1 18 1.34E-5
1A 1 18.5 4.60E-5
1 A 1 19 5.20E-6
4A 3 1 3.03E-04
4A 3 2 2.64E-05
4A 3 3 3.65E-05
4A 3 5 8.42E-05
4A 3 5.5 9.00E-05
4A 3 6 8.22E-05
4A 3 7 7.30E-05
4A 3 1 1 1.50E-05
4A 3 11.3 6.40E-06
4A 3 11.5 9.60E-06
4A 3 11.7 1.20E-05
4A 3 12 5.40E-06
4A 3 13 1.00E-05
4A 3 13.5 1.20E-05
4A 3 14 1.90E-05
4A 3 15 2.60E-05
4A 3 15.5 0.00E+00
4A 3 1 6 4.30E-05
4A 3 1 8 4.60E-05
4A 3 18.5 5.00E-06
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Subject Sex Age Twin?
Bronch or
Dissected
Lung?
bronchoscopy
bronchoscopy
bronchoscopy
bronchoscopy
bronchoscopy
bronchoscopy
bronchoscopy
bronchoscopy
bronchoscopy
bronchoscopy
bronchoscopy
bronchoscopy
bronchoscopy
bronchoscopy
bronchoscopy
bronchoscopy
bronchoscopy
bronchoscopy
bronchoscopy
bronchoscopy
bronchoscopy
bronchoscopy
bronchoscopy
bronchoscopy
bronchoscopy
bronchoscopy
bronchoscopy
bronchoscopy
bronchoscopy
bronchoscopy
bronchoscopy
bronchoscopy
bronchoscopy
bronchoscopy
bronchoscopy
bronchoscopy
bronchoscopy
bronchoscopy
bronchoscopy
bronchoscopy
bronchoscopy
bronchoscopy
bronchoscopy
bronchoscopy
bronchoscopy
bronchoscopy
bronchoscopy
bronchoscopy
bronchoscopy
bronchoscopy
bronchoscopy
bronchoscopy
bronchoscopy
bronchoscopy
bronchoscopy
bronchoscopy
bronchoscopy
bronchoscopy
Smoker? Gel Lobe
JC
KH
KH
KH
KH
KH
KW
KW
KW
KW
KW
KW
KW
KW
KW
KW
KW
KW
KW
KW
KW
KW
KW
KW
KW
KW
KW
KW
KW
KW
KW
KW
KW
KW
KW
KW
KW
KW
KW
KW
KW
KW
KW
KW
KW
KW
KW
KW
KW
KW
KW
KW
KW
MD)
MD
IVD
MD
MD
PeakSample Bifurcation # Number Mutant Fraction
54
24
24
24
24
24
46
46
46
46
46
46
46
46
46
46
46
46
46
46
46
46
46
46
46
46
46
46
46
46
46
46
46
46
46
46
46
46
46
46
46
46
46
46
46
46
46
46
46
46
46
46
46
46
46
46
46
46
Yes
No
No
No
No
No
Yes
Yes
Yes
Yes
Yes
Yes
Yes
Yes
Yes
Yes
Yes
Yes
Yes
Yes
Yes
Yes
Yes
Yes
Yes
Yes
Yes
Yes
Yes
Yes
Yes
Yes
Yes
Yes
Yes
Yes
Yes
Yes
Yes
Yes
Yes
Yes
Yes
Yes
Yes
Yes
Yes
Yes
Yes
Yes
Yes
Yes
Yes
Yes
Yes
Yes
Yes
Yes
Nonsmoker
Smoker
Smoker
Smoker
Smoker
Smoker
Smoker
Smoker
Smoker
Smoker
Smoker
Smoker
Smoker
Smoker
Smoker
Smoker
Smoker
Smoker
Smoker
Smoker
Smoker
Smoker
Smoker
Smoker
Smoker
Smoker
Smoker
Smoker
Smoker
Smoker
Smoker
Smoker
Smoker
Smoker
Smoker
Smoker
Smoker
Smoker
Smoker
Smoker
Smoker
Smoker
Smoker
Smoker
Smoker
Smoker
Smoker
Smoker
Smoker
Smoker
Smoker
Smoker
Smoker
Nonsmoker
Nonsmoker
Nonsmoker
Nonsmoker
Nonsmoker
J26
J15
J15
J15
J15
J15
J20
J20
J20
J20
J20
J20
J20
J21
J21
J21
J21
J21
J21
J21
J21
J21
J21
J21
J21
J21
J21
J21
J21
J21
J21
J21
J21
J21
J24
J24
J24
J24
J24
J24
J24
J24
J24
J24
J24
J24
J24
J24
J24
J24
J24
J24
J24
J20
J20
J20
J20
J20
right lower lobe
right main carina
right main carina
right main carina
right main carina
right main carina
right main carina
right main carina
right main carina
right main carina
right main carina
right main carina
right main canrina
right upper lobe
right upper lobe
right upper lobe
right upper lobe
right upper lobe
right upper lobe
right upper lobe
right upper lobe
right upper lobe
right upper lobe
right upper lobe
right upper lobe
right upper lobe
right upper lobe
right upper lobe
right upper lobe
right upper lobe
right upper lobe
right upper lobe
right upper lobe
right upper lobe
right lower lobe
right lower lobe
right lower lobe
right lower lobe
right lower lobe
right lower lobe
right lower lobe
right lower lobe
right lower lobe
right lower lobe
right lower lobe
right lower lobe
right lower lobe
right lower lobe
right lower lobe
right lower lobe
right lower lobe
right lower lobe
right lower lobe
right mamin carina
right mamin carina
right main carina
right main carina
right main carina
4A
1A
1 A
1A
1A
1 A
1A
1A
1 A
1A
1 A
1A
1A
2A
2A
2A
2A
2A
2A
2A
2A
2A
2A
2A
2A
2A
2A
2A
2A
2A
2A
2A
2A
2A
4A
4A
4A
4A
4A
4A
4A
4A
4A
4A
4A
4A
4A
4A
4A
4A
4A
4A
4A
1A
1A
1A
1A
1A
19
1
2
3
5
7
1
2
3
5
5.5
6
7
1
2
3
5
5.5
6
7
11
11.3
11.5
11.7
12
13
13
13.5
14
15.7
16
18
18.5
19
1
2
3
5
6
7
11
11.3
11.5
12
13
13.5
14
15
15.7
16
18
18.5
19
1
2
3
5
5.5
6.30E-06
7.62E-5
0.00E+0
3.62E-5
8.67E-5
0.00E+0
9.25E-05
2.42E-06
3.40E-5
2.00E-5
9.74E-05
5.36E-6
6.09E-6
5.68E-4
1.84E-5
2.31E-4
7.50E-5
2.34E-4
2.00E-5
1.30E-04
1.52E-04
3.20E-05
0
1.20E-06
3.00E-05
1.00E-04
1.00E-04
1.93E-05
3.50E-05
6.45E-05
1.68E-04
5.90E-06
2.80E-05
1.30E-05
4.67E-04
5.33E-04
1.50E-04
1.50E-04
1.50E-04
1.88E-05
1.00E-05
6.25E-06
1.56E-06
1.00E-04
4.38E-06
1.25E-05
1.06E-05
9.38E-06
9.38E-06
5.13E-05
6.88E-07
1.63E-06
6.72E-4
2.64E-5
9.24E-5
1.06E-4
2.65E-5
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Bronch or
Dissected Subject Sex Age Twin?
Lung?
bronchoscopy
bronchoscopy
bronchoscopy
bronchoscopy
bronchoscopy
bronchoscopy
bronchoscopy
bronchoscopy
bronchoscopy
bronchoscopy
bronchoscopy
bronchoscopy
bronchoscopy
bronchoscopy
bronchoscopy
bronchoscopy
bronchoscopy
bronchoscopy
bronchoscopy
bronchoscopy
bronchoscopy
bronchoscopy
bronchoscopy
bronchoscopy
bronchoscopy
bronchoscopy
bronchoscopy
bronchoscopy
bronchoscopy
bronchoscopy
bronchoscopy
bronchoscopy
bronchoscopy
bronchoscopy
bronchoscopy
bronchoscopy
bronchoscopy
bronchoscopy
bronchoscopy
bronchoscopy
bronchoscopy
bronchoscopy
bronchoscopy
bronchoscopy
bronchoscopy
bronchoscopy
bronchoscopy
bronchoscopy
bronchoscopy
bronchoscopy
bronchoscopy
bronchoscopy
bronchoscopy
bronchoscopy
bronchoscopy
bronchoscopy
bronchoscopy
bronchoscopy
MD
MD
IDMD
MD
MD
MD
MD
MD
MD
MD
vD
MD
IVlDMDMDMDMD
IVIDMD
MDMDMDIVIDMD
MD
MD
IV1JMDMDMDMDMD
MD
rvuMD
MDMVD
MDMVDIvID
IVID
MDIVID
MD
MD
MD
MD
MD
MD
MD
MD
MD
MD
MD
MD
MDNOE)
rv
Smoker? Gel Lobe
Yes
Yes
Yes
Yes
Yes
Yes
Yes
Yes
Yes
Yes
Yes
Yes
Yes
Yes
Yes
Yes
Yes
Yes
Yes
Yes
Yes
Yes
Yes
Yes
Yes
Yes
Yes
Yes
Yes
Yes
Yes
Yes
Yes
Yes
Yes
Yes
Yes
Yes
Yes
Yes
Yes
Yes
Yes
Yes
Yes
Yes
Yes
Yes
Yes
Yes
Yes
Yes
Yes
Yes
Yes
Yes
Yes
Yes
Nonsmoker
Nonsmoker
Nonsmoker
Nonsmoker
Nonsmoker
Nonsmoker
Nonsmoker
Nonsmoker
Nonsmoker
Nonsmoker
Nonsmoker
Nonsmoker
Nonsmoker
Nonsmoker
Nonsmoker
Nonsmoker
Nonsmoker
Nonsmoker
Nonsmoker
Nonsmoker
Nonsmoker
Nonsmoker
Nonsmoker
Nonsmoker
Nonsmoker
Nonsmoker
Nonsmoker
Nonsmoker
Nonsmoker
Nonsmoker
Nonsmoker
Nonsmoker
Nonsmoker
Nonsmoker
Nonsmoker
Nonsmoker
Nonsmoker
Nonsmoker
Nonsmoker
Nonsmoker
Nonsmoker
Nonsmoker
Nonsmoker
Nonsmoker
Nonsmoker
Nonsmoker
Nonsmoker
Nonsmoker
Nonsmoker
Nonsmoker
Nonsmoker
Nonsmoker
Nonsmoker
Nonsmoker
Nonsmoker
Nonsmoker
Nonsmoker
Nonsmoker
Sample
J20
J20
J20
J20
J20
J20
J20
J20
J20
J20
J20
J20
J20
J20
J20
J20
J21
J21
J21
J21
J21
J21
J21
J21
J21
J21
J21
J21
J21
J21
J21
J21
J21
J21
J21
J21
J21
J21
J21
J26
J26
J26
J26
J26
J26
J26
J26
J26
J26
J26
J26
J26
J26
J26
J26
J26
J26
J26
PeakBifurcation # Number Mutant FractionNumber
right main canrina
right main carina
right main carina
right main canrina
right main carina
right main carina
right main carina
right main carina
right main carina
right main carina
right main carina
right main carina
right main carina
right main carina
right main carina
right main carina
right upper lobe
right upper lobe
right upper lobe
right upper lobe
right upper lobe
right upper lobe
right upper lobe
right upper lobe
right upper lobe
right upper lobe
right upper lobe
right upper lobe
right upper lobe
right upper lobe
right upper lobe
right upper lobe
right upper lobe
right upper lobe
right upper lobe
right upper lobe
right upper lobe
right upper lobe
right upper lobe
right lower lobe
right lower lobe
right lower lobe
right lower lobe
right lower lobe
right lower lobe
right lower lobe
right lower lobe
right lower lobe
right lower lobe
right lower lobe
right lower lobe
right lower lobe
right lower lobe
right lower lobe
right lower lobe
right lower lobe
right lower lobe
right lower lobe
1 A
1 A
1 A
1A
1A
1A
1 A
1 A
1 A
1 A
1 A
1 A
1 A
1 A
1 A
1 A
2A
2A
2A
2A
2A
2A
2A
2A
2A
2A
2A
2A
2A
2A
2A
2A
2A
2A
2A
2A
2A
2A
2A
4A
4A
4A
4A
4A
4A
4A
4A
4A
4A
4A
4A
4A
4A
4A
4A
4A
4A
4A
6
7
11
11.3
11.5
11.7
12
13
13.5
14
15
15.7
16
18
18.5
19
1
2
3
5
5.5
6
7
11
11.3
11.5
11.7
12
13
13
13.5
14
15
15.5
15.7
16
18
18.5
19
1
2
3
5
5.5
6
7
11
11.3
11.5
12
13
13.5
14
15
15.5
16
18
18.5
4.69E-5
7.04E-5
1.46E-04
6.27E-05
3.00E-05
5.64E-05
1.02E-05
1.00E-04
7.57E-06
3.40E-05
6.27E-06
2.32E-05
9.75E-05
1.99E-04
1.02E-05
3.18E-05
2.32E-4
2.36E-5
7.62E-5
6.72E-5
2.58E-5
4.29E-5
1.69E-5
6.01E-05
1.59E-04
6.23E-06
2.86E-05
4.90E-06
1.00E-04
1.00E-04
1.74E-05
7.49E-05
6.73E-06
0
2.00E-05
4.21E-05
1.57E-05
5.90E-06
2.50E-05
2.81E-04
6.19E-05
2.29E-05
7.62E-05
0
5.71E-05
0
5.31E-05
0
0
0
1.00E-05
2.31E-05
1.38E-05
2.08E-05
2.31E-06
7.15E-05
7.69E-06
3.85E-06
Subject Sex Age Twin? Smoker? Gel
Bronch or
Dissected
Lung?
bronchoscopy
bronchoscopy
bronchoscopy
bronchoscopy
bronchoscopy
bronchoscopy
bronchoscopy
bronchoscopy
bronchoscopy
bronchoscopy
bronchoscopy
bronchoscopy
bronchoscopy
bronchoscopy
bronchoscopy
bronchoscopy
bronchoscopy
bronchoscopy
bronchoscopy
bronchoscopy
bronchoscopy
bronchoscopy
bronchoscopy
bronchoscopy
bronchoscopy
bronchoscopy
bronchoscopy
bronchoscopy
bronchoscopy
bronchoscopy
bronchoscopy
bronchoscopy
bronchoscopy
bronchoscopy
bronchoscopy
bronchoscopy
bronchoscopy
bronchoscopy
bronchoscopy
bronchoscopy
bronchoscopy
bronchoscopy
bronchoscopy
bronchoscopy
bronchoscopy
bronchoscopy
bronchoscopy
bronchoscopy
bronchoscopy
bronchoscopy
bronchoscopy
bronchoscopy
bronchoscopy
bronchoscopy
bronchoscopy
bronchoscopy
bronchoscopy
bronchoscopy
MD
ND
ND
ND
ND
ND
ND
ND
ND
ND
ND
ND
ND
ND
ND
ND
ND
ND
ND
ND
ND
ND
ND
ND
ND
ND
ND
ND
ND
ND
ND
ND
ND
ND
ND
ND
ND
ND
ND
ND
ND
ND
ND
ND
ND
ND
ND
ND
ND
ND
ND
ND
ND
ND
ND
ND
ND
ND
46
54
54
54
54
54
54
54
54
54
54
54
54
54
54
54
54
54
54
54
54
54
54
54
54
54
54
54
54
54
54
54
54
54
54
54
54
54
54
54
54
54
54
54
54
54
54
54
54
54
54
54
54
54
54
54
54
54
Yes
Yes
Yes
Yes
Yes
Yes
Yes
Yes
Yes
Yes
Yes
Yes
Yes
Yes
Yes
Yes
Yes
Yes
Yes
Yes
Yes
Yes
Yes
Yes
Yes
Yes
Yes
Yes
Yes
Yes
Yes
Yes
Yes
Yes
Yes
Yes
Yes
Yes
Yes
Yes
Yes
Yes
Yes
Yes
Yes
Yes
Yes
Yes
Yes
Yes
Yes
Yes
Yes
Yes
Yes
Yes
Yes
Yes
Lobe PeakSample Bifurcation # Number Mutant FractionNumber
Nonsmoker
Smoker
Smoker
Smoker
Smoker
Smoker
Smoker
Smoker
Smoker
Smoker
Smoker
Smoker
Smoker
Smoker
Smoker
Smoker
Smoker
Smoker
Smoker
Smoker
Smoker
Smoker
Smoker
Smoker
Smoker
Smoker
Smoker
Smoker
Smoker
Smoker
Smoker
Smoker
Smoker
Smoker
Smoker
Smoker
Smoker
Smoker
Smoker
Smoker
Smoker
Smoker
Smoker
Smoker
Smoker
Smoker
Smoker
Smoker
Smoker
Smoker
Smoker
Smoker
Smoker
Smoker
Smoker
Smoker
Smoker
Smoker
J26
G26
G26
G26
G26
G26
G26
G26
G26
G26
G26
G26
G26
G26
G26
G26
G26
G26
G26
J16
J16
J16
J16
J16
J16
J16
J16
J16
J16
J16
J16
J16
J16
J16
J16
J16
J16
J16
J16
J24
J24
J24
J24
J24
J24
J24
J24
J24
J24
J24
J24
J24
J24
J24
J24
J24
J24
J24
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right lower lobe
right main carina
right main carina
right main carina
right main carina
right main carina
right main carina
right main carina
right main carina
right main carina
right main carina
right main canna
right main carina
right main carina
right main carina
right main carina
right main carina
right main carina
right main carina
right upper lobe
right upper lobe
right upper lobe
right upper lobe
right upper lobe
right upper lobe
right upper lobe
right upper lobe
right upper lobe
right upper lobe
right upper lobe
right upper lobe
right upper lobe
right upper lobe
right upper lobe
right upper lobe
right upper lobe
right upper lobe
right upper lobe
right upper lobe
right lower lobe
right lower lobe
right lower lobe
right lower lobe
right lower lobe
right lower lobe
right lower lobe
right lower lobe
right lower lobe
right lower lobe
right lower lobe
right lower lobe
right lower lobe
right lower lobe
right lower lobe
right lower lobe
right lower lobe
right lower lobe
right lower lobe
19
1
2
3
5
5.5
6
7
11
11.3
12
13
13.5
14
15
16
18
18.5
19
1
2
3
5
5.5
6
7
11
11.3
11.5
12
13
13.5
14
15
15.5
16
18
18.5
19
1
2
3
5
5.5
6
7
11
11.3
11.5
12
13
13.5
14
15
15.7
16
18
18.5
7.38E-06
5.00E-5
1.82E-6
7.91 E-6
2.09E-5
4.55E-6
9.09E-6
5.64E-6
9.20E-06
6.21 E-6
5.50E-05
1.00E-4
2.80E-05
1.52E-5
7.93E-6
1.40E-05
2.50E-05
6.40E-6
6.30E-6
9.02E-5
5.12E-6
1.39E-5
1.15E-4
1.32E-5
1.15E-5
3.66E-6
1.10E-05
6.00E-6
0.OOE+0
3.00E-6
1.00E-4
9.70E-07
1.50E-5
8.00E-5
0.OOE+0
1.10E-5
1.10E-05
1.10E-04
3.70E-06
8.22E-4
1.10E-4
6.11E-5
3.33E-4
6.67E-5
8.89E-5
8.89E-5
2.90E-05
2.80E-05
3.60E-06
3.20E-05
1.00E-04
7.30E-06
3.50E-05
1.39E-05
5.56E-06
7.10E-05
4.80E-05
2.20E-05
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Bronch or
Dissected Subject Sex Age Twin? Smoker? Gel Lobe PeakSample Bifurcation # Number Mutant FractionNumber
Lung?
bronchoscopy
bronchoscopy
bronchoscopy
bronchoscopy
bronchoscopy
bronchoscopy
dissected lung
dissected lung
dissected lung
dissected lung
dissected lung
dissected lung
dissected lung
dissected lung
dissected lung
dissected lung
dissected lung
dissected lung
dissected lung
dissected lung
dissected lung
dissected lung
dissected lung
dissected lung
dissected lung
dissected lung
dissected lung
dissected lung
dissected lung
dissected lung
dissected lung
dissected lung
dissected lung
dissected lung
dissected lung
dissected lung
dissected lung
dissected lung
dissected lung
dissected lung
dissected lung
dissected lung
dissected lung
dissected lung
dissected lung
dissected lung
dissected lung
dissected lung
dissected lung
dissected lung
dissected lung
dissected lung
dissected lung
dissected lung
dissected lung
dissected lung
dissected lung
dissected lung
ND
WS
WS
WS
WS
WS
28-Mar
28-Mar
28-Mar
28-Mar
28-Mar
28-Mar
28-Mar
28-Mar
28-Mar
28-Mar
28-Mar
28-Mar
28-Mar
28-Mar
28-Mar
28-Mar
28-Mar
28-Mar
28-Mar
28-Mar
28-Mar
28-Mar
28-Mar
28-Mar
28-Mar
28-Mar
28-Mar
28-Mar
28-Mar
28-Mar
28-Mar
28-Mar
28-Mar
28-Mar
28-Mar
28-Mar
28-Mar
28-Mar
28-Mar
28-Mar
28-Mar
28-Mar
28-Mar
28-Mar
28-Mar
28-Mar
28-Mar
28-Mar
28-Mar
28-Mar
28-Mar
28-Mar
Yes
No
No
No
No
No
No
No
No
No
No
No
No
No
No
No
No
No
No
No
No
No
No
No
No
No
No
No
No
No
No
No
No
No
No
No
No
No
No
No
No
No
No
No
No
No
No
No
No
No
No
No
No
No
No
No
No
No
Smoker
Nonsmoker
Nonsmoker
Nonsmoker
Nonsmoker
Nonsmoker
Nonsmoker
Nonsmoker
Nonsmoker
Nonsmoker
Nonsmoker
Nonsmoker
Nonsmoker
Nonsmoker
Nonsmoker
Nonsmoker
Nonsmoker
Nonsmoker
Nonsmoker
Nonsmoker
Nonsmoker
Nonsmoker
Nonsmoker
Nonsmoker
Nonsmoker
Nonsmoker
Nonsmoker
Nonsmoker
Nonsmoker
Nonsmoker
Nonsmoker
Nonsmoker
Nonsmoker
Nonsmoker
Nonsmoker
Nonsmoker
Nonsmoker
Nonsmoker
Nonsmoker
Nonsmoker
Nonsmoker
Nonsmoker
Nonsmoker
Nonsmoker
Nonsmoker
Nonsmoker
Nonsmoker
Nonsmoker
Nonsmoker
Nonsmoker
Nonsmoker
Nonsmoker
Nonsmoker
Nonsmoker
Nonsmoker
Nonsmoker
Nonsmoker
Nonsmoker
J24
J15
J15
J15
J15
J15
J28
J28
J28
J28
J28
J28
J28
J28
J28
J28
J28
J28
J28
J28
J28
J28
J28
J28
J28
J28
J28
J28
J28
J28
J28
J28
J28
J28
J28
J28
J28
J28
J28
J28
J28
J28
J28
J28
J28
J28
J28
J28
J28
J28
J28
J28
J28
J28
J28
J28
J28
J28
right lower lobe
right main carina
right main carina
right main carina
right main carina
right main carina
right upper lobe
right upper lobe
right upper lobe
right upper lobe
right upper lobe
right upper lobe
right upper lobe
right upper lobe
right upper lobe
right upper lobe
right upper lobe
right upper lobe
right upper lobe
right upper lobe
right upper lobe
right upper lobe
right upper lobe
right upper lobe
right upper lobe
right upper lobe
right upper lobe
right upper lobe
right upper lobe
right upper lobe
right upper lobe
right upper lobe
right upper lobe
right upper lobe
right upper lobe
right upper lobe
right upper lobe
right upper lobe
right upper lobe
right upper lobe
right upper lobe
right upper lobe
right upper lobe
right upper lobe
right upper lobe
right upper lobe
right upper lobe
right upper lobe
right upper lobe
right upper lobe
right upper lobe
right upper lobe
right upper lobe
right upper lobe
right upper lobe
right upper lobe
right upper lobe
right upper lobe
4A
1A
1A
1A
1A
1A
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
11
1
8
8
8
8
810
810
810
810
810
810
810
810
810
810
8108
8
8
8
8
8
10
10
10
10
10
10
10
10
10
10
10
19
1
2
3
5
7
1
2
3
5
5.5
6
7
11
11.3
11.5
12
13
13.5
14
15
15.7
16
18
18.5
19
1
2
3
5
5.5
6
7
11
11.3
11.5
11.7
12
13
13.5
14
15
15.7
16
18
18.5
19
1
2
3
6
7
11
11.3
11.5
12
13
13.5
1.80E-05
6.00E-5
0.00E+0
3.60E-5
6.90E-5
2.40E-5
6.88E-04
?
7.50E-05
2.56E-04
3.13E-05
4.81E-05
4.38E-05
1.07E-05
1.55E-05
0
0
1.00E-04
0
2.10E-05
3.83E-05
1.72E-05
1.72E-05
7.93E-06
0
0
5.00E-04
2.28E-05
7.22E-05
1.22E-04
5.00E-05
5.56E-05
7.22E-05
3.70E-05
8.10E-05
0
9.40E-06
4.90E-05
1.00E-04
1.10E-05
4.80E-05
1.14E-05
6.70E-05
3.90E-05
2.00E-05
1.10E-05
2.30E-05
1.11E-03
5.26E-05
8.42E-05
8.95E-05
3.74E-05
4.23E-05
5.64E-05
7.82E-06
1.03E-05
1.00E-04
2.95E-05
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Bronch or Peak
Dissected Subject Sex Age Twin? Smoker? Gel Lobe Sample Bifurcation # Number Mutant Fraction
Lung?
dissected lung 28-Mar M 84 No Nonsmoker J28 right upper lobe 10 5 14 5.13E-05
dissected lung 28-Mar M 84 No Nonsmoker J28 right upper lobe 10 5 1 5 1.67E-05
dissected lung 28-Mar M 84 No Nonsmoker J28 right upper lobe 10 5 15.7 4.23E-05
dissected lung 28-Mar M 84 No Nonsmoker J28 right upper lobe 10 5 16 1.92E-05
dissected lung 28-Mar M 84 No Nonsmoker J28 right upper lobe 10 5 18 6.92E-05
dissected lung 28-Mar M 84 No Nonsmoker J28 right upper lobe 10 5 18.5 7.31E-06
dissected lung 28-Mar M 84 No Nonsmoker J28 right upper lobe 10 5 19 ?
dissected lung 28-Mar M 84 No Nonsmoker J28 right upper lobe 11 6 11 4.30E-05
dissected lung 28-Mar M 84 No Nonsmoker J28 right upper lobe 11 6 11.3 3.97E-05
dissected lung 28-Mar M 84 No Nonsmoker J28 right upper lobe 11 6 11.5 3.90E-06
dissected lung 28-Mar M 84 No Nonsmoker J28 right upper lobe 11 6 12 2.00E-05
dissected lung 28-Mar M 84 No Nonsmoker J28 right upper lobe 11 6 13 1.00E-04
dissected lung 28-Mar M 84 No Nonsmoker J28 right upper lobe 11 6 13.5 4.30E-05
dissected lung 28-Mar M 84 No Nonsmoker J28 right upper lobe 11 6 14 1.28E-04
dissected lung 28-Mar M 84 No Nonsmoker J28 right upper lobe 11 6 15 3.72E-05
dissected lung 28-Mar M 84 No Nonsmoker J28 right upper lobe 1 1 6 15.5 2.56E-05
dissected lung 28-Mar M 84 No Nonsmoker J28 right upper lobe 11 6 15.7 7.69E-05
dissected lung 28-Mar M 84 No Nonsmoker J28 right upper lobe 11 6 16 1.40E-04
dissected lung 28-Mar M 84 No Nonsmoker J28 right upper lobe 11 6 1 8 4.30E-05
dissected lung 28-Mar M 84 No Nonsmoker J28 right upper lobe 11 6 18.5 3.00E-05
dissected lung 28-Mar M 84 No Nonsmoker J28 right upper lobe 11 6 19 2.20E-05
dissected lung 28-Mar M 84 No Nonsmoker J28 right upper lobe 12 7 1 7.63E-04
dissected lung 28-Mar M 84 No Nonsmoker J28 right upper lobe 12 7 2 ?
dissected lung 28-Mar M 84 No Nonsmoker J28 right upper lobe 12 7 3 8.13E-05
dissected lung 28-Mar M 84 No Nonsmoker J28 right upper lobe 12 7 5 2.19E-04
dissected lung 28-Mar M 84 No Nonsmoker J28 right upper lobe 12 7 5.5 4.38E-05
dissected lung 28-Mar M 84 No Nonsmoker J28 right upper lobe 12 7 6 6.06E-05
dissected lung 28-Mar M 84 No Nonsmoker J28 right upper lobe 1 2 7 7 3.81 E-05
dissected lung 28-Mar M 84 No Nonsmoker J28 right upper lobe 12 7 11 3.41E-05
dissected lung 28-Mar M 84 No Nonsmoker J28 right upper lobe 12 7 11.3 6.35E-06
dissected lung 28-Mar M 84 No Nonsmoker J28 right upper lobe 12 7 11.5 2.12E-06
dissected lung 28-Mar M 84 No Nonsmoker J28 right upper lobe 12 7 12 2.12E-06
dissected lung 28-Mar M 84 No Nonsmoker J28 right upper lobe 1 2 7 1 3 1.00E-04
dissected lung 28-Mar M 84 No Nonsmoker J28 right upper lobe 12 7 13.5 9.41E-06
dissected lung 28-Mar M 84 No Nonsmoker J28 right upper lobe 1 2 7 1 4 3.41 E-05
dissected lung 28-Mar M 84 No Nonsmoker J28 right upper lobe 12 7 15 1.76E-05
dissected lung 28-Mar M 84 No Nonsmoker J28 right upper lobe 12 7 15.7 1.41E-05
dissected lung 28-Mar M 84 No Nonsmoker J28 right upper lobe 1 2 7 1 6 4.82E-06
dissected lung 28-Mar M 84 No Nonsmoker J28 right upper lobe 1 2 7 1 8 2.59E-05
dissected lung 28-Mar M 84 No Nonsmoker J28 right upper lobe 12 7 18.5 6.12E-06
dissected lung 28-Mar M 84 No Nonsmoker J28 right upper lobe 12 7 19 ?
dissected lung 14-Nov F 47 No Smoker J22 right lower lobe 1 2 1 2.19E-4
dissected lung 14-Nov F 47 No Smoker J22 right lower lobe 1 2 2 7.10E-5
dissected lung 14-Nov F 47 No Smoker J22 right lower lobe 1 2 3 9.00E-5
dissected lung 14-Nov F 47 No Smoker J22 right lower lobe 1 2 5 1.57E-4
dissected lung 14-Nov F 47 No Smoker J22 right lower lobe 1 2 5.5 1.00E-6
dissected lung 14-Nov F 47 No Smoker J28 right lower lobe 1 2 5.5 1.13E-05
dissected lung 14-Nov F 47 No Smoker J22 right lower lobe 1 2 6 7.12E-5
dissected lung 14-Nov F 47 No Smoker J22 right lower lobe 1 2 7 1.75E-4
dissected lung 14-Nov F 47 No Smoker J23 right lower lobe 1 2 11 2.65E-05
dissected lung 14-Nov F 47 No Smoker J23 right lower lobe 1 2 11.3 1.90E-05
dissected lung 14-Nov F 47 No Smoker J23 right lower lobe 1 2 11.5 2.40E-05
dissected lung 14-Nov F 47 No Smoker J23 right lower lobe 1 2 11.7 3.90E-6
dissected lung 14-Nov F 47 No Smoker J23 right lower lobe 1 2 12 3.70E-06
dissected lung 14-Nov F 47 No Smoker J23 right lower lobe 1 2 13 1.00E-4
dissected lung 14-Nov F 47 No Smoker J28 right lower lobe 1 2 13 1.00E-04
dissected lung 14-Nov F 47 No Smoker J23 right lower lobe 1 2 13.5 9.60E-06
dissected luna 14-Nov F 47 No Smoker J23 right lower lobe 1 2 14 3.50E-05
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Subject Sex Age Twin? Smoker? Gel Lobe
Peak
Sample Bifurcation # Number Mutant FractionNumber
Bronch or
Dissected
Lung?
dissected lung
dissected lung
dissected lung
dissected lung
dissected lung
dissected lung
dissected lung
dissected lung
dissected lung
dissected lung
dissected lung
dissected lung
dissected lung
dissected lung
dissected lung
dissected lung
dissected lung
dissected lung
dissected lung
dissected lung
dissected lung
dissected lung
dissected lung
dissected lung
dissected lung
dissected lung
dissected lung
dissected lung
dissected lung
dissected lung
dissected lung
dissected lung
dissected lung
dissected lung
dissected lung
dissected lung
dissected lung
dissected lung
dissected lung
dissected lung
dissected lung
dissected lung
dissected lung
dissected lung
dissected lung
dissected lung
dissected lung
dissected lung
dissected lung
dissected lung
dissected lung
dissected lung
dissected lung
dissected lung
dissected lung
dissected lung
dissected lung
dissected lung
14-Nov
14-Nov
14-Nov
14-Nov
14-Nov
14-Nov
14-Nov
14-Nov
14-Nov
14-Nov
14-Nov
14-Nov
14-Nov
14-Nov
14-Nov
14-Nov
14-Nov
14-Nov
14-Nov
14-Nov
14-Nov
14-Nov
14-Nov
14-Nov
14-Nov
14-Nov
14-Nov
14-Nov
14-Nov
14-Nov
14-Nov
14-Nov
14-Nov
14-Nov
14-Nov
14-Nov
14-Nov
14-Nov
14-Nov
14-Nov
14-Nov
14-Nov
14-Nov
14-Nov
14-Nov
14-Nov
14-Nov
14-Nov
14-Nov
14-Nov
14-Nov
14-Nov
14-Nov
14-Nov
14-Nov
14-Nov
14-Nov
14-Nov
47
47
47
47
47
47
47
47
47
47
47
47
47
47
47
47
47
47
47
47
47
47
47
47
47
47
47
47
47
47
47
47
47
47
47
47
47
47
47
47
47
47
47
47
47
47
47
47
47
47
47
47
47
47
47
47
47
47
No
No
No
No
No
No
No
No
No
No
No
No
No
No
No
No
No
No
No
No
No
No
No
No
No
No
No
No
No
No
No
No
No
No
No
No
No
No
No
No
No
No
No
No
No
No
No
No
No
No
No
No
No
No
No
No
No
No
Smoker
Smoker
Smoker
Smoker
Smoker
Smoker
Smoker
Smoker
Smoker
Smoker
Smoker
Smoker
Smoker
Smoker
Smoker
Smoker
Smoker
Smoker
Smoker
Smoker
Smoker
Smoker
Smoker
Smoker
Smoker
Smoker
Smoker
Smoker
Smoker
Smoker
Smoker
Smoker
Smoker
Smoker
Smoker
Smoker
Smoker
Smoker
Smoker
Smoker
Smoker
Smoker
Smoker
Smoker
Smoker
Smoker
Smoker
Smoker
Smoker
Smoker
Smoker
Smoker
Smoker
Smoker
Smoker
Smoker
Smoker
Smoker
J23
J23
J23
J23
J23
J23
J22
J22
J22
J22
J22
J22
J22
J23
J23
J23
J23
J23
J23
J23
J23
J23
J23
J23
J23
J23
J22
J22
J22
J22
J22
J22
J22
J22
J22
J22
J22
J22
J22
J22
J23
J23
J23
J23
J23
J23
J23
J23
J23
J23
J23
J23
J23
J22
J22
J22
J22
J22
right lower lobe
right lower lobe
right lower lobe
right lower lobe
right lower lobe
right lower lobe
right lower lobe
right lower lobe
right lower lobe
right lower lobe
right lower lobe
right lower lobe
right lower lobe
right lower lobe
right lower lobe
right lower lobe
right lower lobe
right lower lobe
right lower lobe
right lower lobe
right lower lobe
right lower lobe
right lower lobe
right lower lobe
right lower lobe
right lower lobe
right lower lobe
right lower lobe
right lower lobe
right lower lobe
right lower lobe
right lower lobe
right lower lobe
right lower lobe
right lower lobe
right lower lobe
right lower lobe
right lower lobe
right lower lobe
right lower lobe
right lower lobe
right lower lobe
right lower lobe
right lower lobe
right lower lobe
right lower lobe
right lower lobe
right lower lobe
right lower lobe
right lower lobe
right lower lobe
right lower lobe
right lower lobe
right lower lobe
right lower lobe
right lower lobe
right lower lobe
right lower lobe
15
15.7
16
18
18.5
19
1
2
3
5
5.5
6
7
11
11.3
11.5
12
13
13.5
14
15
15.7
16
18
18.5
19
1
2
3
5
5.5
6
7
1
2
3
5
5.5
6
7
11
11.3
11.5
12
13
13.5
14
15
15.7
16
18
18.5
19
1
2
3
5
5.5
1.47E-5
5.60E-5
6.70E-05
3.30E-05
2.30E-05
1.30E-05
4.80E-4
6.67E-5
4.53E-5
1.87E-4
4.67E-5
1.13E-4
1.13E-4
5.34E-5
7.81 E-5
2.74E-6
2.60E-5
1.00E-4
1.51E-5
8.22E-5
9.73E-6
8.22E-5
8.22E-5
2.05E-5
5.48E-6
7.53E-6
4.41 E-4
?
2.59E-5
7.06E-5
1.41 E-5
5.41 E-5
3.00E-5
3.00E-4
2.73E-6
2.09E-5
7.45E-5
1.00E-5
7.00E-5
1.64E-5
2.30E-5
1.03E-5
6.08E-6
1.22E-5
1.00E-4
5.27E-6
3.92E-5
1.35E-5
1.22E-4
1.35E-5
5.41 E-5
2.70E-5
6.76E-6
3.60E-4
?
4.20E-5
8.00E-5
3.00E-6
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Bronch or Peak
Dissected Subject Sex Age Twin? Smoker? Gel Lobe Sample Bifurcation # Number Mutant Fraction
Lung?
dissected lung 14-Nov F 47 No Smoker J22 right lower lobe 13 5 6 3.25E-5
dissected lung 14-Nov F 47 No Smoker J22 right lower lobe 13 5 7 3.25E-5
dissected lung 14-Nov F 47 No Smoker J23 right lower lobe 1 3 6 11 3.92E-5
dissected lung 14-Nov F 47 No Smoker J23 right lower lobe 13 6 11.3 1.31E-5
dissected lung 14-Nov F 47 No Smoker J23 right lower lobe 13 6 11.5 1.00E-6
dissected lung 14-Nov F 47 No Smoker J23 right lower lobe 1 3 6 12 6.15E-6
dissected lung 14-Nov F 47 No Smoker J23 right lower lobe 13 6 13 1.00E-4
dissected lung 14-Nov F 47 No Smoker J23 right lower lobe 13 6 13.5 1.23E-5
dissected lung 14-Nov F 47 No Smoker J23 right lower lobe 13 6 14 2.08E-5
dissected lung 14-Nov F 47 No Smoker J23 right lower lobe 13 6 15 7.69E-6
dissected lung 14-Nov F 47 No Smoker J23 right lower lobe 13 6 15.7 5.31E-5
dissected lung 14-Nov F 47 No Smoker J23 right lower lobe 13 6 16 3.08E-7
dissected lung 14-Nov F 47 No Smoker J23 right lower lobe 13 6 18 2.77E-5
dissected lung 14-Nov F 47 No Smoker J23 right lower lobe 13 6 18.5 4.62E-6
dissected lung 14-Nov F 47 No Smoker J23 right lower lobe 13 6 19 2.31E-6
dissected lung 14-Nov F 47 No Smoker J22 right lower lobe 22 8 1 3.58E-4
dissected lung 14-Nov F 47 No Smoker J22 right lower lobe 22 8 2 1.43E-6
dissected lung 14-Nov F 47 No Smoker J22 right lower lobe 22 8 3 6.35E-5
dissected lung 14-Nov F 47 No Smoker J22 right lower lobe 22 8 5 2.31 E-4
dissected lung 14-Nov F 47 No Smoker J22 right lower lobe 22 8 5.5 5.20E-6
dissected lung 14-Nov F 47 No Smoker J22 right lower lobe 22 8 6 4.93E-5
dissected lung 14-Nov F 47 No Smoker J22 right lower lobe 22 8 7 4.39E-5
dissected lung 14-Nov F 47 No Smoker J23 right lower lobe 22 8 11 1.76E-5
dissected lung 14-Nov F 47 No Smoker J23 right lower lobe 22 8 11.3 1.18E-5
dissected lung 14-Nov F 47 No Smoker J23 right lower lobe 22 8 11.5 3.25E-6
dissected lung 14-Nov F 47 No Smoker J23 right lower lobe 22 8 12 7.53E-6
dissected lung 14-Nov F 47 No Smoker J23 right lower lobe 22 8 13 1.00E-4
dissected lung 14-Nov F 47 No Smoker J28 right lower lobe 22 8 13 1.00E-04
dissected lung 14-Nov F 47 No Smoker J23 right lower lobe 22 8 13.5 6.18E-6
dissected lung 14-Nov F 47 No Smoker J23 right lower lobe 22 8 14 1.73E-5
dissected lung 14-Nov F 47 No Smoker J23 right lower lobe 22 8 15 2.20E-5
dissected lung 14-Nov F 47 No Smoker J23 right lower lobe 22 8 15.7 5.80E-5
dissected lung 14-Nov F 47 No Smoker J23 right lower lobe 22 8 16 2.90E-5
dissected lung 14-Nov F 47 No Smoker J23 right lower lobe 22 8 18 3.48E-5
dissected lung 14-Nov F 47 No Smoker J28 right lower lobe 22 8 18.5 0
dissected lung 14-Nov F 47 No Smoker J28 right lower lobe 22 8 19 0
dissected lung 14-Nov F 47 No Smoker J22 right lower lobe 24 9 1 2.94E-4
dissected lung 14-Nov F 47 No Smoker J22 right lower lobe 24 9 2 9.80E-6
dissected lung 14-Nov F 47 No Smoker J22 right lower lobe 24 9 3 7.06E-5
dissected lung 14-Nov F 47 No Smoker J22 right lower lobe 24 9 5 1.18E-4
dissected lung 14-Nov F 47 No Smoker J22 right lower lobe 24 9 5.5 2.94E-5
dissected lung 14-Nov F 47 No Smoker J22 right lower lobe 24 9 6 8.82E-5
dissected lung 14-Nov F 47 No Smoker J22 right lower lobe 24 9 7 3.92E-6
dissected lung 14-Nov F 47 No Smoker J23 right lower lobe 24 9 11 1.60E-5
dissected lung 14-Nov F 47 No Smoker J23 right lower lobe 24 9 11.3 1.80E-5
dissected lung 14-Nov F 47 No Smoker J23 right lower lobe 24 9 11.5 1.10E-6
dissected lung 14-Nov F 47 No Smoker J23 right lower lobe 24 9 12 7.00E-6
dissected lung 14-Nov F 47 No Smoker J23 right lower lobe 24 9 13 1.00E-4
dissected lung 14-Nov F 47 No Smoker J23 right lower lobe 24 9 13.5 3.50E-6
dissected lung 14-Nov F 47 No Smoker J23 right lower lobe 24 9 14 2.50E-5
dissected lung 14-Nov F 47 No Smoker J23 right lower lobe 24 9 15 2.70E-5
dissected lung 14-Nov F 47 No Smoker J23 right lower lobe 24 9 15.5 3.00E-5
dissected lung 14-Nov F 47 No Smoker J23 right lower lobe 24 9 16 2.50E-5
dissected lung 14-Nov F 47 No Smoker J23 right lower lobe 24 9 18 3.60E-5
dissected lung 14-Nov F 47 No Smoker J23 right lower lobe 24 9 18.5 6.00E-7
dissected lung 14-Nov F 47 No Smoker J23 right lower lobe 24 9 19 1.60E-5
dissected lung 20-Dec M 58 No Smoker J25 right upper lobe 1 2 1 6.08E-04
dissected lung 20-Dec M 58 No Smoker J25 right upper lobe 1 2 2 2.00E-05
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4 2
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6 1
6 2
6 3
6 5
6 5.5
6 6
6 7
6 11
6 11.3
6 11.5
6 12
6 13
6 13.5
6 14
6 15
6 15.7
6 16
6 18
6 18.5
6 19
6 1
6 2
6 3
6 5
6 5.5
6 6
6 7
6 11
6 11.3
6 11.5
6 12
6 13
6 13
6 13.5
6 14
6 15
6 15.7
6 16
6 18
6 18.5
0
1.50E-04
1.10E-03
2.00E-05
2.00E-05
1.57E-5
1.71 E-5
1.57E-6
1.21 E-5
1.00E-04
0
4.29E-05
1.43E-06
2.50E-05
2.50E-05
1.57E-05
2.86E-06
1.07E-05
8.65E-05
2.70E-06
1.11E-05
8.65E-05
0
1.89E-05
1.89E-05
2.57E-06
6.29E-06
4.29E-07
0
1.00E-04
0
8.57E-07
7.14E-06
0
1.63E-05
2.69E-06
5.71 E-07
1.37E-06
6.15E-04
3.85E-06
5.77E-05
1.23E-04
0
5.38E-05
0
5.97E-05
2.70E-05
0
5.19E-05
1.00E-04
1.00E-04
0
5.70E-05
2.56E-05
2.33E-05
6.75E-05
3.63E-05
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